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ABSTRACT
 A member of the nuclear receptor superfamily, the estrogen receptor (ER) is a ligand-
regulated transcription factor responsible for the regulation of hundreds of  genes. 
Consequently, ERs are involved in numerous disease states, including cellular proliferation, 
post-menopausal symptoms, inflammation, and neurodegeneration, all of which represent 
potential opportunities for endocrine therapies.  Sustained efforts in structural biology have led 
to the deposition of many high resolution x-ray crystal structures of  ligand-receptor complexes 
into the PDB, and provide valuable insight into the key ligand-receptor interactions determining 
binding affinity and, in some cases, specific macroscopic structural attributes that directly affect 
ER function.  As described herein, we have leveraged selected PDB structures, supplemented 
by additional unpublished structures obtained from collaborators, to design and develop 
chemical probes of ER function.
 The underlying mechanisms driving ligand affinity and selectivity remain a key focus in 
understanding ER function.  Correspondingly, we describe the development of  imidazo[1,2-
a]pyridine ligands to probe the importance of the core scaffold structure in ligand binding affinity. 
Computational analysis of ligand and receptor structures has led to the identification of the 
interaction between their respective dipole moments as an important receptor-ligand interaction. 
We also set out to discover novel ER scaffolds through a virtual screening approach and follow-
up synthetic efforts to identify and further investigate a thiadiazole scaffold bearing an extended 
alkyl substituent.  Docking structures suggest an intriguing binding mode probing the presence 
of a putative second binding volume reminiscent of that observed for the high affinity and highly 
selective glucocorticoid receptor (GR) ligand, deacylcortivazol (DAC).
 The diverse biological roles of ERs also provide opportunities to probe receptor function 
through alternative mechanisms.  We report the use of recent crystal structures to design novel 
modifications of known ER ligands in probing the molecular basis for receptor crosstalk between 
ER and NF-!B, and the resulting effect on inflammatory pathways.  These ligand modifications 
are centered on destabilizing helix 12 by disrupting the position of a single histidine residue 
within the binding pocket, and have been shown to effect antagonist activity on both classical 
ER pathways and the expression of IL-6, the latter being representative of inflammatory 
responses, in vivo.  Previous work in our labs has also demonstrated that the assessment of 
ER-dependent targets can provide a better indication of ER function in vivo than assaying ER 
itself.  To this end, we have developed new  scoring functions for evaluating docked structures of 
fluorinated analogues of Tanaproget for the progesterone receptor (PR), whose expression is 
tightly controlled by ER.  These functions have been applied in the design and selection of new 
synthetic targets for use in imaging ER-positive tumors via positron emission tomography (PET).
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CHAPTER 1
INTRODUCTION
I. Estrogen Receptor Background
 The estrogen receptor (ER) belongs to a superfamily of 48 known nuclear receptors 
(NRs), 24 of which have known endogenous ligands.  NRs consist of three modular domains: an 
N-terminal transactivation domain, a central DNA binding domain (DBD), and a C-terminal 
ligand binding domain (LBD).1  The general three-dimensional structure of NRs is conserved 
through the receptor superfamily and is well illustrated by the recently solved crystal structure of 
a RXR/PPAR heterodimer bound to all of the individual elements required for transcriptional 
competency, which include a ligand, coactivator binding protein, and DNA response element 
(Fig. 1.1).2  While each of these elements has been targeted in efforts to modulate NR-mediated 
activity,3 a long-standing interest in the Katzenellenbogen laboratory has been the modulation of 
ER activity by targeting the ligand binding pocket.  The specific monomeric complex for ER 
bound to its endogenous ligand, estradiol (E2), is shown in Figure 1.2 and provides more ER-
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Figure 1.1.  Crystal structure illustrating the important elements for the transcriptional competency of a 
NR. The dimeric  receptor structure is comprised of RXR (green) and PPAR (grey) monomers bound to a 
DNA response element (yellow).  The translucent molecular surface of the PPAR monomer reveals the 
positioning of Rosiglitazone (red) in the ligand binding pocket and the zinc atoms (pink) located within the 
zinc  fingers responsible for binding DNA.  A short peptide bearing an LXXLL motif (purple) is bound into 
each of the coactivator binding grooves, where full-length coactivator proteins bind.  Figure prepared from 
pdb structure 3DZY.2
specific structural details.4  The bound ligand is completely surrounded by the receptor in a 
pocket which is formed by 11 helices and capped by a 12th helix (H12) that serves as the ‘lid’ for 
the binding pocket.  This receptor conformation positions H12 in a manner that exhibits a 
hydrophobic groove above the binding pocket that recruits associated coactivator proteins 
bearing an LXXLL motif  (L = Leu, X = any amino acid) and initiates a biochemical sequence that 
activates transcriptional machinery.  In this manner, ERs regulate hundreds of  genes and are 
involved in numerous physiological and disease states, including cellular proliferation,5,6 post-
menopausal symptoms,7,8 inflammation,9-12 and neurodegeneration,13 all of which represent 
potential opportunities for the expanded development of endocrine therapies.
 ERs play a diverse role across a spectrum of biological functions, and an important aim 
in endocrine therapies has been that of designing ligands that exhibit tissue-specific activity. 
For instance, antagonist ligands are desired for treatment of estrogen-dependent cancer by 
slowing cell growth, while agonist ligands are sought to stimulate bone and cardiovascular 
tissues.  However, agonism versus antagonism of  a ligand is not fully tissue specific, and 
unwanted side-effects can occur.  The pharmacological profiles of the so-called “selective 
estrogen receptor modulators (SERMs) tamoxifen and raloxifene (Table 1.1) are classic 
examples demonstrating ligand tissue-specificity.14-16  While tamoxifen acts as an antagonist in 
breast tissue, as an anti-cancer therapy it is plagued by agonist activity that can stimulate new 
cancers in uterine tissue.  Raloxifene, however, acts as an antagonist in breast and uterine 
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Figure 1.2.  Panel A.  Upon the binding of an agonist (e.g., estradiol  [blue]) within the ligand binding 
pocket of ER, the conformation of H12 is stabilized in a position over the face of the pocket, forming a 
hydrophobic region between helices 3, 4, 5 and 12 (orange).  Panel  B.  Coactivator proteins (green) 
bearing an LXXLL motif bind to the surface of the protein (wireframe), such that two leucine residues are 
buried into the hydrophobic core (pink) of the groove, and charged residues Lys362 and Glu542 (blue) 
form a charge-clamp with the intrinsic dipole of the helix.  Figure prepared from pdb structure 1GWR.4
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tissue, but as an agonist in bone leading to its use as both an anti-cancer agent and in hormone 
replacement therapies.  This tissue selectivity stands in stark contrast to that of E2, which acts 
as an agonist in each of these tissues, and ICI 182,780 (fulvestrant), which is known as a “pure 
antagonist.”17,18  Several factors influence the pharmacological profile of SERMs.19  The 
structural attributes of  the ligand itself  impacts both agonism/antagonism and a selectivity for 
one of two different ER subtypes (discussed in detail below).  Furthermore, every receptor-
ligand complex functions in an environment that includes a constellation of  effectors, such as 
coactivators, corepressors, and DNA response elements that constitute a cellular and tissue-
specific context.20,21  Combined, these three component parts result in a model of  “tripartite 
pharmacology”22-24 for ERs within which synthetic ligands are currently under development.
 The literature regarding ER is quite expansive, and several reviews have recently been 
published covering biological functions,25-27 molecular actions,28,29 and the state-of-the-art in 
ligand development.30-32  Much of the work presented in the following chapters is founded or 
otherwise inspired by structural underpinnings of ER function, and are greatly aided by a firm 
understanding of several important structural aspects of the ligand binding pocket of ER.
II. Structural Attributes of the Estrogen Receptor
A. Topology of the Ligand Binding Pocket
 The first x-ray crystal structure of a ligand-bound ER was solved by Brzozowski et al. in 
1997,33 and was only preceded by structures of TR34 and RXR35,36 within the NR superfamily. 
While the ER structure carried with it a broader applicability to NRs as a superfamily, it provided 
for the first time a direct description of receptor-ligand interactions in ER explaining observed 
trends in binding affinity.  From this model, the topology of  the pocket is typically defined in 
terms of  its relationship to the bound E2 ligand, and consists of A-ring and D-ring ends, a central 
core, and the B-ring sub-pocket (Fig. 1.3.A).  Important hydrogen bonding contacts are present 
at both ends of  the pocket.  The A-ring of E2 participates in a hydrogen bonding network 
between Glu353, Arg394, and a highly ordered water molecule.  This network of interactions is 
essential for high affinity to ER.  The 17!-hydroxyl of E2 also forms a hydrogen bond to His524 
3
Ligand Breast Uterine Bone
Estradiol + + +
Tamoxifen - + +
Raloxifene - - +
ICI 182,780 - - -
Table 1.1. Ligand-Dependent Pharmacological Profiles of ER .
at the D-ring end of the pocket; however, this contact is less essential to achieving high affinity. 
The central core of  the binding pocket, in contrast, is largely lipophilic and interacts with the 
ligand through non-specific van der Waals (vdW) interactions.  Finally, the B-ring sub-pocket is 
frequently accessed to engender subtype selectivity and is the site of receptor remodeling to 
induce the antagonist structure, as described in more detail in the following sections.
 The total volume of  the binding pocket is significantly larger than the volume occupied by 
the E2 ligand, 450 Å3 and 245 Å3, respectively (Fig. 1.3.B).33  The majority of  this unoccupied 
space exists above and below  the plane of the steroidal scaffold.  Ligands designed with a 
larger three-dimensional cross section aimed at filling this space, such as the bicyclononane 
ligand shown in Figure 1.4, demonstrate significantly higher binding affinity than that of E2.37
 The bulk electronic properties of the ligand binding pocket are noticeably lacking from 
discussions of pocket structure in the literature; however, we have recently acquired quantum 
mechanical and semi-empirical derived data indicating that the dipole moment within the local 
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Figure 1.3.  The topology of the ER ligand binding pocket is often defined relative to the endogenous 
ligand, E2.  These attributes include hydrogen bonding contacts at the A and D-ring ends of the pocket, a 
central  lipophilic core (magenta = lipophilic, blue = hydrophilic), and additional  volume above the B-ring 
(Panel  A).  The volume of the pocket is significantly larger than is required for E2, with the majority of the 
unoccupied space above and below the steroidal  scaffold (Panel B).  Figure prepared from pdb structure 
1ERE.33
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Figure 1.4. A bicyclononane scaffold was employed to yield a larger three dimensional van der Waals 
surface (blue), yielding a 5-fold increase in binding affinity relative to E2.
environment of the binding volume is rather large (~36 Debye).  The alignment of receptor and 
ligand dipoles appears to have significant implications on binding affinity, and by extension, 
overall ligand design, and is described in further detail in Chapter 3.
B. Structural Models of Agonism vs. Antagonism
 Pharmacophores for agonism versus antagonism have long been established based on 
medicinal chemistry; however, the specific molecular mechanisms remained poorly understood 
until the crystal structures of  ER bound to E2 and raloxifene were solved in 1997,33 and 
supplemented by the publication of many additional structures since that time.  The structures of 
agonist-bound receptor-ligand complexes highlight that the ligand is completely surrounded by 
the receptor, forming a closed ligand binding pocket and the hydrophobic coactivator binding 
groove depicted in Figure 1.2.  Antagonist-bound ER structures, in contrast, generally contain a 
sidechain that is extended through the B-ring sub-pocket, introducing a significant 
conformational change that opens a channel out of  the binding pocket, and precludes the 
binding of  these coactivators through one of two mechanisms representing classical 
antagonism.  The first of these mechanisms is demonstrated by raloxifene-bound ER!,33 as 
shown in Figure 1.5.A.  The bulky basic sidechain of  the ligand extends into the position 
occupied by H12 in agonist-bound structures.  Accordingly, H12 undergoes a major shift so that 
it binds in the coactivator binding groove itself, with two leucine residues within H12 mimicking 
the LXXLL motif  of  coactivator binding proteins.  Alternatively, the pure antagonist ICI 164,384 
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Figure 1.5.  Panel  A.  The bulky basic  sidechain of raloxifene (blue) exits the ligand binding pocket and 
shift H12 into the coactivator binding groove, where leucine residues (green) mimic the LXXLL motifs of 
coactivator proteins.  Panel B.  The longer sidechain of ICI 164,384 (blue) extends out of the ligand 
binding pocket and binds directly into the coactivator binding groove.  The position of H12 is disordered, 
and is not present in the structure.  Figure prepared from pdb structures 1ERR33 and 1HJ1.39
A B
(an analogue of ICI 182,780)17,38 bears a substantially longer sidechain that is capable of 
extending out of  the ligand binding pocket and binding directly within the coactivator binding 
groove (Fig. 1.5.B).39  In this structure, H12 is disordered and is not observed.
 Additional structural data has also resulted in the several hypotheses regarding non-
classical modes of antagonism.  Wang et al. have reported a crystal structure of ER that 
contains hydroxytamoxifen within the ligand binding pocket and a second hydroxytamoxifen 
molecule bound directly in the coactivator binding groove.40  The binding mode of this second 
ligand molecule buries the unsubstituted phenyl group deep within the lipophilic coactivator 
binding groove; however, the remainder of  the molecule does not appear to form any other 
specific interactions (e.g., hydrogen bonds) with the receptor surface.  Based on the presented 
data, we believe that this binding mode is unlikely at physiologically relevant ligand 
concentrations, and not a true mode of antagonism.3,41  More convincing, however, is recent 
structural data suggesting antagonism through the destabilization of  the last two turns in helix 11 
by disrupting the position of His524 within the ligand binding pocket.  Termed “passive 
antagonism”, this phenomenon has only recently been observed for a limited number of  ligands 
including tetrahydrochrysenes (in ER! only),42 oxabicycloheptenes, pyrazolopyrimidines,43 and 
indazoles.44
 While the described structural attributes broadly define agonism vs. antagonism for ERs, 
it is important to note that the position of H12 is not accurately described in the binary context of 
“on” or “off.”  More recently, it has been suggested that H12 can adopt intermediate positions 
and exists as a dynamic ensemble of receptor conformations that blurs the distinction between 
agonist and antagonist activity.42,44-46
C. Receptor Plasticity
 The extensive ligand-induced remodeling of  the receptor structure illustrated by 
antagonist conformations of ER indicates a degree of  receptor flexibility.  Not all facets of the 
ligand binding pocket are flexible, and modifications of the A-ring mimetics, or increasing the 
steric bulk of  certain internal substituents result in significant reductions in binding affinity. 
While introduction of  new  substituents that challenge binding constraints often initially form 
unfavorable steric interactions, when properly positioned, these interactions can cause a 
remodeling of the receptor structure to open new  pockets or channels with the opportunity to 
increase receptor-ligand interactions yielding an overall increase in binding affinity and/or 
specificity.  The latter is particularly important due to the conserved structural attributes across 
NRs that can lead to cross reactivity.  For these reasons, ER is referred to as having “plasticity.” 
Receptor plasticity, however, is difficult to model by computational techniques47 and therefore, 
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investigation is heavily reliant on experimental approaches, namely synthetic efforts through 
medicinal chemistry and structural biology.
 In this manner, a second area of receptor flexibility has recently been demonstrated in 
ER below  the D-ring of the E2 steroidal scaffold.  Ligands bearing an extended 17!-phenylvinyl 
substituent causes residues Met421 and Phe425 to rotate out of  position and open a potentially 
solvent accessible sub-pocket (Fig. 1.6).48  The incorporation of  an ortho-trifluoromethyl group in 
the aryl linker is proposed to form positive interactions with several methionine residues that 
significantly stabilize receptor remodeling and result in an increase in binding affinity of 3-fold 
over parent compounds.
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Figure 1.6. Panel A.  The incorporation of a 17!-trifluromethylphenylvinyl  substituent on E2 causes a 
reorganization of the receptor to open an extended pocket below the D-ring of the steroidal scaffold. 
Panel B.  Overlaying the binding pocket observed for E2 (cyan) highlights the rotation of Met421 and 
Phe425 residues to create the extended pocket (black arrows).  Figure prepared from pdb structures 
2P1548 and 1GWR.4
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Figure 1.7. Panel A.  Crystal  structure of Dexamethasone bound to glucocorticoid receptor (GR).  Panel 
B.  The N-phenylpyrazole of deacylcortivazol (DAC) causes Gln570 and Arg611 to adopt new positions 
double the binding volume.  Panel  C.  Residues Glu363 and Arg394 block access to a potential  extended 
binding volume in ER.  Figure prepared from pdb structures 1M2Z,49 3BQD,50 and 1GWR.4
Gln570
Arg611
Gln570
Arg611
A B C
Glu363
Arg394
Li
ga
nd
 B
in
di
ng
 P
oc
ke
t
2
n
d
 B
in
d
in
g
 V
o
lu
m
e
?
 An important example of receptor plasticity was recently disclosed for the glucocorticoid 
receptor (GR) that holds potential implications for ERs as well.  Deacylcortivazol (DAC) is a well 
established high affinity steroidal ligand for GR that contradicts the steric sensitivity associated 
with NR pharmacophores regarding substitutions on the A-ring.  The molecular mechanisms 
explaining the increased affinity were only recently elucidated via a crystal structure indicating 
that the N-phenyl pyrazole causes residues Gln570 and Arg611 to rotate out of position and 
allow  access to the adjoining solvent channel.49,50  This structural insight has been key to the 
design of novel, non-steroidal, high affinity, high selectivity ligands for use as anti-inflammatory 
therapeutics.51  A similar structural motif is observed in ER, and has been postulated as a 
putative second binding volume based on modeling studies52, in conjunction with non-
competitive binding of a tetrahydrochrysene ketone and E2.53  This hypothesis is the foundation 
for the synthesis of thiadiazole-based ligands identified by virtual screening as described in 
Chapter 5.
D. Subtype Selectivity: ER! vs. ER"
 The estrogen receptor and all structures described up until this point have been for what 
is now  known as ER!.  In 1996, Kuiper et al.54,55 discovered a second subtype of ER, termed 
ER".  This new  receptor subtype represents a completely different gene product from ER!, and 
contains only 59% amino acid sequence identity within the ligand binding domain.  The interior 
of the ligand binding pocket, however, remains largely unchanged, containing only two 
conservative amino acid residue changes: Leu384 to Met336, and Met421 to Ile373, and a 
slightly smaller binding volume for ER" (390 Å3) relative to ER! (490 Å3).56,57
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Figure 1.8. The ligand binding pocket of ER! (red, 490 Å3) is slightly larger than that of ER" (blue, 390 
Å3), and differs by only two amino acids: Leu384 to Met336 and Met421 to Ile373.  Figure prepared from 
pdb structures 1ERE33 and 1X7B.57
 While subtle, these differences have provided adequate opportunity for the discovery 
and design of  subtype-selective ligands.31  Many ligands leverage the differential placement of 
the branched aliphatic residues (Leu, Ile) versus the linear nature of  the methionine residue. 
The introduction of  substituents that initiate unfavorable steric interactions yield a reduction in 
binding affinity, thereby favoring binding to the opposing receptor subtype.  By this mechanism, 
ER!-selective ligands typically project a substituent towards the Ile373 residue of ER", such as 
the !-lactone-estradiol shown in Figure 1.9.A.58  Similarly, ER"-selectivity can be engendered 
by directing a substituent towards the Leu384 residue in ER! (Fig. 1.9.B)59 or, alternatively, 
positioning a substituent that fits within the confines defined by Ile373 of ER" but clashes with 
the extended sidechain of Met421 in ER! (Fig. 1.9.C).57
 Subtype selectivity can also be influenced by establishing a positive interaction with 
either of these differential residue pairs.  This proposed mechanism explains the ER"-selectivity 
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Figure 1.9.  The unfavorable steric interaction of the lactone substituent with Ile373 of ER" engenders 
subtype selectivity favoring ER! for !-lactone estradiol  (A).  Similarly, ER"-selectivity can be achieved 
through unfavorable interactions with Leu384 (B) or Met421 (C) of ER!.
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of DPN (Fig. 1.10),60 and is supported by quantum mechanical calculations that invoke a 
polarized interaction between the !-system of the nitrile substituent and the sulfur atom of  the 
Met336 sidechain.57  Potentially, the most straightforward approach to engendering selectivity in 
favor of  ER"-selectivity is by taking advantage of the larger binding volume of  ER" through size 
exclusion principles.  Ligands, such as PPT (Fig. 1.10)61 that include an internal aromatic 
substituent that fits well within ER", however, exceed the confines of  the narrower pocket in 
ER#.  While the reverse philosophy may work to engender a degree of ER#-selectivity based on 
reduced vdW contacts of smaller ligands in a larger pocket, this approach lacks a clearly 
defined example.
III. Non-steroidal Ligand Pharmacophores
 The elucidation of structural attributes of NRs, and more specifically ER, has resulted in 
a more complete understanding of ER pharmacophores.  A strong emphasis has been placed 
on non-steroidal ligands due to their synthetic tractability and superior selectivity compared to 
many steroidal scaffolds.  As described in Figure 1.11, these compounds contain a core scaffold 
bearing several substituents.61,62  All structures contain a phenolic moiety to mimic the A-ring of 
E2, and this is required for high binding affinities.  ER" selective ligands typically contain two 
additional aryl substituents (often phenolic) and a fourth smaller (generally alkyl) internal 
substituent.  The phenolic substituents typically serve as a hydrogen bond donor to interact with 
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Figure 1.11. Pharmacophores for non-steroidal ER" (left) or ER# (right) selective ligands.
Diarylpropionitrile (DPN) propylpyrazole triol (PPT)
Figure 1.10. Structures of ER#-selective DPN and ER"-selective PPT ligands.
His524 at the D-ring end of the pocket, and the internal aryl group is directed into the B-ring 
sub-pocket.  The alkyl substituent generally serves to fill the remainder of  the available binding 
volume, forming vdW interactions with the lipophilic central core region.
 The ER! selective ligand pharmacophore is similar, with slight modifications based on 
the structural differences described above.  While the A-ring pendant phenol remains in place, 
the D-ring phenol is often fused to the central core, reducing overall ligand size while retaining a 
hydrogen bond donor to interact with His524.  This is typically achieved through a 5,6- or 6,6-
fused bicyclic core.  The reduced width of the binding pocket precludes the incorporation of the 
internal aryl substituent; however, the smaller internal substituent remains and plays an 
important role in establishing binding affinity and selectivity.
 While these pharmacophores provide a guide for many considerations in ligand design, 
there are a number of  aspects that require continued investigation and development.  For 
instance, it remains unclear whether the core scaffold plays a direct role in influencing ligand 
binding affinity, or is simply responsible for displaying each substituent in the necessary spatial 
location.61  Furthermore, many pharmacophores can be converted from agonist to antagonist 
structures by attaching an extended B-ring substituent similar to raloxifene or ICI 164,384; 
however, the specific mechanisms controlling the tissue specificity of  agonism vs. antagonism 
for SERMs have not been fully elucidated.20
IV. Conclusions
 The complex role played by the two ERs in an array of  biological functions provides 
many opportunities for the further development of endocrine therapeutics.  As synthetic 
chemists, however, our power to modulate the activity of ERs within the context of a tripartite 
pharmacology model is currently limited to manipulation of  protein structure through ligand 
design.  The deposition of  hundreds of ER and ER-related crystal structures into the PDB since 
Brzozowski’s first structures in 1997 has greatly improved our understanding of  receptor-ligand 
interactions, multiple modes of agonism vs. antagonism, subtype selectivity, and receptor 
plasticity.  In many cases, the impact of each structural attribute on ER pharmacology is clear 
directly from the structure itself; however, others still fail to provide a solid understanding of how 
subtle changes in the ligand binding pocket specifically affect the receptor dynamics underlying 
observed phenotypes.
 Within this context, we have embarked on several projects described in the following 
chapters that utilize a mixture of  organic synthesis and computational techniques to probe 
unresolved aspects of receptor-ligand complexes.  In Chapter 2, we further investigate how  the 
nature of the core scaffold structure affects binding affinity by replacing the indazole scaffold of 
known high affinity, ER!-selective ligands62 with the geometrically equivalent imidazo[1,2-
11
a]pyridine constitutional isomer.  Subsequently, in Chapter 3 we disclose our initial results in 
structure-aided design of ER ligands that enforce an alternate conformation of  His524 correlated 
to ER-dependent inhibition of inflammatory pathways mediated by NF-!B.43  Switching gears 
slightly in Chapter 4, we describe the use of computational methods to elucidate the molecular 
mechanisms behind observed trends in binding affinity for fluorinated analogs of  the non-
steroidal progesterone receptor (PR) ligand, Tanaproget.63  Finally, in Chapter 5 we report on 
our use of virtual screening to identify a thiadiazole core scaffold and followup synthetic efforts 
in probing the presence and importance of a second putative binding volume in the ligand 
binding pocket of ER.
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CHAPTER 2
THE DESIGN AND SYNTHESIS OF IMIDAZO[1,2-a]PYRIDINES TO INVESTIGATE THE
ROLE OF THE CORE SCAFFOLD IN SELECTIVE ESTROGEN RECEPTOR MODULATORS
I. Introduction
 The discovery of the ER! subtype in 19961,2 served to reenergize research efforts in 
understanding the complex pharmacology of ERs.  Much of this enthusiasm was driven by the 
differential tissue distributions of ER" and ER!,3 which many believe is the key to harnessing 
many “good” effects of ER stimulation (through ER!) without activating cellular proliferation 
pathways (through ER").  Consequently, several high affinity, highly ER!-selective compounds 
have been reported in the literature,4 the design of  which is discussed more extensively in 
Chapter 1.  Very recently the high affinity ER!-selective chloroindazole (Fig. 2.1), synthesized in 
our labs by Dr. Meri De Angelis,5 has demonstrated unique potent neuroprotective activity in 
models of  neurodegenerative diseases that is not observed for other ER!-selective ligands such 
as DPN6 and ERB-041.7,8
 This chloroindazole compound originates from a series of  ligands based on the indazole 
core scaffold and substituted in accordance with the pharmacophore for ER!-selective ligands 
(Fig. 2.1; see also Chapter 1).5  Varying the internal substituent profoundly affected both ER 
affinity and selectivity in in vitro binding assays.  Incorporating a nitrile at this position yielded 
the highest binding affinity (RBA=69, !/"=18), while a chloro-substituent maximized affinity and 
ER!-selectivity (RBA=32, !/"=107).  Crystal structures of  both the ethyl- (1.89Å, pdb accession 
code: 2QAB) and chloro-substituted (2.39Å, pdb accession code: 2QGW) indazoles bound to 
ER"9 indicate a binding mode in which the pendant phenol serves as the A-ring mimetic, 
engaging the hydrogen bonding network between Glu353, Arg394, and a water molecule, while 
the heterocyclic hydroxyl group hydrogen bonds to His524 at the opposite end of the pocket. 
The internal substituent is directed towards the B-ring pocket.  From this structural data, the 
basis behind the observed ER!-selectivity is non-obvious; however, a similar binding orientation 
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Figure 2.1.  Using the chloroindazole as a reference, the indazole scaffold will be replaced by an 
imidazo[1,2-a]pyridine.  Both of these structures adhere to the general  pharmacophore of non-steroidal 
ER!-selective ligands.
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in the ER! pocket would position the core directly beneath the sidechain of  the Met336 residue, 
implying a positive interaction similar to that proposed for ER!-selectivity of  DPN.6,10,11  The 
presence of such an interaction would provide evidence towards clarifying the role of  the 
scaffold core in affecting ligand binding affinity.  Using this ER!-selective indazole core as a 
reference, we set out to investigate the nitrogen isomer imidazo[1,2-a]pyridine as a scaffold 
replacement in order to probe how  the identity of the heterocyclic core scaffold specifically 
affects ligand binding to ER and neuroprotective activity in vivo.
 Many derivatives of imidazo[1,2-a]pyridines have previously been investigated as 
sedatives (e.g., Ambien®),12 anti-malarial agents,13 anti-implantation agents,14 and the treatment 
of neurological disorders,15,16 ulcers,17 and anxiety disorders18 among many other uses.  While 
many derivatives of  imidazo[1,2-a]pyridines exist in the literature, we are aware of only one 
report in which this chemotype has been directly utilized as an ER ligand.19  This example, 
bearing 2-(4-hydroxyphenyl) and 3-(4-bromophenyl) substituents, bound at micromolar 
concentrations for ER! and sub-micromolar for ER", demonstrating modest affinity but ~30-fold 
ER"-selectivity.
 In line with the established pharmacophore model (Fig. 2.1) and using the indazoles as a 
guide, we planned p-hydroxyphenyl as the A-ring mimetic, a second hydroxyl substituent at the 
6- or 7-position to interact with His475, and a series of  internal substituents including halo, alkyl, 
nitrile, and phenyl.  Retrosynthetically, we envisioned the imidazo[1,2-a]pyridines to be formed 
through a condensation of  a 2-aminopyridine with an "-bromoacetophenone.  We imagined that 
the hydroxyl group on the heterocyclic ring would be installed via Ullmann-type coupling or 
SNAr, which can be installed either before or after the condensation.  Alkyl substituents at the 3-
position would be installed by pre-functionalizing the "-bromoacetophenone via Friedel-Crafts 
acylation.  We envisioned all other substituents would be introduced by taking advantage of the 
inherent reactivity of the parent imidazopyridine scaffold in selective electrophilic aromatic 
substitution reactions, and subsequent Pd-mediated coupling of the 3-halo intermediates.
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Figure 2.2.  Retrosynthetic Analysis of Imidazo[1,2-a]pyridine Core and Planned Substitutions
II. Chemistry
A. Construction of Imidazo[1,2-a]pyridine Core
 The unsubstituted parent imidazo[1,2-a]pyridine core was synthesized through the 
condensation of  2-aminopyridine and 2-bromoacetophenone according to a known procedure, 
as shown in Scheme 2.1.20-22  Construction of the heterocylic core in this manner allowed for the 
easy installation of a 2-(4-methoxyphenol) substituent necessitated by our pharmacophore from 
commercially available 2-bromo-4’-methoxyacetophenone.  Furthermore, the simple 
modification of the !-bromoketone to include an !-alkyl substituent represents a straightforward 
method for the installation of 3-alkyl substituents upon forming the core scaffold.  The necessary 
ketones were either commercially available or could be synthesized via a Friedel-Crafts 
acylation of anisole23 using the appropriate acyl chloride to yield intermediates 2a-d.  The 
subsequent bromination of  each ketone was initially conducted by the addition of Br2 in 
methylene chloride (DCM) followed by aqueous NaHCO3 to furnish the desired !-bromoketones 
3a,b in moderate to excellent yield.24  This reaction, however, was accompanied by the 
bromination of the electron-rich aryl ring, giving a byproduct that was not separable from the 
desired product at this stage.  Accordingly, all subsequent brominations were conducted by 
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Scheme 2.2. Synthesis of 3-Alkyl Imidazo[1,2-a]pyridines
adding a solution of ketone dissolved in EtOAc into a solution of  CuBr2 refluxing in a mixture of 
EtOAc/CHCl3.25-27  Under these conditions, 3a-d were synthesized in good to excellent yields 
without any detection of the over-brominated product.  Each !-bromoketone was then 
condensed with 2-aminopyridine to yield 4a-c in low  to moderate yields.  The desired product 
was easily removed from any over-brominated impurities at this stage, where needed.
B. Installation of Protected 6-OH
 The protected 6-OH functional group was installed as an alkyl ether via Ullmann-type 
coupling between the corresponding alcohol and aryl halide.  This reaction could be 
implemented at a number of  steps highlighted by paths A, B, and C in Scheme 2.3, each 
stemming from 2-amino-5-iodopyridine (5) as a common precursor.  This compound was 
synthesized through the iodination of 2-aminopyridine with periodic acid and iodine in a mixture 
of refluxing aqueous acetic and sulfuric acids.28  The reaction was quenched with saturated 
aqueous sodium thiosulfate upon observation of  2-amino-3,5-diiodopyridine formation by TLC, 
achieving 5 in good yield.  Allowing further reaction time resulted in increased recovery of  the 
diiodo-product and decreased yields of the desired product.  Following path A, 5 was transferred 
to a pressure tube charged with CuI, 1,10-phenanthroline, and Cs2CO3 suspended in anhydrous 
methanol.29  The tube was sealed using a teflon screw  cap and heated to 110 °C for ~24 hours 
behind a weighted blast shield.  The crude product was filtered and isolated using column flash 
chromatography to yield 6.  This material, however was substantially contaminated with a 5-H 
reduction side product that could not be separated at this stage.  An alternative route, path B, 
utilized a pyrrole protection scheme30-34 to facilitate the purification of the Ullmann coupling 
product.34  Via this pathway, 5 was protected through a condensation with acetonyl acetone with 
a catalytic amount of  p-TsOH in refluxing toluene or THF under dehydrating conditions using 
either a Dean-Stark apparatus or adding molecular sieves (4Å), respectively, to afford 7.  The 
previously described Ullmann methoxylation conditions were used to install the 5-methoxy 
substituent.  The 5-H reduction product was removed using dry column vacuum 
chromatography (DCVC)35,36 followed by recrystallization from hexanes to yield 8.  The 2,5-
dimethylpyrrole was removed by refluxing with hydroxylamine in an ethanol-water mixture to 
afford 9.  In the final step, paths A and B converge, whereby 2-amino-5-methoxypyridine (6, 9) 
was condensed with a series of !-bromoketones to yield the imidazo[1,2-a]pyridines 10a-d.
 Paths A and B represented divergent syntheses for imidazo[1,2-a]pyridines bearing alkyl 
substituents at the 3-position; however, we developed a more efficient method for the synthesis 
of imidazo[1,2-a]pyridine bearing the protected 6-OH, but lacking a 3-substituent.  Following 
path C, condensing 5 directly with 2-bromo-4’-methoxypyridine gave the fully formed core 11 
directly in good yield.  This intermediate contained no acidic hydrogens or sensitive functional 
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Scheme 2.3. Synthesis of 6-Alkoxyimidazo[1,2-a]pyridines
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groups and thus was established as a target for Ullmann-type alkoxylation.  Carrying out this 
reaction under optimized reaction conditions, 10a and 12 were achieved in good yield with 
<10% reduction product as determined by 1H-NMR.  This material was further purified by flash 
column chromatography followed by careful recrystallization from EtOAc/hexanes to yield 10a 
containing ~3% 5-H impurity, or 12 containing no detectable amount of 5-H impurity by 1H-NMR.
C. Installation of Protected 7-OH
 Initially, we intended to install a protected 7-OH through an analogous reaction scheme 
proceeding through a 2-amino-4-iodopyridine intermediate, which was primed for Ullmann-type 
coupling.  Literature procedures for synthesizing this intermediate installed the iodide through 
displacement of  chloride from 4-chloro-2-picolinic methyl ester.37-39  We recognized this as 
proceeding through an addition-elimination mechanism facilitated by the electron poor nature of 
the picolinic ester, and found that the chloride could also be displaced using alkoxide 
nucleophiles (Scheme 2.4).  Unfortunately, the subsequent Curtius rearrangement used to 
install the 2-amino functionality appeared to be negatively affected by this replacement, as we 
never successfully achieved 2-amino-4-methoxypyridine through this scheme. 
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Scheme 2.4. Attempted Synthesis of 2-Amino-4-methoxypyridine via Curtius Rearrangement
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Scheme 2.5. Synthesis of 7-Alkoxyimidazo[1,2-a]pyridines
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 While these investigations were ongoing, 2-amino-4-chloropyridine became 
commercially at reasonable cost.  We promptly discovered that by utilizing the 2,5-
dimethylpyrrole protection scheme to yield intermediate 15, we could take advantage of the 
electron poor position of the 4-chloro-substituent and access the same type of SNAr reactivity 
described above.  15 was treated with a freshly prepared solution of MeONa/MeOH to furnish 
16 without further purification.  The pyrrole protecting group was then removed to yield 2-
amino-4-methoxypyridine (17) in excellent overall yield.  Finally, 17 was condensed with a series 
of !-bromoketones to yield the imidazo[1,2-a]pyridines 18a,b.
D.  Functionalization of the 3-Position
 Alkyl substituents at the 3-position were primarily installed by pre-functionalizing the !-
bromoketones as described in Schemes 2.2 and 2.5.  Additional substitution patterns, however, 
were accessed by taking advantage of the inherent reactivity of the imidazopyridine core.22,40-42 
The scaffold was easily halogenated in acetonitrile with the corresponding N-
halosuccinimide43-45 to give 21-23 in excellent yield.  The substantial cost of NIS, however, 
precluded the scaled synthesis of 23, which also served as a common intermediate for products 
derived from transition metal-catalyzed couplings.  As an alternative procedure, 12 was stirred 
with iodine and potassium hydroxide in ACN42 until the starting material was consumed, as 
monitored by TLC.  The reaction was then quenched with aqueous sodium thiosulfate to give 
23.
 Aryl iodides 23a-c served as advanced common intermediates from which a variety of  
substitutions were accessible via transition metal catalyzed-coupling, namely palladium 
catalysis.  To install a 3-cyano group, 23b, Pd(dba)2Cl2, dppf, Cs2CO3, Zn(CN)2, and zinc dust 
were suspended in DMA and heated to 130°C to give 24 after isolation and purification.5,46-48 
Both of the 3-phenyl and 3-cyclopropyl substituents were installed via Suzuki-Miyaura (SM) 
coupling44,49,50 of  the corresponding commercially available boronic acids in a suspension of 
Pd(dppf)Cl2·CHCl3 and Cs2CO3 in anhydrous THF, followed by heating to 130 °C in a sealed 
tube to yield 25 and 26.  This reaction required significant optimization which included screening 
the base, solvent, Pd-source, aryl halide, and temperature to arrive at optimal conditions 
favoring product formation and minimizing the 3-H reduction side product.
 Additional carbon-carbon bond forming reactions at the 3-position could also be effected 
through specialized electrophilic reagents.  Heating the parent core 12 with a 
dibenzothiophenium trifluoromethylating reagent51-55 in anhydrous THF for 4 hours gave the 
desired product 27.  Attempts to optimize this reaction by changing solvent, temperature, or 
stoichiometry, adding a base, or employing metal-halogen exchange of  a 3-haloimidazopyridine 
analog failed to achieve yields above 40%.  The core was also formylated at the 3-position via 
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the Vilsmeier-Haack reaction.56  Thionyl chloride was heated in DMF for one hour followed by 
the addition of  12 dissolved in DMF and further heating for 2.5 hrs.  Aqueous workup gave 19 
after isolation and purification.  This intermediate was further manipulated to generate the 3-
vinyl substituent by Wittig reaction, furnishing 20 in moderate yield.
E. Deprotection
 The final step in all cases required the cleavage of each alkyl ether to yield the desired 
mono- or bis-hydroxyl product, and a number of reagents were employed to effect this 
transformation.  The majority of  compounds in Table 2.1 were deprotected using large excess of 
BF3.SMe2 (>50 equiv/ether) in CH2Cl2 overnight.5  Quenching such a large excess of Lewis acid 
greatly complicated the aqueous workup and extraction of the desired product using common 
organic solvents.  In order to mitigate the amounts of Lewis acid required, we employed two 
equivalents of the more reactive reagent BBr3.  In most cases, these conditions yielded 
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Scheme 2.6. Synthesis of Functionalized Imidazo[1,2-a]pyridines
N
N
OMeR
CHO
N
N
OMeR
N
N
OMeR
CF3
N
N
OMeR
X
N
N
OMeR
R'
N
N
OMeR
CN
N
N
OMeR
a
b
c or d
e f
g
(a) POCl3, DMF, 100°C. (b) Ph3PMeBr, n-BuLi, THF, -78°C to RT. (c) NXS, ACN. (d) I2, KOH, ACN. (e) 
Pd2(dba)3, dppf, Zn(CN)2, Zn, DMA, 130°C. (f) Pd(dppf)Cl2•CHCl3, boronic acid, Cs2CO3, THF, sealed
tube, 130°C. (g) 5-(Trifluoromethyl)dibenzothiophenium trifluoromethanesulfonate, THF, 60°C.
20a, R=6-OMe, 84%
20b, R=6-Oi-Pr, 59%
24, R=6-OMe, 57%
27a, R=6-OMe, 31%
27b, R=7-OMe, 41%
19a, R=6-OMe, 57%
19b, R=6-Oi-Pr, 73%
25a, R'=Ph, R=6-OMe, 89%
25b, R'=Ph, R=6-Oi-Pr, 78%
26a, R'=c-Pr, R=6-OMe, 82%
26b, R'=c-Pr, R=6-Oi-Pr, 62%
X
Cl
Br
I
R = H
21a, 86%
22a, 86%
23a, 94
6-OMe
21b, 92%
22b, 81%
23b, 95%
6-Oi-Pr
21c, 66%
22c, 66
23c, 63%
7-OMe
21d, 77%
22d, 59%
23d, 54%
decomposition products; however, 27a was successfully deprotected to give 29k.  Alternatively, 
compound 24 was deprotected using a pyridine·HCl melt at 220°C for 2 hours57 to give 29j in 
moderate yields.  The deprotection of 25a and 26a proved difficult under each of  the 
aforementioned conditions.  Based on test reactions, we suspected that the methyl ether at the 
6-position of the imidazopyridine was proving to be significantly more difficult to cleave than the 
methyl ether on the phenolic ring.  Modifying our protection scheme at this position from a 
methyl ether to an isopropyl ether allowed for the use of significantly fewer equivalents of Lewis 
acid to effect cleavage (2.5-10 equiv BF3.SMe2/ether).  During this optimization, we also found 
that buffering the aqueous solution to pH ~7.55 using KH2PO4/K2HPO4 enhanced the efficiency 
of product recovery through extraction with EtOAc.  Despite multiple attempts using a variety of 
conditions, we were unable to isolate and purify the deprotected products for compounds 19, 
20, 21-23a, which we believe to be unstable based on physical observations.
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N
N
OMe
R3
N
N
OH
R3
BF3·SMe2
DCM
0°C-RT
R1
R2
R1
R2
Starting Material Product
Cmpd R1 R2 R1 R2 R3 Cmpd Yield
4a H H H H H 28a 50%
4b H H H H Me 28b 100%
4c H H H H Et 28c 70%
21a H H H H Cl 28d 100%
22a H H H H Br 28e 75%
23a H H H H I 28f 48%
10a H OMe H OH H 29a 94%
10b H OMe H OH Me 29b 31%
10c H OMe H OH Et 29c 83%
10d H OMe H OH n-Pr 29d 90%
26b H Oi-Pr H OH c-Pr 29e 28%
21b H OMe H OH Cl 29f 88%
22b H OMe H OH Br 29g 27%
23b H OMe H OH I 29h 43%
25b H Oi-Pr H OH Ph 29i 62%
24a H OMe H OH CN 29j 36%
27ab H OMe H OH CF3 29k 16%
18a OMe H OH H H 30a 93%
18b OMe H OH H Et 30b 27%
a deprotected in neat pyridine!HCl at 220°C, b deprotected with BBr3 in DCM at -78°C-RT
Table 2.1. Deprotection of Imidazo[1,2-a]pyridines
F. Alternative Syntheses
 The generation of the side product resulting from the reductive cleavage of the aryl-
halide bond in the Ullmann-type coupling proved to be a substantial stumbling block in Scheme 
2.3.  Consequently, we sought out methods for installing the heterocyclic hydroxyl functionality 
that accessed a different reaction mechanism to avoid these impurities.  The following strategies 
accomplish this task by changing the synthetic disconnect, such that the 6- and 7-hydroxyl 
substituents could easily be incorporated from commercially available m- or p-pyridinol.
 In this fashion, we synthesized 2-amino-5-benzyloxypyridine from m-pyridinol via 
nucleophilic amination of an activated N-oxide.58  The hydroxyl substituent of m-pyridinol was 
alkylated using benzyl bromide and NaH in DMF to give intermediate 31.  The pyridinyl nitrogen 
was subsequently oxidized to the N-oxide with m-CPBA in DCM, followed by treatment with 
tosyl chloride and t-butyl amine in toluene affording protected product 32.  Using the same 
methods, 2-amino-4-methoxypyridine (17) was synthesized from commercially available 4-
methoxypyridine-N-oxide to furnish the isomer with the oxygen in the alternate position.
 Literature precedent exists for an alternative route in the construction of the imidazo[1,2-
a]pyridine scaffold through an intramolecular cyclization of a substituted phenacyl bromide O-
methyloxime.59  Following this scheme, the synthesis of  4a proceeds through oxime formation 
by heating 2-bromo-4’-methoxyacetophenone with methoxyamine hydrochloride in methanol60,61 
to give intermediate 34 after isolation and purification.  34 was then reacted in neat pyridine, 
which after initial dissolution quickly yielded a light pink precipitate that was filtered and washed 
to afford 35 in near quantitative yield.  We subsequently screened numerous conditions to 
facilitate the cyclization of  this intermediate, and it was found that only NaH in anhydrous DMF 
yielded the desired product, albeit in only 14% yield.  Based on the low  yield of the cyclization 
reaction and uncertainty regarding the reactivity and regioselectivity of cyclization upon 
exchanging pyridine for m-pyridinol, this synthetic route was not pursued further.
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Scheme 2.7. Alternative Synthesis of Substituted 2-Aminopyridines
N
HO
N
BnO NBnO
NHt-Bu
N
MeO
O
N
NH2MeO
N
NHt-BuMeO
a b
b c
(a) NaH, BnBr, DMF. (b) 1) m-CPBA, DCM; 2) TsCl, t-BuNH2, THF. (c) TFA, MeOH.
31, 23% 32, 36%
33, 96% 17, 59%
III. in vitro Binding Affinity
 The relative binding affinity (RBA) of  each successfully deprotected imidazopyridine was 
determined by radiometric competitive binding assay, using 17!-[3H]estradiol as the tracer.62,63 
This assay was performed by Kathryn Carlson, and the resulting data for both ER" and ER! 
are given in Table 2.2 as a percentage relative to estradiol (E2=100%).  These data can be 
easily converted to IC50 or Ki values, as described elsewhere.4,64
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Entry Compound R1 R2 R3 ER" ER! !/"
1 28a H H H 0.001 0.001 1
2 28b H H Me 0.002 <0.001 <0.5
3 28c H H Et 0.016 0.016 1.0
4 28d H H Cl 0.009 0.014 1.60
5 28e H H Br 0.015 0.012 0.80
6 28f H H I 0.022 0.019 0.86
7 29a H OH H <0.002 0.006 >3
8 29b H OH Me 0.017 0.347 20
9 29c H OH Et 0.031 0.920 30
10 29d H OH n-Pr 0.017 0.313 18
11 29e H OH c-Pr 0.015 0.324 22
12 29f H OH Cl 0.021 0.866 41
13 29g H OH Br 0.006 0.099 17
14 29h H OH I 0.016 0.058 3.6
15 29i H OH Ph 0.054 1.93 36
16 29j H OH CN 0.111 3.44 31.0
17 29k H OH CF3 0.893 13.51 15.1
18 30a OH H H 0.006 0.043 7
19 30b OH H Et 0.039 0.025 0.64
N
N
OH
R3
R1
R2
Table 2.2. Relative Binding Affinity of Imidazo[1,2-a]pyridines
Scheme 2.8. Alternative Construction of Imidazo[1,2-a]pyridine Core Scaffold
O
OMe
Br
N
OMe
Br
OMe
N
OMe
OMe
N
Br-
a b c
(a) NH2OMe•HCl, KOH, MeOH, reflux. (b) neat pyridine. (c) NaH, DMF, 90°C.
34, 71% 35, 94%
4a, 14%
IV. Structure-Based Modeling
 Structural models of each receptor-ligand pair were constructed in silico by docking each 
compound into the ligand binding pocket of  both the ER! and ER" receptor subtypes.  Several 
high resolution crystal structures for each receptor subtype were available in the PDB; we 
selected ER! complexed with a chloroindazole (2.39 Å resolution, accession code 2QGW9) and 
ER" complexed with a benzofuran (2.4 Å resolution, accession code 1U9E11) due to the 
geometric similarities of the ligands as 5,6-fused bicyclic cores containing heteroatoms.  All 
docked ligands were constructed using the Molecular Operating Environment (MOE)65 and 
docked into the protein structure using AutoDock Tools (ADT)66 and AutoDock Vina (ADV).67 
Acceptable low  energy poses were selected using the lowest energy ADV score, and in the 
case of  ER" structures, additional low  energy poses were manually selected by visual analysis. 
The selected poses were further minimized using a multistep protocol and analyzed using a 
battery of commercial scoring functions and custom-built numerical analyses.
 Visual analysis of the lowest energy poses as determined by using ADV’s built-in scoring 
function yielded contrasting results for each of the receptor subtypes.  Overlaying the output for 
each ligand docked in ER! (Fig. 2.3A) suggests that all ligands bind in the same orientation and 
adopt strikingly similar poses.  In each pose, the pendant phenol is directed towards a hydrogen 
bonding network between Glu353, Arg394, and a crystallographic water, while the heterocyclic 
hydroxyl group is positioned within hydrogen bonding distance of His524, a known hydrogen 
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Figure 2.3. The lowest energy poses for ligands 
docked into ER! (A), all  demonstrate identical 
binding orientation.  The same ligands docked into 
ER" (B), however, suggested different binding 
orientations based on the identity of the 3-
substituent.  The five lowest energy docking poses 
for imidazopyridine 29k bearing a 3-CF3 (C), for 
example, yields two opposing binding orientations 
within 0.1 kcal/mol  as scored by the docking 
routine.
A B
C
bond acceptor, and the 3-substituent is directed towards the B-ring pocket of the binding 
volume.  These binding poses closely mirror the positioning of the chloroindazole present in the 
initial crystal structure.  The corresponding lowest energy poses for ligands docked into ER!, 
however, show  multiple binding orientations (Fig. 2.3B) within the binding volume.  Upon further 
analysis of all docking output for ER!, we inferred that multiple binding orientations could not be 
eliminated based on ADV scoring.  The docking output for 2-hydroxyphenyl-3-
trifluoromethylimidazo[1,2-a]pyridin-6-ol (29k) serves as a particularly illustrative example.  An 
overlay of the five lowest energy poses is shown in Figure 3C, which represents two unique 
binding orientations with ADV calculated binding affinities within 0.1 kcal/mol.  To avoid 
misidentifying the correct binding orientation in ER!, we selected all unique low  energy poses 
for followup analysis.  Based on the relatively low  binding affinities observed for all 
imidazopyridines in ER" (Table 2.2), we chose to focus on identifying a numerical scoring 
function that correlates to the observed RBA for ligands in ER!.
 The inability to predict the correct binding orientation in ER! with any certainty obscures 
the identification of a clear molecular basis for binding affinity or subtype-selectivity based on 
visual analysis alone.  Accordingly, we sought out a quantitative method for analyzing all 
potential binding modes for each receptor-ligand complex, with the goal of identifying a metric or 
series of  metrics, that would correlate to the observed RBA data.  In addition to the ADV scoring 
output, we re-scored the raw  docking output (poses prior to multistep minimization) using 8 
additional scoring algorithms implemented in FRED68-73 (Table 2.3)  We also applied methods 
for analyzing receptor-ligand contacts that we had previously developed to assess the binding 
affinity for ligands docked into the progesterone receptor (see Chapter 4).74  Focusing on 
receptor-ligand interaction energies, approximated binding energies, and scoring hydrogen 
bonding contacts, these methods were applied to both the raw  docking output and the 
minimized structures (Tables 2.4 and 2.5).  Unfortunately, in all cases we were unable to predict 
even the relative order of binding affinity based on these data.
V. Ligand-Based Modeling
 The difficulties encountered during our attempts at utilizing receptor-based methods 
described above, speaks to the complexity of the molecular system under investigation and the 
variety of  interactions that drive ligand binding.  In order to apply a more rigorous computational 
analysis, we drastically simplified the molecular system to consider only the ligand itself  so as to 
identify the major differences in electronic properties.  A geometry optimization was performed 
for each ligand using closed-shell Restricted Hartree-Fock (RHF) gas phase calculations at the 
6-31G* level of  theory, followed by a single point energy calculation using DFT B3LYP 
27
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Table 2.4. Interaction and Binding Energies of Receptor-Ligand Complex
Raw Docking Posesa Minimized Docking Posesb
Compound R pose # E_intb E_binc E_intb E_binc
29a H 2 -8.4 -215.9 -36.5 -252.9
29b Me 1 7.6 -186.1 -35.9 -249.5
29c Et 1 2.0 -187.4 -38.9 -252.7
29c Et 8 18.6 -184.7 -55.3 -268.4
29d n-Pr 1 -8.3 -203.7 -44.4 -253.9
29e c-Pr 1 -4.3 -169.2 -41.9 -260.5
29f Cl 1 -11.5 -216.3 -60.2 -273.6
29g Br 1 -11.2 -204.8 -38.1 -251.1
29g Br 4 -6.0 -215.0 -56.5 -268.8
29h I 1 -9.2 -197.8 -58.2 -268.7
29h I 4 -2.0 -207.5 -55.4 -269.1
29i Ph 1 -0.1 -207.6 -54.1 -264.6
29j CN 1 -10.1 -211.6 -61.3 -275.1
29j CN 4 -5.3 -215.8 -56.8 -270.4
29k CF3 1 8.3 -198.5 -51.1 -261.8
29k CF3 4 -36.5 -244.2 -59.1 -272.1
a Raw docking poses were merged back into the receptor structure and rescored.  b Merged docking poses were minimized 
using a multistep minimization routine prior to rescoring.  c Interaction Energy = ERL - (ER + EL).  d Binding Energy = ERL - 
(ERmin + ELmin).
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functionals at the 6-311+G** level of  theory.75  The calculations were performed in both 
GAMESS76 and Spartan’08,77 and the output was further analyzed as described in the following 
sections.
A. Proton Affinity/Relative Basicity
 Simple pKa approximations (see Section VI, Fig. 2.9) backed by experimental 
observations indicates that the 1,2-configuration of nitrogen atoms in the indazole structures 
yields a much less basic heterocyclic core relative to the imidazopyridine core.  To further probe 
this difference in a more rigorous fashion, we calculated two measures of  proton affinity based 
on the quantum mechanical calculations described above.
 The first of  these is a calculation of the energy of  proton transfer in an isodesmic 
reaction between each compound and imidazole (Scheme 2.9), which will be denoted as E(PT).
75  The energy associated with proton transfer, E(PT), was calculated from eq. (2.1) and is given 
in Table 2.6.  Favorable reaction energies, negative values for E(PT), indicate that the 
compound is more basic than imidazole, leading to proton transfer; the reverse is true for 
positive values of  the E(PT) calculation.  The experimental pKa for imidazole in water is 6.993,78 
conveniently close to neutral.  For all cases involving the imidazopyridine cores, the protonated 
state is favored, while two out of  8 indazole compounds disfavored protonation.  In all cases, 
protonation of the indazole compound was significantly less favored relative to the 
correseponding imidazopyridine analogue.
 An important limitation of the E(PT) calculation is that the indazole core is less 
chemically similar to imidazole compared to imidazo[1,2-a]pyridine, and therefore, potentially 
introduces error into the calculation as the reaction is no longer isodesmic.  In order to address 
this shortcoming, we additionally calculated the gas phase proton affinity, P(A),79,80 for each of 
the compounds listed in Table 2.6.  This calculation follows the form given in Scheme 2.10, in 
which the change in energy for the protonation reaction is calculated directly from eq. (2.2), and 
is also given in Table 2.6.  While the P(A) is an absolute energy (e.g., not relative to a reference 
compound), an additional calculation to define the P(A) relative to imidazole allows a direct 
comparison to the E(PT) calculations.  Unsurprisingly, these data also indicate that the 
imidazopyridine core is substantially more basic than the indazole analogues.  Furthermore, the 
relative P(A) values are in good agreement with the E(PT) calculations.
B. Electrostatic Potential
 The electrostatic potential for selected imidazopyridines and the corresponding 
indazoles was projected on the 0.02 au density isosurface, as shown in Figures 2.4 and 2.5. 
This visual technique is generally suitable for visualizing the charge distribution for each 
31
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Imidazo[1,2-a]pyridine Indazole
R E(PT)a P(A)b Rel. P(A)c pKad E(PT)a P(A)b Rel. P(A)c pKad
H -12.9 -238.1 -13.3 6.11 -3.7 -229.6 -4.8 0.95
Me -16.2 -241.5 -16.7 6.63 -9.2 -235.5 -10.8 1.44
Et -17.1 -242.3 -17.5 6.54 -10.3 -236.3 -11.5 1.39
Pr -17.5 -242.7 -17.9 6.52 -10.8 -236.8 -12.0 1.37
c-Pr -17.2 -242.5 -17.7 6.42 -9.4 -235.4 -10.6 1.31
Cl -9.1 -234.5 -9.7 4.87 -2.5 -228.5 -3.7 0.54
CN -2.1 -227.6 -2.8 3.73 8.1 -217.9 6.9 0.22
CF3 -6.8 -232.0 -7.3 4.75 8.9 -217.2 7.6 0.49
a Relative basicity calculated according to Eq. (2.1) using imidazole as the reference base.  b Proton affinity calculated 
according to Eq. (2.2).  c Relative to imidazole.  d pKa calculated using MarvinSketch
 E(PT) = (EcmpdH! + EB) - (Ecmpd + EBH!) (2.1)
Table 2.6. Energy of Proton Transfer (E[PT]), Proton Affinity (P[A]), and pKa
 P(A) = -!H = -!Eele - !ZPE + (5/2)RT (2.2)
Scheme 2.9. Isodesmic Proton Transfer Between an Imidazo[1,2-a]pyridine and Imidazole
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Scheme 2.10. General Reaction Scheme for Proton Affinity
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compound.  Within each scaffold type, the nature of  the 3-substituent appears to play a 
significant role in shifting the charge distribution relative to the parent compound (i.e., H).  In the 
case of  alkyl substituents (e.g., Et), electron density is donated from the substituent to the 
heterocyclic core where it is mostly denoted by larger electron density on N1.  Electron 
withdrawing substituents (e.g., Cl, CF3) indeed appear to reduce the charge associated with N1 
and increase the charge localized to the substituent.  Comparing the electrostatic potential 
between the two scaffolds also indicates a difference in charge distribution.  In the 
imidazopyridine series, the majority of the charge density is located in the pendant phenol, while 
it is more evenly distributed but generally more localized to the heterocyle core in the indazole 
series.
C. HOMO and LUMO
 A similar analysis to the electrostatic potential was performed for the highest occupied 
molecular orbital (HOMO) and lowest unoccupied molecular orbital (LUMO) for each set of 
ligands.  The effect of electron donating substituents at the 3-position appears to have minimal 
effect on the size of the HOMO; however, the electron withdrawing groups serve to reduce the 
size of the HOMO on the heterocycle, particularly on N1, by an appreciable amount.  Between 
the two heterocycle core types the HOMOs differ extensively.  The orbitals associated with the 
pendant phenol are substantially larger for the imidazopyridines series relative to the indazoles. 
The reverse is true for the orbitals located on the heterocyclic core, and the arrangement and 
shape of the orbitals differ as well.  The arrangement of the LUMO within each series failed to 
yield any generally insightful characteristics.  Between each heterocycle series, the LUMO 
associated with the pendant phenol was noticeably larger for each indazole relative to the 
imidazopyridines.  The size, shape, and arrangement were similar for the LUMOs of  the 
heterocyclic core.
D. Dipole Moment
 The dipole moment was calculated for all compounds and a representative selection is 
shown in Figures 2.5 and 2.6. This quantity is particularly convenient as it simplifies the various 
elements of charge distribution typically visualized as surfaces (e.g., electrostatic potentials, 
HOMO, LUMOs) into a discrete vector quantity.  It is clear from visual analysis that the direction 
of the vector is heavily dependent on the identity of the 3-substituent.  Electron donating groups 
(EDGs) at the 3-position direct the vector away (e.g., Me, Et, Pr, c-Pr, i-Pr), while electron 
withdrawing groups (EWGs) cause the vector to align more along the principal axis of the 
structure (e.g., Cl, Br, CF3), or even back towards the 3-position (e.g., CN; data not shown). 
These observations are in line with the previously discussed effect of  substituent identity on 
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proton affinity and charge distribution.  Visual comparison of the dipoles for imidazo[1,2-
a]pyridines relative to the analogous indazoles, indicates that the dipole is roughly reflected 
across a vertical plan perpendicular to the principal axis of the ligand.  The magnitude of each 
dipole moment ranged from 2.08-3.52 Debye for the imidazo[1,2-a]pyridines, and 0.98-4.79 
Debye for the corresponding indazole analogs.
 Motivated by the opposing dipoles between scaffolds, we calculated the local dipole 
moment of the ligand binding pocket.  All residues within 4.5 ! of the benzofuran ligand were 
extracted from the 2QGW crystal structure,11 and the backbone carboxyls were capped as 
amides.  Based on the number of heavy atoms involved (190 heavy atoms, 244 light atoms), 
rigorous ab initio calculations (e.g., DFT, RHF-MP2) were prohibitively costly.  Alternatively, we 
used three different semi-empirical methods (AM1, PM3, MNDO) for single point energy 
calculations, from which the dipole moment was taken.  All three methods were in agreement 
regarding the direction of the dipole, as shown in Figure 2.6, and in the magnitude of  the vector, 
measured at 36.97, 37.80, and 35.44 Debye for AM1, PM3, and MNDO, respectively.
VI. Discussion
A. Chemical Synthesis
 With the exception of  a few  examples involving specialized substitution patterns,22,59,81,82 
imidazo[1,2-a]pyridines are typically synthesized through the condensation of  a 2-aminopyridine 
with an "-bromoketone,20,21 and this route generally proceeds in moderate to good yields.  The 
reaction generates an equivalent of HBr, which necessitated an aqueous workup under basic 
conditions (e.g., saturated aq. NaHCO3, 1M KOH) in order to effect efficient extraction into 
organic solvents.  The increasing concentration of  HBr as the reaction proceeds does not 
appear to affect the overall yield of the isolated condensation product, as the addition of a base 
(e.g., Et3N, Na2CO3) to the reaction mixture did not result in markedly increased yields. 
Substitution of  the 2-aminopyridine (4-Cl, 4-OMe, 5-Br, 5-I, 5-OMe) was generally well tolerated; 
however, the reaction was sensitive to substitution at the 2-position of  the "-bromoketone, as 
evidenced by reduced yields with increasing steric bulk as indicated in Scheme 2.3.  The most 
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A B
Figure 2.6.  The dipole moment was calculated for the ligand binding pocket 
of ER# using three semi-empirical  methods, AM1 (blue), PM3 (red), and 
MNDO (green).  The normalized vector is directed along the principal  axis of 
the pocket as shown from the front (A), top (B), and side (C).
Glu305 Glu305
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Arg346
Arg346
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His475His475
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C
drastic case was the failure of  the condensation reaction when R=i-Pr, even under forcing 
conditions such as extended reaction times, elevated temperatures, and the addition of silver-
based additives to facilitate displacement of the bromide.
 The installation of  the hydroxyl functional group on the heterocyclic core proved 
challenging.  Based on the binding data for the indazole analogues,5 we initially focused on 
positioning the hydroxyl at the 6-position via an Ullmann-type alkoxylation.  A known drawback 
to Ullmann-type coupling is the generation of a reduction side product in which the aryl-halide 
bond is cleaved.83-89  In preliminary attempts at the coupling of methanol with either 2-amino-5-
iodopyridine (5) or 6-iodo-2-(4-methoxyphenyl)imidazo[1,2-a]pyridine (11) through paths A and 
C, this side product was observed in quantities up to 20% under conventional conditions (i.e., 
CuCl, MeONa/MeOH), and was inseparable from the desired product using common 
chromatographic methods.  Optimization of  the reaction conditions,86,87,90-92 including 
implementing conditions developed by Buchwald,29,93 and using freshly distilled or commercially 
available anhydrous methanol, were capable of reducing the percentage of side product to 
~5-10%, but did eliminate it completely (Path C, R=6-OMe).
 Based on previous work by Lützen and coworkers,94 we found that the use of a 2,5-
dimethylpyrrole protection scheme was necessary to facilitate purification and was successfully 
leveraged to remove all traces of  the 5-H impurity via path B.  Cleavage of the pyrrole to unveil 
the desired intermediate 9, however, proved operationally difficult due to the greatly increased 
polarity engendered by the newly installed methoxy-substituent.  Consequently, we considered 
a number of alternative protection schemes with more favorable deprotection strategies.  Benzyl 
protecting groups (i.e., Bn, PMB) could not be hydrogenolyzed, as the benzyl-nitrogen bond is 
substantially more difficult to cleave than the analogous benzyl-oxygen bond.  Furthermore, 
conditions to effect cleavage of PMB groups through a quinone-methide intermediate using 
Lewis acids, would also cleave the newly installed methyl-aryl ether.  Carbamate protecting 
groups (e.g., Boc, or di-Boc)95,96 were found to cleave under the Ullmann coupling conditions. 
Finally, we were unable to form either benzophenone imine or benzyl imine,33 even in the 
presence of  silyl transfer reagents (e.g., BSA), presumably due to the reduced nucleophilicity of 
the exocyclic amine based on resonance delocationalization of charge into the !-system of the 
pyridinyl ring.
 While we were able to generate enough material to proceed with the synthesis of 
compounds 10a-d using the chemistries in paths A and B, we remained unconvinced that these 
were the most efficient methods for the scaled synthesis of advanced common intermediates 
10a and 12.  In order to optimize path C, we screened alternative coupling partners that would 
serve as a protected hydroxyl substituent and potentially change the Rf of  the product enough to 
allow  a complete separation from the reduction impurity using chromatographic methods. 
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Benzyl alcohol (BnOH), p-methoxybenzyl alcohol (PMBOH), t-butyl alcohol (t-BuOH), 
monomethylethylene glycol, and Wang resin were among the alcohols tested.  Coupling to 
BnOH and PMBOH afforded the desired product, but it was not separable from reduction 
impurities.  Careful analysis of the PMBOH reaction mixture led to the identification of p-
methoxybenzaldehyde as an additional side product, suggesting that reductive cleavage of  the 
aryl-halide bond was accompanied by oxidation of the alcohol.84,89  Substituting in t-BuOH,85 
which would not be susceptible to this type of  oxidative process, however, resulted only in the 
recovery of  starting material, presumably due to the high steric hindrance of the alcohol. 
Attempts to couple monomethylethyleneglycol,85 a relatively high polarity alcohol, or Wang 
resin, a solid phase reagent bearing a benzylic alcohol,97 both also failed under the given 
reaction conditions.
 In order to alleviate problems during the deprotection step, we investigated isopropanol 
as a coupling partner85 (Path C, R=6-Oi-Pr), and found that it drastically changed the 
chromatographic properties of the desired product.  Installation of the 6-Oi-Pr both changed the 
order of  elution for the products, such that the desired product now  eluted before the reduction 
product and offered a partial separation of these products using the acetone/DCM solvent 
system optimized for 6-OMe products.  More importantly, the isopropyl group greatly increased 
the product solubility in EtOAc relative to the methyl group; this allowed us to switch to an 
EtOAc/hexanes solvent system and yielded increased separation.  These changes, however, 
came with the drawback that the 6-Oi-Pr compounds were less crystalline than the 6-OMe 
analogs, slightly complicating the recrystallization process.
 In contrast, the installation of  the hydroxyl substituent in the 7-position of the 
imidazo[1,2-a]pyridine core was accessible through SNAr of  the 2-amino-4-chloropyridine37-39 
precursor, as outlined in Scheme 2.5.  While this reaction was not susceptible to the reduction 
processes that plagued our synthetic strategies described above,97-99 it hinged on taking 
advantage of the electron poor nature of  pyridine ring systems.  As such, we screened several 
protection strategies for the exocyclic nitrogen, and found that only the 2,5-dimethylpyrrole 
protecting group facilitated the desired reactivity.  We suspect that the success of this protection 
strategy is founded on the electron withdrawing effects of the conjugated pyrrole ring system, 
which is twisted out of  plane from the pyridine !-system by the steric encumbrance of the 2,5-
dimethyl substituents.  This hypothesis is backed by analysis of  quantum mechanical DFT 
calculations of geometry optimized structures (Fig. 2.7, Table 2.7).  These data show  that alone 
neither rotation of  the exocyclic nitrogen out of plane, nor the electron withdrawing effect of the 
pyrrole, are sufficient for reducing the charge observed at C4.  The combination of these two 
effects through the dimethyl pyrrole protection scheme, however, yields a positive charge at C4 
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and completely reverses the direction of  the dipole moment relative to the unprotected 2-
amino-4-chloropyridine.
 Attempts to extend this methodology to the synthesis of 2-amino-5-methoxypyridine 
were universally met with failure.  By placing the halogen at the 5-position, there no longer 
exists a resonance structure placing the negative charge that builds during the addition step on 
the pyridinyl nitrogen, as is observed for the 4-position. However, such a structure exists for 5-
bromo-2-nitropyridine in which the accumulating charge can be delocalized through the nitro 
group via stable resonance structures.  Initial attempts to displace the bromide revealed that in 
all cases we displaced the 2-nitro group instead (Scheme 2.11).  Subsequent reactions 
employing silver-based additives to reverse the selectivity by promoting the displacement of the 
bromide through the formation of insoluble silver bromide salts were met with failure.
 Functionalization of the imidazopyridine core proceeded smoothly and selectively at the 
3-position via eletrophilic aromatic substitution.  The selectivity of  this reaction proved superior 
than what was previously observed for the corresponding indazole analogs,5,100 and can be 
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Table 2.7. Quantitative Analysis of Geometry Optimized Masked 2-Amino-4-Chloropyridines.a
Protection Scheme Mulliken Charge on C4 Dihedral Angle (degrees) Dipole Moment (Debye)
None 0.0042 0 1.88
Dibenzyl -0.214 11.17 1.74
Di-Boc -0.088 67.32 2.14
Dimethyl Pyrrole 0.125 59.85 1.92
Pyrrole -0.098 0 0.92
a All values calculated in Spartan’08.  Geometry Optimized at RHF/6-31G*; Single Point Energy at DFT/B3LYP/6-311+G**
Figure 2.7. QM-Optimized Geometry and Dipole Moment of Masked 2-Amino-4-Chloropyridines
Scheme 2.11. Reaction of 5-Bromo-2-nitropyridine with Alkoxide Nucleophiles
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justified by the observed charge buildup at C3 through quantum mechanical DFT calculations, 
as shown in Figure 2.8.
 Our initial investigations into the further manipulation of aryl iodides 23a-d to install 
additional functionality via Pd-catalyzed reaction manifolds were met with minimal success. 
Common conditions for SM couplings failed to yield product, while more rigorous microwave-
catalyzed conditions39 yielded 50% of  the 3-H reduction product in the synthesis of  23a (R=Ph). 
Notably, the installation of the 3-nitrile proceeded in good yield via a similar reaction 
mechanism, leading us to pursue experiments aimed at optimizing SM reaction conditions. 
Starting from boronic acid, Pd, and base in dioxane, we found that the reaction only proceeded 
to give the desired product at 130 °C; however, product formation was accompanied by a 
significant amount of 3-H reduction product.  The strict elimination of water by replacing reagent 
grade dioxane and bench-stored K3PO4 with anhydrous THF from a solvent delivery system and 
Cs2CO3 stored in a desiccator, resulted in the significant diminution in observed 3-H reduction 
product.  The identity of the halogen appeared to greatly affect the rate of  reaction, as judged by 
TLC, such that I>Br>>Cl.  The palladium source did not appear to greatly affect reaction course, 
as both Pd(dppf)Cl2 and Pd2dba3 yielded comparable results.  While phenylboronic acid reacted 
with good conversion, the coupling of  cyclopropylboronic acid was further optimized by adding 
an additional equivalent of boronic acid after 30 minutes of reaction time.  The related 
isopropylboronic acid,44 however, failed to give the desired product under all conditions tested. 
We made several attempts at installing the 3-vinyl substituent using analogous methodologies.
101  The vinylboronic anhydride pyridine complex, a stable vinyl boronic acid equivalent,102 gave 
the desired product; however, significant quantities of  the 3-H reduction side product formed and 
was not separable at this stage.  Unfortunately the required elevated temperature precluded the 
use of other technologies such as the slow  release of  MIDA-protected vinylboronic acids.103 
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Figure 2.8.  Highest Occupied Molecular Orbitals (HOMO) for the imidazopyridine (left) and indazole 
(right) scaffolds.  The large coefficient for the orbital  localized on C3 in the imidazopyridine leads to 
enhanced selectivity for electrophilic  aromatic substitution.  Delocalization of the corresponding orbital for 
the indazole scaffold results in reduced regioselectivity, yielding competing substitution at C3 and C4.100
This product was accessible through more traditional chemistries, as described in Scheme 2.6, 
and thus was not pursued further by other transition-metal coupling methods (e.g., Stille 
coupling).45,104-106
 The successful deprotection, isolation, and purification of each imidazopyridine was 
heavily dependent on the substituent at the 3-position.  This resulted in the use of a variety of 
reagents to affect cleavage of  the alkyl ethers, as described in section II.E.  Efficient extraction 
of the deprotected product from the quenched reaction mixture proved to be extremely pH 
sensitive.  Based on the approximation of  pKa using MarvinSketch,107,108 we designed a 
potassium buffer to enable efficient extraction that maximized product recovery and was 
generally applicable (Fig. 2.9).  The final purification using flash column chromatography was 
particularly important for compounds originating from path A (Scheme 2.3), as the reduction 
product impurities were only separable after deprotection.  The separation of  final products was 
greatly improved by using a highly controlled gradient elution on a CombiFlash® MPLC 
instrument.  Despite substantial effort, we were unable to develop conditions for the 
recrystallization of the free base or HCl salts.
B. Biological Data
 From the relative binding affinity (RBA) data given in Table 2.2, a number of trends 
become apparent.  As highlighted by entries 29f-k, all compounds lacking a hydroxyl group on 
the heterocyclic core demonstrated extremely low  affinities for either ER subtype.  The 
incorporation of  a hydroxyl substituent at either 6- or 7-position alone is not sufficient for 
increased binding affinity (Table 2.2, entries 7, 13, 14, 18, 19), as only in cases bearing a 6-OH 
and a suitable 3-substituent (Table 2.2, entries 9, 12, 16, 17) was increased binding observed. 
41
!"
#"
$"
%"
&"
'"
("
)"
*"
+"
#!"
," -." /0" 1234" 5234" 67" 84" 9" 3:" 6;" 6<%"
!
"
#$
%
#"
&'
(
)*
+
"
)
,%-./&%'0&)"&)1234.5/40)
3:=,"
(2=,"
;,>"
Figure 2.9.  Calculated pKa for Substituted Imidazo[1,2-a]pyridinols
While comparing Me to Et shows approximately 3-fold increased affinity, extending to n-propyl 
or cyclopropyl leads to reduced affinities comparable to Me.  Entry 12 bearing the 3-Cl 
demonstrates good affinity and high selectivity for the ER!-subtype; however, moving down the 
group to 3-Br and 3-I significantly reduces both affinity and selectivity.  Other electron 
withdrawing substituents, such as 3-Ph, 3-CN, and 3-CF3 show  increased affinity with moderate 
ER!-selectivity.  Entry 17 where R=CF3 represents the highest affinity imidazopyridine 
synthesized herein, with and RBA of 13.5%, corresponding to a Ki=2.9 nM.
 Comparing these data to the RBA data for the corresponding indazole,5 the 
imidazopyridines generally bind with significantly reduced affinity and moderately reduced !-
selectivity relative to the corresponding indazole analog.  The lone exception to this is entry 4 in 
Table 2.8, where 3-Ph, which binds with an RBA of 1.93%, 4-fold higher than the indazole 
analog.  Curiously, this compound is also the only example that we are aware of  for a ligand 
bearing an internal aromatic substituent that retains ER!-selectivity.  Ligands of this structure 
are generally quite selective for ER".
C. Molecular Modeling
 Our attempts to identify a molecular basis to explain the observed trends in binding 
affinity through the quantitation of each receptor-ligand complex proved disappointing.  We are 
primarily concerned with the selection of  the crystal structure used as a guide for each receptor 
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Imidazopyridines Indazoles
Entry Cmpd R ER" ER! !/" ER" ER! !/"
1 29f Cl 0.021 0.866 41.2 0.30 32.1 107
2 29g Br 0.006 0.099 16.5 0.18 18.4 102
3 29h I 0.016 0.058 3.63 0.17 8.5 50
4 29i Ph 0.054 1.93 35.7 0.04 0.46 12
5 29j CN 0.111 3.44 31.0 1.4 30.1 22
6 29k CF3 0.893 13.51 15.1 3.9 69 18
N
N
HO
OH
R
N
N OH
HO
R
Table 2.8. Comparison of Relative Binding Affinity Across Scaffold Structure
subtype, which was carefully selected based on the geometric similarity to the heterocyclic core 
of our designed imidazopyridine ligands.  Overlaying the binding volumes obtained from crystal 
structures of ER! bound to three different classes of ligands suggests that the shape of the 
pocket remains relatively consistent (Fig. 2.10A).  The ER" overlay, in contrast, emphasizes that 
the shape of the pocket is heavily dependent on structural characteristics of the bound ligand 
(Fig. 2.10B).  This apparent flexibility of the ER" receptor reinforces the concept that the 
selection of  the reference crystal structure used as a guide can heavily influence the resulting 
docking poses.  The multistage minimization routine is designed to minimize this dependence 
for small changes in binding volume (e.g., those observed in the ER! overlay); however, it 
would be difficult to extend this methodology to account for the extensive changes in pocket 
shape observed for ER".109
 Our secondary concerns are centered on the use of  molecular mechanics force fields to 
analyze these systems, as implemented in ADV docking and MOE energy minimization 
routines.  As discussed in Chapter 1, one of the major differences in the ligand binding pocket 
between ER! and ER" is the Leu384#Met336.  In ER", this methionine resides over the face 
of the ligand, and we suspect that the ligand interaction with the methionine sidechain is 
responsible for high affinity binding to ER", and by extension engenders subtype selectivity. 
Based on the QM data justifying the ER"-selectivity of DPN,6,10,11 we hypothesized that the 
primary basis of this interaction appears to be a polarized interaction of the methionine 
sidechain and the $-system of the heterocyclic core.  Molecular mechanics force fields, 
however, implement parameterized point charges and were not explicitly developed to handle 
interactions founded on atom polarization.  The inability to take this important interaction into 
account potentially undermines all of  our attempts at scoring the receptor-ligand complexes 
using molecular mechanics-based approaches.  Accordingly, we refocused our efforts on ligand-
based approaches in which we could circumvent the limitations of  MMFFs through the use of 
quantum mechanical calculations.
 Comparing the observed RBA values from Table 2.8 with the analogous indazole 
structures highlights that with only one exception (entry 4, R=Ph) the imidazopyridines yielded 
significantly lower RBA values than the corresponding indazole compound.  These compounds 
are geometrically identical, merely differing in the position of  a single nitrogen atom; therefore, 
we conclude that the remarkable erosion of binding affinity is due wholly to changes in the 
electronics within the ligand.  We hypothesized that upon identifying the changes in electronic 
structure, these data could ultimately be projected onto the receptor structure, elucidate the 
binding orientation of the ligand, and ascertain the consequences of changing the position of  the 
nitrogen atom within the context of the protein structure.
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Figure 2.10.  A) The crystal structures of  ER! complexed with E2 (blue, pdb code: 1ERE), 
diethylstilbestrol (red, pdb code: 3ERD), and chloroindazole (green, pdb code: 2QGW), 
demonstrate minimal variation in the volume of the ligand binding pocket as shown from the 
front and side views.  B)  Similar views of  crystal structures of ER" complexed with genistein 
(blue, pdb code: 1X7J), ERB-041 (red, pdb code: 1X7B), and WAY-397 (green, pdb code: 
1U9E), however, indicate substantial variation in the shape and size of the ligand binding 
pocket.
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 Expanding upon the pKa approximations in Figure 2.9, the E(PT) and P(A) data (Table 
2.6) yield a more rigorous metric for assessing the impact of  3-substitution and scaffold 
structure on the relative basicity of each compound.  Compounds bearing EDGs are 
substantially more basic than compounds bearing EWGs.  This is due to increased localization 
of charge at N1, as observed from projection of the electrostatic potential over the vdW surface 
and the angle of the dipole moment (Figs. 2.4, 2.5).  Comparing the imidazopyridines to the 
corresponding indazole analogs indicates that the indazole core is substantially less basic, and 
charge density is more evenly distributed throughout the heterocyclic core, as denoted by 
increased yellow  coloration in the electrostatic potential surface compared to the green 
coloration in the imidazopyridines.  The horizontally flipped dipole moment of the indazoles, 
relative to the imidazopyridines, also indicates that the charge density is shifted away from the 
N1 position as well.  The ramifications of  these properties were readily apparent in the pH-
senstitivity of the deprotected compounds that complicated isolation procedures, and by 
extension, may play an important role affecting binding energy by modulating the ligand 
desolvation penalty that must be overcome during a binding event.
 Within the data presented above, there are a number of examples in which compounds 
with higher charge localization (stronger basicity) yield higher RBAs than compounds with lower 
charge localization (e.g., R=CN vs. R=CF3).  Furthermore, smaller magnitude in dipole moment 
does not necessarily correlate to increased affinity.  An effective way of evaluating this latter 
correlation while removing steric variables includes plotting the dipole moment of  each 
imidazopyridine against the dipole moment for the analogous indazole compound, as shown in 
Figure 2.11.  All points above the solid line represent compounds in which the calculated dipole 
moment is larger for the indazole analog, while the reverse is true for points below  the line. 
These data fail to cluster based on RBA trends, indicating the magnitude of the dipole moment 
alone does not appear to be a significant determinant of binding affinity.
 The opposing directions of the dipole moments calculated for imidazopyridine and 
indazole core scaffolds (Figs. 2.4, 2.5) is a striking trend.  Based on these data and their loose 
correlation to the observed trends in RBA, we hypothesized that the ligand binding pocket has 
an intrinsic dipole moment with a significant component directing from the from the His475 end 
to the Glu305/Arg346 end of the pocket.  Assuming that the ligand binds in the generally 
accepted orientation, the dipole moment of the indazole scaffold generally opposes the local 
dipole of the binding pocket, representing a positive electrostatic interaction leading to reduced 
binding energies (higher binding affinity).  The dipole moment of  the imidazopyridines, in 
contrast, would align with the dipole of  the binding pocket, incurring an electrostatic repulsion 
and increased binding energies (lower binding affinity).  Semi-empirical calculations of the 
isolated ligand binding pocket, in fact, support this hypothesis.  The calculated dipole moment is 
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projected onto the ER! ligand binding pocket shown in Figure 12.  Overlaying the 3-CF3 ligand 
for each scaffold demonstrates the opposing relationship of the dipole moments for the indazole 
and receptor (Fig. 2.12A), while the corresponding dipoles are aligned for the imidazopyridine 
(Fig. 2.12B).  We hypothesize that these interactions may also explain the unique reversal in 
binding trends for the 3-phenyl analogs.  In this case, we envision that the relatively large phenyl 
substituent is unable to properly fit within the reduced pocket volume of  ER!, inducing the 
ligand to bind in a “horizontally flipped” orientation, in which the pendant phenol is directed 
towards the His524 residue.  Consequently, the dipole moment of the ligand would also be 
reversed, yielding a positive dipole-dipole interaction for the imidazopyridine, and a repulsive 
interaction for the analogous indazole.
VII. Conclusions.
 We set out to clarify the role of  the ligand core scaffold in determining binding affinity and 
selectivity in ERs by through a combination of synthetic and computational approaches.  Using 
a series of previously synthesized indazoles as a guide, we designed a structurally conservative 
change in the core scaffold by implementing the isomeric imidazo[1,2-a]pyridine as a scaffold 
replacement.  Several compounds were then synthesized and tested for in vitro binding affinity 
to ERs.  The resulting data demonstrated both reduced affinity and subtype selectivity relative to 
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Figure 2.11. Comparing the Magnitude of Dipole Moment For 
Substituted Imidazopyridine and Indazole Scaffolds.
the analogous indazole compounds.  Further investigations using a variety of  molecular 
modeling-based approaches highlighted striking differences in the electronic properties for each 
ligand, most notably the differences in relative basicity and opposing dipole moment between 
the imidazopyridine and indazole scaffolds.  Followup calculations on the ligand binding pocket 
indicated the presence of  a strong dipole moment within the local environment of the ligand. 
From these data, we propose that the electronic properties of the core scaffold play a direct role 
in influencing binding affinity through a strong dipole-dipole interaction between the ligand and 
the net dipole of the ligand binding pocket.  Other contributing factors include the influence of 
charge localization on protonation state and desolvation penalty, in addition to more traditional 
factors such matched hydrogen bonding contacts, lipophilicity profile, and steric constraints.
VIII. Experimental.
 General Considerations.  All chemical reagents were purchased from commercial 
suppliers without further purification.  Anhydrous DMF was obtained from Aldrich in a 
Sureseal™ bottle stored in a secondary container with desiccant; all other anhydrous solvents 
were obtained from a solvent dispensing system unless otherwise stated.  All glassware was 
oven or flame-dried and cooled under vacuum or in a dry box.  All reactions were conducted 
under argon.  NMR spectra were obtained on Varian Oxford instruments and worked up using 
ACD, Inc. 1D-NMR processing software.  The chemical shifts are reported in ppm and 
referenced to the solvent peak.  Electron Impact (EI) mass spectra were obtained on a 70-VSE 
mass spectrometer with an ionization energy of 70 eV.  Electrospray Ionization (ESI) mass 
spectra were obtained on a Q-Tof  mass spectrometer.  Melting point ranges were measured 
using a Thomas Hoover capillary melting point apparatus.
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Figure 2.12.  The dipole moment of the ligand binding pocket (multicolored arrow) and ligand (orange 
arrow) are superimposed over the ligand binding volume (purple surface).  Assuming the standard 
binding orientation, the dipole moment of the indazole ligand generally opposes the dipole vector of the 
binding pocket (A), forming a positive interaction.  The dipole moment of the imidazopyridine (B), in 
contrast, is well aligned with the dipole of the binding pocket, inducing an electrostatic repulsion that 
would negatively affect binding affinity.
A B
 General procedure for the acylation of anisole.  A round bottomed flask charged with 
AlCl3 stirring in anhydrous DCM under argon was cooled in an ice bath.  Anisole and the 
corresponding acyl chloride were in sequentially injected into the reaction mixture, which was 
slowly warmed to ambient temperature as the reaction was allowed proceed for 3-14 hours. 
The reaction mixture was then poured into ice water and exhaustively extracted with DCM, the 
organic layer dried over MgSO4, vacuum filtered, and concentrated by rotary evaporation.  The 
crude material was used in subsequent reactions unless otherwise specified.
 General procedure for the !-bromination of ketones.  A round bottomed flask affixed 
with a reflux condenser was charged with CuBr2 stirring in EOAc and heated to reflux for one 
hour, yielding a green heterogeneous solution.  A solution of ketone dissolved in CHCl3 was 
added to the reaction mixture, which was held at reflux until solution changed color from green 
to amber (usually within 1-3 hours).  The reaction mixture was then filtered through celite, 
washed with EtOAc, and purified by flash chromatography over silica gel (25% EtOAc in 
hexanes).
 General procedure for the formation of imidazo[1,2-a]pyridine core.  The 
corresponding 2-aminopyridine and 2-bromoacetophenone were dissolved in ethanol and 
heated to reflux while stirring until the reaction was complete by TLC (5-20% acetone in DCM), 
usually after 8-12 hours.  The reaction products were isolated using a standard workup 
consisting of   concentration by rotary evaporation, re-suspension in DCM and 1M KOH (aq) or 
saturated NaHCO3 (aq), exhaustive extraction with DCM, drying over MgSO4, vacuum filtration, 
and  concentration by rotary evaporation.  The products were purified by flash chromatography 
over silica gel (5-20% acetone in DCM).
 General procedure for the  halogenation of imidazo[1,2-a]pyridines.  The 
corresponding imidazo[1,2-a]pyridine and N-halosuccinimide were dissolved in acetonitrile and 
stirred at room temperature until the reaction was complete by TLC (5-20% acetone in DCM), 
usually after 30 minutes.  The reaction products were concentrated by rotary evaporation and 
purified by flash chromatography over silica gel (5-20% acetone in DCM).
 General procedure for Ullmann-type alkoxylation of aryl iodides.  A pressure tube or 
heavy walled round bottomed flask was charged with aryl iodide, CuI, 1,10-phenanthroline, 
Cs2CO3, and the corresponding alcohol.  The reaction vessel was sealed using a teflon screw-
cap, covered in aluminum foil, and heated to 110 °C behind a weighted blast shield for ~24 
hours.  The reaction flask was then allowed to cool to ambient temperature, and the reaction 
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mixture filtered through celite, washed with the appropriate organic solvent (R=MeO: DCM, R=i-
PrO:EtOAc), and concentrated by rotary evaporation.  The resulting solid was transferred to a 
separatory funnel containing a brine solution and exhaustively extracted with organic solvent. 
The organic layer was dried over MgSO4, vacuum filtered, and concentrated by rotary 
evaporation.  The desired product was purified by flash chromatography over silica gel using the 
specified solvent system.
 General procedure for Suzuki-Miyaura (SM) coupling of aryl iodides.  A pressure 
tube was charged with aryl iodide, boronic acid, Pd(dppf)·CH2Cl2, and anhydrous THF and 
sealed with a teflon screw  cap.  The reaction vessel was heated to 130°C behind a weighted 
blast shield for one hour.  The reaction mixture was allowed to cool to ambient temperature, 
transferred to a separatory funnel, suspended in distilled water, and exhaustively extracted with 
DCM or EtOAC.  the organic phase was dried over MgSO4, vacuum filtered, and concentrated 
by rotary evaporation.  The desired product was isolated by flash chromatography over silica gel 
as specified.
 General procedure for the cleavage of aryl-alkyl ethers.  The compound bearing an 
aryl-alkyl ether was placed in a dry round bottomed flask charged with DCM and cooled in an 
ice bath.  Boron triflouride as the dimethylsulfide complex was injected via syringe and the 
reaction mixture was slowly warmed to ambient temperature as the reaction was allowed 
proceed for ~24 hours.  The reaction mixture was re-cooled in an ice bath, quenched with 
methanol, stirred for 30 minutes, and concentrated by streaming nitrogen bubbled through 
bleach to contain thiol vapors.  The crude material was re-suspended in EtOAc and water, which 
was buffered to ~7.6 using a K2HPO4/KH2PO4 (aq) solution and allowed to stir until the aqueous 
layer became colorless.  The products were isolated by exhaustive extraction with EtOAc, dried 
over MgSO4, vacuum filtered, and concentrated by rotary evaporation.  The desired product was 
purified by flash chromatography over silica gel (10-20% IPA in DCM) or MPLC using a 
CombiFlash® instrument (gradient elution, 0-20% IPA in DCM).
 2-Phenylimidazo[1,2-a]pyridine (1).  Following the general procedure for the formation 
of imidazo[1,2-a]pyridine core from 2-aminopyridine (5.04g g, 53.6 mmol) and 2-
bromoacetophenone (10.61 g, 53.3 mmol), 1 was isolated as a beige solid (7.37 g, 71.2%).  1H-
NMR (CDCl3, 500 MHz) ! 8.08 (dt, J = 6.75, 1.02 Hz, 1H), 7.95 (dt, J = 8.09, 1.63 Hz, 2H), 7.83 
(s, 1H), 7.62 (dd, J = 9.11, 0.75 Hz, 1H), 7.42 (m, 2H), 7.32 (tt, J = 7.29, 1.29 Hz, 1H), 7.14 
(ddd, J = 9.11, 6.75, 1.29 Hz, 1H), 6.74 (td, J = 6.75, 1.07 Hz, 1H); 13C-NMR (CDCl3, 125 MHz) 
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! 145.77, 145.65, 133.74, 128.69, 127.93, 126.00, 125.55, 124.59, 117.52, 112.36, 108.07; 
HRMS (EI) calcd for C13H10N2 M+ 194.084398, found 194.084433.
 4’-methoxypropiophenone (2a).  Following the general procedure for the acylation of 
anisole from AlCl3 (1.68 g, 12 mmol), propionyl chloride (0.9mL, 10 mmol), and anisole (1.0 mL, 
10 mmol), to yield 2a as a cloudy white oil (1.64 g, 96.6%).  1H-NMR (CDCl3, 500 MHz) ! 7.96 
(AA’XX’, 2 H), 6.94 (AA’XX’, 2 H), 3.87 (s, 3 H), 2.96 (q, J=7.29 Hz, 2 H), 1.22 (t, J=7.29 Hz, 3 
H); 13C-NMR (CDCl3, 125 MHz) ! 199.52, 163.25, 130.19, 129.96, 113.62, 55.41, 31.37, 8.38; 
HRMS (ESI) calc’d for C10H13O2 [M+H]+ 165.0916, found 165.0912. 
 4‘methoxybutyrophenone (2b).  Following the general procedure for the acylation of 
anisole from AlCl3 (1.64 g, 12 mmol), butyryl chloride (1.0 mL, 10 mmol), and anisole (1.0 mL, 
10 mmol), to yield 2b as a cloudy oil (2.82 g, quant.).  1H-NMR (CDCl3, 500 MHz) ! 7.95 
(AA’XX’, 2 H), 6.94 (AA’XX’, 2 H), 3.87 (s, 3 H), 2.90 (t, J=7.29 Hz, 2 H), 1.76 (sxt, J=7.42 Hz, 2 
H), 1.00 (t, J=7.50 Hz, 3 H); 13C-NMR (CDCl3, 125 MHz) ! 199.11, 163.26, 130.28, 130.15, 
129.41, 120.60, 113.82, 113.61, 55.40, 40.16, 17.95; HRMS (ESI) calc’d for C11H15O2 [M+H]+ 
179.1072, found 179.1072.
 4’-methoxyvalerophenone (2c).  Following the general procedure for the acylation of 
anisole from AlCl3 (1.7 g, 12.7 mmol) valeryl chloride (1.2mL, 10 mmol), and anisole (1.0 mL, 10 
mmol), to yield 2c (1.56 g, 81.2%).  1H-NMR (CDCl3, 400 MHz) ! 7.95 (AA’XX’, 2 H), 6.94 
(AA’XX’, 2 H), 3.87 (s, 2 H), 2.92 (m, 2 H), 1.71 (dt, J=15.08, 7.48 Hz, 1 H), 1.41 (dq, J=14.98, 
7.46 Hz, 2 H), 0.95 (t, J=7.32 Hz, 2 H); 13C-NMR (CDCl3, 100 MHz) ! 199.21, 163.25, 130.29, 
130.17, 113.62, 77.00, 55.43, 37.99 , 26.73, 22.52, 13.94; HRMS (ESI) calc’d for C12H17O2 [M
+H]+ 193.1229, found 193.1225.
 4’-methoxyisovalerophenone (2d).  Following the general procedure for the acylation 
of anisole from AlCl3 (1.6 g, 12 mmol), isovaleryl chloride (1.2mL, 10 mmol), and anisole (1.0 
mL, 10 mmol), to yield 2d as a colorless oil (1.97 g, quant.).  1H-NMR (CDCl3, 400 MHz) ! 7.94 
(AA’XX’, 2 H), 6.93 (AA’XX’, 2 H), 3.87 (s, 3 H), 2.78 (d, J=7.08 Hz, 2 H), 2.29 (m, 1 H), 0.99 (d, 
J=6.84 Hz, 6 H); 13C-NMR (CDCl3, 100 MHz) ! 198.86, 163.22, 130.33, 113.58, 77.76, 55.40, 
47.14, 25.34, 22.77.
 2-Bromo-4’ -methoxyphenylpropiophenone (3a) .  Method A.  4 ’ -
methoxypropiophenone (827 mg, 5 mmol) was dissolved in methylene chloride (2 mL) and 1,4-
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dioxane (4 mL).  A solution of Br2 (800 mg, 5mmol) dissolved in methylene chloride (2 mL) was 
added drop-wise with stirring at 0 °C.  Upon completion of Br2 addition, the reaction was allowed 
to warm to room temperature and stir for one hour.  Aqueous saturated sodium bicarbonate 
solution (4 mL) was added and stirred for an additional one hour.  The reaction was quenched 
with sodium thiosulfate, exhaustively extracted with methylene chloride, dried over magnesium 
sulfate, vacuum filtered, and concentrated by rotary evaporation.  The product solidified upon 
cooling to 0 oC, and was further purified by trituration from hexanes to yield 3a as a white solid 
(821 mg, 67%).  Method B. Following the general procedure for !-bromination of ketones from 
2a (1.50 g, 9.1 mmol) and CuBr2 (3.59 g, 16.2 mmol), yielded 3a as light green oil (1.34 g, 
87.5%).  1H-NMR (CDCl3, 500 MHz) " 7.99 (AA’XX’, 2H), 6.92 (AA’XX’, 2H), 5.24 (q, J = 6.65 
Hz), 1H), 3.85 (s, 1H), 1.86 (d, J = 6.43 Hz, 3H); 13C-NMR (CDCl3, 125 MHz) " 191.93, 163.86, 
131.23, 126.70, 113.88, 55.46, 41.38, 20.14; HRMS (ESI) calc’d for C10H11O2NaBr [M+Na]+ 
264.9840, found 264.9850.
 2-Bromo-4’-methoxyphenylbutyrophenone (3b).  Following the same procedure for 
3a Method A, the bromination of  4’-methoxyphenylbutryophenone (723 mg, 4 mmol) yielded 3b 
as a white solid (1.01 g, 97%).  Method B.  Following the general procedure for !-bromination of 
ketones from 2a (2.82 g, 10.0 mmol) and CuBr2 (3.61 g, 16.7 mmol), to yield 3b as light yellow 
oil (2.43 g, 94.7%).  1H-NMR (CDCl3, 400 MHz) " 8.00 (AA’XX’, 2H), 6.95 (AA’XX’, 2H), 5.03 
(dd, J = 7.81, 6.35 Hz, 1H), 2.21 (m, J = 7.3, 0.7 Hz, 1H), 2.12 (m, J = 7.3 Hz, 1H), 1.06 (t, J = 
7.32 Hz, 3H); 13C-NMR (CDCl3, 100 MHz), "  191.84, 163.88, 131.19, 127.26, 113.92, 55.52, 
48.98, 26.98, 12.20; HRMS (ESI) calc’d for C11H13O2NaBr [M+Na]+ 278.9997, found 278.9996.
 2-Bromo-4’-methoxyvalerophenone (3c).  Following the general procedure for !-
bromination of a ketone from 2c (2.06 g, 10.0 mmol) and CuBr2 (3.95 g, 17.3 mmol) to yield 3c 
as light green oil (2.70 g, 93.2%).  1H-NMR (CDCl3, 500 MHz) " 8.01 (AA’XX’, 2 H), 6.96 
(AA’XX’, 2 H), 5.13 (dd, J=7.81, 6.35 Hz, 1 H), 3.89 (s, 3 H), 2.14 (m, 2 H), 1.56 (m, 1 H), 1.44 
(m, 1 H), 0.99 (t, J=7.45 Hz, 3 H); 13C-NMR (CDCl3, 125 MHz) " 191.89, 163.90, 131.19, 
127.31, 113.95, 77.00, 55.53, 47.00, 35.57, 20.79 , 13.58;  HRMS (ESI) calc’d for C12H16O2Br 
[M+H]+ 271.0334, found 271.0328.
 2-Bromo-4’-methoxyisovalerophenone (3d).  Following the general procedure 
(method B) for !-bromination of  ketones from 2d (1.97, 10.0 mmol) and CuBr2 (3.71 g, 16.7 
mmol) to yield 3d as light yellow-green solid (2.42 g, 89.7%).  1H-NMR (CDCl3, 500 MHz) " 8.00 
(AA'XX', 2 H), 6.97 (AA'XX', 2 H), 4.91 (d, J=8.79 Hz, 1 H), 3.89 (s, 3 H), 2.48 (m, 1 H), 1.22 (d, 
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J=6.65 Hz, 3 H), 1.02 (d, J=6.65 Hz, 3 H); 13C-NMR (CDCl3, 125 MHz) ! 192.19, 163.87, 
131.10, 113.96, 55.74, 55.52, 31.14, 20.80, 20.38; HRMS (ESI) calc’d for C12H15O2NaBr [M+Na]
+ 293.0153, found 293.0163.
 2-(4-Methoxyphenyl)imidazo[1,2-a]pyridine (4a). Method A. Following the general 
procedure for the formation of the imidazo[1,2-a]pyridine core from 2-aminopyridine (1.63 g, 17 
mmol) and 2-bromo-4’-methoxyacetophenone (3.94 g, 17 mmol), 4a was isolated as a yellow-
green solid (2.72 g, 71%).  Method B.  Sodium hydride (60% in a mineral oil dispersion, 48 mg, 
1.2 mmol) was added to a solution of 38 (332 mg, 1 mmol) in anhydrous DMF (3 mL).  A short 
path distillation head was attached and the solution stirred at 90oC for six hours.  The reaction 
products were isolated by concentration by rotary evaporation, re-suspension in DCM and 1M 
KOH (aq), exhaustive extraction with DCM, drying over MgSO4, vacuum filtration, concentration 
by rotary evaporation, and flash chromatography over silica gel (25% hexanes in EtOAc) to yield 
4a as a pale yellow  solid (30.1 mg, 14%).  1H-NMR (CDCl3, 500 MHz) ! 8.03 (dt, J = 6.75, 1.23 
Hz, 1H), 7.86 (AA’XX’, 2H), 7.72 (s, 1H), 7.58 (ddd, J = 9.11, 1.82, 1.07 Hz, 1H), 7.11 (ddd, J = 
9.11, 6.75, 1.29 Hz, 1H), 6.95 (AA’XX’, 2H), 6.70 (td, J = 6.70, 1.18 Hz, 1H), 3.82 (s, 3H); 13C-
NMR (CDCl3, 125 MHz) ! 159.49, 145.66, 145.55, 127.21, 126.45, 125.40, 124.35, 117.20, 
114.05, 112.13, 107.16, 55.22; HRMS (ESI): calc’d for C14H12N2O [M+H]+ 225.1028, found 
225.1035.
 3-Methyl-2-(4-methoxyphenyl)imidazo[1,2-a]pyridine (4b).  Following the general 
procedure for the formation of the imidazo[1,2-a]pyridine core from 2-aminopyridine (282 mg, 3 
mmol) and 3a (609 mg, 2.5 mmol), 4b was isolated as a yellow  solid (168 mg, 28%).  1H-NMR 
(CDCl3, 500 MHz) ! 7.85 (dt, J = 6.86, 1.18 Hz, 1H), 7.72 (AA’XX’, 2H), 7.60 (dt, J = 9.06, 1.05 
Hz, 1H), 7.13 (ddd, J = 9.00, 6.75, 1.18 Hz, 1H), 7.00 (AA’XX’, 2H), 6.80 (td, J = 6.75, 1.07 Hz, 
1H), 3.84 (s, 3H), 2.59 (s, 3H); 13C-NMR (CDCl3, 125 MHz) ! 159.00, 144.22, 142.28, 129.46, 
127.45, 123.23, 122.70, 117.19, 115.12, 113.92, 111.81, 55.24, 9.56; HRMS (ESI): calc’d for 
C15H14N2O [M+H]+ 239.1184, found 239.1189.
 3-Ethyl-2-(4-methoxyphenyl)imidazo[1,2-a]pyridine (4c).  Following the general 
procedure for the formation of  the imidazo[1,2-a]pyridine core from 2-aminopyridine (223.7 mg, 
2.2 mmol) and 3b (513.2 mg, 2 mmol), 4c was isolated as a yellow  solid (300 mg, 60%).  1H-
NMR (CDCl3, 400 MHz) ! 7.93 (dt, J = 6.84, 1.10 Hz, 1H), 7.71 (m, 2H), 7.64 (dt, J = 9.03, 1.10 
Hz, 1H), 7.15 (ddd, J = 9.03, 6.71, 1.34 Hz, 1H), 7.00 (m, 2H), 6.82 (td, J = 6.84, 1.22 Hz, 1H), 
3.84 (s, 3H), 3.07 (q, J = 7.57 Hz, 2H), 1.33 (t, J = 7.57 Hz, 3H); 13C-NMR (CDCl3, 100 MHz) ! 
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159.11, 144.05, 141.39, 129.30, 127.14, 123.61, 122.75, 121.06, 117.31, 113.97, 112.02, 55.26, 
17.02, 12.19.
 2-Amino-5-iodopyridine (5).  2-Aminopyridine (7.58 g, 80 mmol) was added to a 
solution of  periodic acid (3.67 g, 16 mmol), and iodine (3.13 g, 32) stirring in distilled water (16 
mL).  Glacial acetic acid (80 mL) and concentrated sulfuric acid (2.4 mL) were slowly added, 
and the reaction heated to 100oC until 2-amino-3,5-diiodopyridine was observed by TLC (Rf 
0.55, 1:1 hexanes:ethyl acetate), usually within one hour.  The reaction was then quenched with 
sodium thiosulfate, cooled to 0oC, and neutralized with concentrated aqueous potassium 
hydroxide.  The products were then isolated by exhaustive extraction with EtOAc, dried over 
magnesium sulfate, vacuum filtered and concentrated by rotary evaporation.  The products were 
purified by flash chromatography over silica gel (1:1 hexanes:EtOAc) to yield 5 as a beige 
crystalline solid (11.2 g, 63%).  Alternatively, upon neutralization of the quenched reaction 
mixture, the precipitate was vacuum filtered, thoroughly washed with distilled water, dried 
overnight under reduced pressure, and recrystallized from toluene to yield 5 directly.  1H-NMR 
(CDCl3, 400 MHz) ! 8.21 (dd, J = 2.32, 0.73 Hz, 1H), 7.61 (dd, J = 8.67, 2.32 Hz, 1H), 6.34 (dd, 
J = 8.67, 0.73 Hz, 1H), 4.49 (s, 2H); 13C-NMR (CDCl3, 100 MHz), ! 157.23, 153.77, 145.29, 
110.84, 77.89; HRMS (ESI) calcd for C5H4IN2 [M+H]+ 220.9576, found 220.9571.
 2-Amino-5-methoxypyridine (6).  Following the general procedure for Ullmann-type 
alkoxylation of  5 (5.05 g, 22.9 mmol) and distilled MeOH (~25 mL) yielded 6 as a red oil (2.06 g, 
49.8%) after purification by flash chromatography over silica gel (15% IPA in DCM).  This 
product contained 27% 5-H impurity.  1H-NMR (CDCl3, 500 MHz) ! 7.76 (d, J=2.93 Hz, 1 H), 
7.07 (dd, J=8.79, 2.93 Hz, 1 H), 6.47 (m, 1 H), 4.31 (br. s., 1 H), 3.76 (s, 2 H);  13C-NMR (CDCl3, 
125 MHz) ! 149.40, 147.89, 137.67, 125.56, 113.85, 56.23; LRMS (ESI) C6H8N2O [M+H]+ 
found 125.0.
 2-(2,5-dimethyl-pyrrol-1-yl)-5-iodopyridine (7).  Acetonyl acetone (1.8 mL, 16 mmol) 
and 5 (1.77 g, 8 mmol) were added to molecular sieves (4 Å) and p-toluenesulfonic acid (62 mg, 
0.35 mmol) stirring in anhydrous toluene (10 mL).  The reaction was heated to 130°C under 
argon for four hours.  The products were filtered, washed with EtOAc, concentrated by rotary 
evaporation, and subsequently purified by flash chromatography over silica gel (20% EtOAc in 
hexanes) to yield 7 as a yellow  solid (2.06 g, 86%).  1H-NMR (CDCl3, 400 MHz) ! 8.79 (dd, J = 
2.38, 0.67 Hz, 1H), 8.10 (dd, J = 8.30, 2.32 Hz, 1H), 7.02 (dd, J = 8.30, 0.61 Hz, 1H), 5.90 (s, 
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2H), 2.13 (s, 6H); 13C-NMR (CDCl3, 100 MHz) ! 155.37, 151.11, 146.08, 128.51, 123.47, 
107.39, 90.91, 13.20; HRMS (ESI) calc’d for C11H10IN2 [M+H]+ 299.0045, found 299.0058.
 2-(2,5-Dimethyl-pyrrol-1-yl)-5-methoxypyridine (8).  7 (pyrrole protected) (15.02 g, 50 
mmol) and distilled MeOH (~100 mL) were coupled following the general procedure for 
Ullmann-type alkoxylation of  aryl iodides.  The desired product was isolated by dry column 
vacuum chromatography (DCVC, 0-80% EtOAc in hexanes), and purified by recrystalliation 
from hexanes to yield 8 as beige needles (7.94 g, 77.9%).  1H-NMR (CDCl3, 500 MHz) ! 8.29 
(d, J=3.17 Hz, 1 H), 7.34 (dd, J=8.67, 3.05 Hz, 1 H), 7.17 (d, J=8.55 Hz, 1 H), 5.89 (s, 2 H), 3.93 
(s, 3 H), 2.10 (s, 6 H); 13C-NMR (CDCl3, 125 MHz) ! 154.72, 144.94, 136.10, 128.65, 122.56, 
122.38, 106.29, 55.87, 12.91; HRMS (ESI) calc’d for C12H15N2 [M+H]+ 203.1184, found 
203.1183.
 2-Amino-5-methoxypyridine hydrochloride (9).  Hydroxylamine hydrochloride (10.9 g, 
157 mmol), potassium hydroxide (5.9 g, 105 mmol), and 8 (7.68 g, 38.0 mmol) were dissolved in 
EtOH (133 mL) and water (67 mL) and stirred at 110°C for 10 hours behind a weighted blast 
shield.  The reaction was cooled to ambient temperature and the EtOAc removed by rotary 
evaporation.  The mixture was then transferred to a liquid-liquid continuous extractor, the pH 
adjusted to ~8 with a saturated NaHCO3 (aq) solution, and extracted with DCM for 10 hours. 
The organic layer was concentrated by rotary evaporation and the desired product isolated by 
flash chromatography over silica get (25% hexanes in EtOAc followed by 20% IPA in DCM). 
This material was taken up in diethyl ether, cooled to 0°C, and ~100 mL 2M HCl in ether was 
added by cannula transfer with rapid stirring.  The resulting purple precipitate was filtered, 
washed with diethyl ether, and recrystallized from EtOH to yield 9 (4.10 g, 67.2%) as a beige 
solid.  1H-NMR (DMSO-d6, 500 MHz) ! 8.01 (m, 1 H), 7.72 (dd, J=9.52, 2.93 Hz, 1 H), 7.64 (d, 
J=2.69 Hz, 1 H), 7.06 (dd, J=9.52, 0.49 Hz, 1 H), 3.72 (s, 3 H);  13C-NMR (DMSO-d6, 125 MHz) 
! 150.76, 147.10, 136.08, 116.97, 114.73, 56.58.
 6-Methoxy-2-(4-methoxyphenyl)imidazo[1,2-a]pyridine (10a).  Method A.  Following 
the general procedure for the formation of the imidazo[1,2-a]pyridine core from 6 (1.0 g, 8 mmol) 
and 2-bromo-4’-methoxyacetophenone (1.87 g, 8.2 mmol) yielded 10a (1.0 g, 51%) as a red 
solid.  Method B.  Following a modified procedure for the formation of  the imidazo[1,2-a]pyridine 
core, 9 (2.9 g, 18 mmol) and 2-bromo-4’-methoxyacetophenone (5.0 g, 21.8 mmol) were 
dissolved in t-BuOH (100 mL) and Et3N (3 mL) to yield 10a (1.6 g, 35%) as a red solid.  Method 
C.  Following the general procedure for the Ullman-type alkoxylation of aryl iodides from 11 
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(6.49 mg, 18.6 mmol), 1,10-phenanthroline (678.9 mg, 3.7 mmol), copper (I) iodide (381 mg, 1.9 
mmol), Cs2CO3 (12.2 g, 37.2 mmol) to which freshly distilled methanol (~100-150 mL) yielded 
10a (2.49 g, 52.7%) as a brick-red crystalline solid.  1H-NMR (CDCl3, 500 MHz) ! 7.84 (AA'XX', 
2 H), 7.68 (d, J=0.49 Hz, 1 H), 7.59 (dd, J=2.32, 0.61 Hz, 1 H), 7.48 (dt, J=9.77, 0.73 Hz, 1 H), 
6.95 (AA’XX’, 2 H), 3.84 (s, 3 H), 3.79 (s, 3 H); 13C-NMR (CDCl3, 125 MHz) ! 159.32, 149.08, 
145.57, 142.71, 126.94, 126.68, 119.38, 117.35, 114.04, 108.30, 107.36, 56.08, 55.24; HRMS 
(ESI): calc’d for C15H15N2O2 [M+H]+ 255.1164, found 255.1126.
 3-Methyl-6-methoxy-2-(4-methoxyphenyl)imidazo[1,2-a]pyridine  (10b).  Following 
the general procedure for the formation of the imidazo[1,2-a]pyridine core from 6 (450.0 mg, 2.5 
mmol) and 3a (693.3 mg, 2.5 mmol), 10b (256.1 mg, 38.2%) was isolated as a light yellow  solid. 
This product contained ~25% 6-H impurity.  1H-NMR (CDCl3, 500 MHz)  ! 7.71 (AA'XX', 2 H), 
7.53 (dd, J=9.64, 0.61 Hz, 1 H), 7.35 (d, J=1.95 Hz, 1 H),  7.00 (AA'XX', 2 H), 6.97 (dd, J=9.64, 
2.32 Hz, 1 H), 3.87 (s, 3 H), 3.86 (s, 3 H), 2.58 (s, 3 H); 13C (CDCl3, 125 MHz) ! 158.91, 149.15, 
142.31, 141.31, 129.29, 127.52, 118.22, 117.37, 116.15, 113.92, 104.78, 56.24, 55.27, 9.86; 
HRMS (ESI): calc’d for C16H17N2O2 [M+H]+ 269.1290, found 269.1292.
 3-Ethyl-6-methoxy-2-(4-methoxyphenyl)imidazo[1,2-a]pyridine (10c).  Following the 
general procedure for the formation of the imidazo[1,2-a]pyridine core from 6 (723.6 mg, 4.0 
mmol) and 3b (1.30 g, 4.1 mmol), 10c as a yellow-green solid (459.0 mg, 22.5%).  This product 
contains ~50% 6-H impurity.  1H-NMR (CDCl3, 500 MHz) ! 7.70 (AA'XX', 2 H), 7.53 (dd, J=9.77, 
0.49 Hz, 1 H), 7.43 (d, J=1.95 Hz, 1 H), 7.00 (AA'XX', 2 H), 6.97 (dd, J=9.64, 2.32 Hz, 1 H), 3.87 
(s, 3 H), 3.86 (s, 3 H), 3.08 (q, J=7.57, 2 H), 1.36 (t, J=7.57 Hz, 3 H);  13C-NMR (CDCl3, 125 
MHz) ! 158.96, 149.06, 141.96, 141.44, 129.12, 127.69, 122.00, 121.04, 118.14, 117.66, 
113.93, 56.31, 55.26, 17.24, 11.96; HRMS (ESI): calc’d for C17H19N2O2 [M+H]+ 283.1447, found 
283.1449.
 6-Methoxy-2-(4-methoxyphenyl)-3-n-propylimidazo[1,2-a]pyridine (10d).  Following 
a modified version of the general procedure for the formation of  the imidazo[1,2-a]pyridine core, 
9 (520.2 mg, 3.24 mmol) and 3c (1.36 g, 4.9 mmol) were condensed in t-BuOH (6 mL) with 
triethyl amine (450 "L) to yield 10d as a red oil (205.3 mg, 21.4%).  1H-NMR (CDCl3, 500 MHz) 
! 7.70 (AA'XX', 2 H), 7.53 (dd, J=9.77, 0.49 Hz, 1 H), 7.42 (d, J=1.95 Hz, 1 H), 7.00 (AA'XX', 2 
H), 6.97 (dd, J=9.64, 2.32 Hz, 1 H), 3.87 (s, 3 H), 3.86 (s, 3 H), 3.00 (t, J=7.81 Hz, 2 H), 1.76 
(sext., J=8.06 Hz, 2 H), 1.05 (t, J=7.32 Hz, 3 H); 13C-NMR (CDCl3, 125 MHz) ! 158.94, 149.01, 
55
142.38, 141.42, 129.17, 127.72, 120.92, 118.10, 117.60, 113.91, 105.17, 56.34, 55.27, 25.98, 
20.86, 14.15; HRMS (ESI): calc’d for C18H21N2O2 [M+H]+ 297.1603, found 297.1597.
 6-Iodo-2-(4-methoxyphenyl)imidazo[1,2-a]pyridine (11).  Following the general 
procedure for the formation of  the imidazo[1,2-a]pyridine core from 5 (16.55 g, 75.2 mmol) and 
2-bromo-4’-methoxyacetophenone (17.12 g, 74.8 mmol), 11 (15.3g, 58.4%) was isolated as a 
beige crystaline solid after recrystallization (EtOAc/hexanes).  1H-NMR (CDCl3, 500 MHz) ! 8.35 
(dd, J=1.59, 0.85 Hz, 1 H), 7.86 (AA'XX', 2 H), 7.70 (d, J=0.49 Hz, 1 H), 7.41 (m, 1 H), 7.31 (dd, 
J=9.40, 1.59 Hz, 1 H), 6.97 (AA'XX', 2 H), 3.86 (s, 3 H); 13C-NMR (CDCl3, 125 MHz) ! 159.86, 
146.29, 144.14, 132.31, 130.27, 127.40, 125.89, 118.28, 114.22, 106.87, 74.75, 55.32; HRMS 
(ESI) calc’d for C14H12N2OI [M+H]+ 350.9994, found 350.9992.
 6-isopropoxy-2-(4-methoxyphenyl)imidazo[1,2-a]pyridine (12).  Following the 
general procedure for the Ullmann-alkoxylation of aryl iodides from 11 (10.6 g, 30 mmol), CuI 
(1.2 g, 6 mmol), 1,10-phenanthroline (2.2 g, 12 mmol), and Cs2CO3 (19.5 g, 60 mmol), yielded 
crude material that was isolated by flash chromatography over silica gel (50% EtOAc in 
hexanes), and purified by recrystallization (EtOAc/hexanes) to give 12 (4.8 g, 57%) as a fluffy 
white solid.  1H-NMR (CDCl3, 500 MHz) ! 7.82 (AA’XX’, 2 H), 7.63 (s, 1 H), 7.62 (dd, J=2.32, 
0.61 Hz, 1 H), 7.48 (d, J=9.52 Hz, 1 H), 6.93 (AA’XX’, 2 H), 6.90 (d, J=2.20 Hz, 1 H), 4.34 (spt, 
J=6.06 Hz, 1 H), 3.81 (s, 3 H), 1.32 (d, J=6.10 Hz, 6 H); 13C-NMR (CDCl3, 125 mHz) !  159.29, 
146.58, 145.57, 142.75, 126.93, 126.60, 120.56, 117.13, 113.98, 111.30, 107.95, 72.11, 55.15, 
21.77; HRMS (ESI) calc’d for C17H19N2O2 [M+H]+ 283.1447, found 283.1435.
 4-Chloro-pyridine-2-carboxylic acid methyl ester (13).  Thionyl chloride (18 mL, 250 
mmol) was placed in a round bottomed flask charged with argon.  Picolinic acid (6.14 g, 50 
mmol) was then added, followed by the slow  addition of  anhydrous DMF (0.8 mL, 10 mmol). 
The mixture was heated to 70°C and stirred for 44 hours.  The reaction was quenched by the 
slow  addition of anhydrous MeOH (20 mL) and Et3N (5 mL), stirring for thirty minutes, and 
concentration by rotary evaporation.  This process was repeated until the evolution of HCl (g) 
was no longer observed upon addition of  MeOH/Et3N.  The products were purified by flash 
chromatography over silica gel (25% hexanes in EtOAc) to yield 13 as a green-yellow  solid 
(6.02 g, 70%).  1H NMR (CDCl3, 400 MHz) ! 8.63 (dd, J = 5.13, 0.61 Hz, 1H), 8.12 (dd, J = 2.08, 
0.61 Hz, 1H), 7.48 (dd, J = 5.25, 2.08 Hz, 1H), 4.00 (s, 3H); 13C NMR (CDCl3, 100 MHz) ! 
164.56, 150.56, 149.11, 145.34, 127.08, 125.58, 53.16; HRMS (ESI) calc’d for C7H6ClNO2 [M
+H]+ 172.0165, found 172.0168.
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 4-Methoxy-pyridine-2-carboxylic acid methyl ester (14).  Sodium metal (720 mg, 31 
mmol) was added to anhydrous MeOH (30 mL) stirring at 0°C under argon.  The solution was 
allowed to warm to room temperature with continuous stirring until all of the sodium was 
dissolved.  Subsequently, 13 was added.(2.57 g, 15 mmol) and heated to 90°C for 12 hours. 
The solvent was removed by rotary evaporation, and the products isolated by basic aqueous 
extraction with DCM, dried over MgSO4, vacuum filtered, and concentrated by a second rotary 
evaporation to yield 14 as a light-yellow  solid (1.02 g, 41%).  1H NMR (CDCl3, 400 MHz) ! 8.53 
(dd, J = 5.62, 0.49 Hz, 1H), 7.67 (dd, J = 2.69, 0.49 Hz, 1H), 6.97 (dd, J = 5.74, 2.56 Hz, 1H), 
3.99 (s, 3H), 3.91 (s, 3H); 13C NMR (CDCl3, 100 MHz) !  166.47, 165.71, 150.87, 149.49, 
113.08, 111.09, 55.50, 52.96; HRMS (ESI) calc’d for C8H9NO3 [M+H]+ 168.0661, found 
168.0654.
 4-Chloro-2-(2,5-dimethyl-pyrrol-1-yl)-pyridine (15).  A round bottomed flask charged 
with 2-amino-4-chloropyridine(1.1g, 8.4 mmol), acetonyl acetone (2.0 mL, 16.5 mmol), 
molecular sieves (4Å), a catalytic amount of p-tosylic acid, and anhydrous toluene (30mL), was 
heated to reflux for 14 hours.  The reaction mixture was cooled, concentrated by rotary 
evaporation, transferred to a separatory funnel, resuspended in saturated NaHCO3 (aq), and 
exhaustively extracted with EtOAc.  The resulting organic phase was dried over MgSO4, 
vacuum filtered, and concentrated by rotary evaporation.  The product was isolated by flash 
chromatography over silica gel (20% EtOAc in hexanes) to yield 15 as a light yellow-green oil 
(1.50 g, 86.5%).  1H-NMR (CDCl3, 500 MHz) ! 8.52 (d, J=5.37 Hz, 1 H), 7.33 (dd, J=5.37, 1.71 
Hz, 1 H), 7.25 (d, J=1.95 Hz, 1 H), 5.92 (s, 2 H), 2.16 (s, 6 H); 13C-NMR (CDCl3, 125 MHz) ! 
153.10, 149.85, 145.14, 128.59, 122.53, 122.06, 107.47, 13.19; HRMS (ESI): calc’d for 
C11H12ClN2 [M+H]+ 207.0689, found 207.0682.
 2-(2,5-Dimethyl-pyrrol-1-yl)-4-methoxypyridine (16).  Potassium metal (1.13 g, 28.9 
mmol) was carefully added to a round bottomed flask charged with anhydrous MeOH (30 mL) 
stirring at 0°C under argon.  A solution of 15 (1.23 g, 6.0 mmol) dissolved in anhydrous MeOH 
(2mL) was slowly injected into the reaction vessel, followed by the addition of  18-crown-6-ether 
(159.4 mg, 0.6 mmol).  The mixture was heated to 90°C for 14 hours, cooled, and concentrated 
by rotary evaporation.  The crude product was transferred to a separatory funnel, resuspended 
in saturated NaHCO3 (aq), and exhaustively extracted with DCM.  The resulting organic phase 
was dried over MgSO4, vacuum filtered, and concentrated by rotary evaporation.  The product 
was isolated by flash chromatography over silica gel (25% EtOAc in hexanes) to yield 16 as an 
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amber oil (1.3g, 100%).  1H-NMR (CDCl3, 500 MHz) !  8.42 (d, J=5.86 Hz, 1 H), 6.85 (dd, 
J=5.86, 2.44 Hz, 1 H), 6.75 (d, J=2.44 Hz, 1 H), 5.90 (s, 2 H), 3.90 (s, 3 H), 2.15 (s, 6 H); 13C-
NMR (CDCl3, 125 MHz) ! 166.99, 153.54, 150.07, 128.48, 108.84, 108.00 , 106.69, 55.45, 
13.08; HRMS (ESI): calc’d for C12H15N2O [M+H]+ 203.1184, found 203.1184.
 2-Amino-4-methoxypyridine (17).  16 (3.5 g, 17.4 mmol) was placed in a round 
bottomed flask and dissolved in an EtOH (60mL)/H2O (30mL) mixture, to which NH2OH·HCl 
(4.90g, 70.5 mmol) and KOH (2.63 g, 47.0 mmol) were added.  The reaction mixture was 
refluxed for 18 hrs, cooled, and then concentrated by rotary evaporation. The resulting solid was 
resuspended in saturated NaHCO3 (aq), transferred to a liquid-liquid continuous extractor, and 
extracted with DCM for 18 hours.  The organic phase collected and concentrated by rotary 
evaporation.  The product was isolated by flash chromatography over silica gel (20% IPA in 
DCM) to yield 17 as light beige solid (1.6g, 73.1%).  1H-NMR (CDCl3, 500 MHz) !  7.88 (d, 
J=5.86 Hz, 1 H), 6.25 (dd, J=5.86, 2.20 Hz, 1 H), 5.96 (d, J=2.20 Hz, 1 H), 4.51 (br. s., 2 H), 
3.76 (s, 3 H); 13C-NMR (CDCl3, 125 MHz) ! 167.20, 160.14, 149.14, 102.44, 92.31, 54.84; 
HRMS (ESI): calc’d for C6H9N2O [M+H]+ 125.0715, found 125.0721.
 7-Methoxy-2-(4-methoxyphenyl)imidazo[1,2-a]pyridine (18a).  Following the general 
procedure for the formation of  the imidazo[1,2-a]pyridine core from 17 (1.45 g, 11.7 mmol) and 
2-bromo-4’-methoxyacetophenone (2.76 g, 12.0 mmol), 18a was isolated as a white fluffy solid 
(1.88 g, 63.5%).  1H-NMR (CDCl3, 500 MHz) ! 7.86 (dd, J=7.32, 0.73 Hz, 1 H) ,7.84 (AA'XX', 2 
H), 7.58 (d, J=0.49 Hz, 1 H), 6.96 (AA'XX', 2 H), 6.89 (d, J=2.44 Hz, 1 H), 6.46 (dd, J=7.45, 2.56 
Hz, 1 H), 3.84 (s, 3 H), 3.84 (s, 3 H); 13C-NMR (CDCl3, 125 MHz) ! 159.27, 157.69, 146.98, 
145.32, 126.93, 126.64, 125.76  114.00, 107.07, 105.82, 94.56, 55.37, 55.24; HRMS (ESI): 
calc’d for C15H15N2O2 [M+H]+ 255.1134, found 255.1125.
 3-Ethyl-7-methoxy-2-(4-methoxyphenyl)imidazo[1,2-a]pyridine (18b).  Following the 
general procedure for the formation of  imidazo[1,2-a]pyridine core from 17 (185.3 mg, 1.5 mmol) 
and 3b (442.6 mg, 1.65 mmol), to give 18b (237.6 mg, 56.4%).  1H-NMR (CDCl3, 500 MHz) ! 
7.75 (d, J=7.32 Hz, 1 H), 7.70 (AA'XX', 2 H), 6.99 (AA'XX', 2 H), 6.90 (d, J=2.44 Hz, 1 H), 6.53 
(dd, J=7.45, 2.56 Hz, 1 H), 3.85 (s, 6 H), 3.03 (q, J=7.57 Hz, 2 H), 1.32 (t, J=7.57 Hz, 3 H); 13C-
NMR (CDCl3, 125 MHz) ! 158.84, 157.11, 145.49, 140.85, 128.98, 127.70, 123.23, 119.79, 
113.87, 106.70, 94.71, 55.36, 55.23, 16.97, 12.57; HRMS (ESI): calc’d for C17H19N2O2 [M+H]+ 
283.1447, found 283.1448.
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 6-Methoxy-2-(4-methoxyphenyl)imidazo[1,2-a]pyridine-3-carboxyaldehyde (19a). 
Phosphorus oxychloride (2.2 mL, 24 mmol) was injected into a round bottomed flask charged 
with anhydrous DMF (3.5 mL, 44 mmol) stirring at 0 °C under argon.  The mixture was 
subsequently heated to 90°C for one hour, followed by the addition of a solution of 10a (1.0 g, 
4.0 mmol) dissolved in anhydrous DMF, and an additional 2.5 hours of  heating.  The solution 
was cooled to ambient temperature, poured over ice, and neutralized with 3M KOH (aq).  The 
resulting mixture was transferred to a separatory funnel, saturated NaHCO3 (aq) added, and 
exhaustively extracted with DCM.  The organic phase was dried over MgSO4, vacuum filtered, 
and concentrated by rotary evaporation.  The crude material was recrystallized (EtOAc/
hexanes) to give 19a (645.1 mg, 56.7%) as strong dark yellow  needles.  1H-NMR (CDCl3, 500 
MHz) ! 10.02 (s, 1 H), 9.29 (dd, J=1.95, 0.49, 1 H), 7.76 (AA’XX’, 2 H), 7.67 (dd, J=9.77, 0.49 
Hz, 1 H), 7.33 (dd, J=9.52, 2.44 Hz, 1 H), 7.04 (AA’XX’, 2 H), 3.92 (s, 3 H), 3.88 (s, 3 H); 13C-
NMR (CDCl3, 125 MHz) ! 179.41, 160.95, 157.54, 151.07, 144.25, 130.95, 124.85 , 124.66 , 
121.12, 117.03, 114.34, 110.84, 56.38, 55.38; HRMS (ESI): calc’d for C16H15N2O3 [M+H]+ 
283.1083, found 283.1079.
 6-isopropoxy-2-(4-methoxyphenyl)imidazo[1,2-a]pyridine-3-carboxaldehyde (19b). 
Following the same procedure described for 19a from phosphorus oxychloride (1.7 mL, 18 
mmol), anhydrous DMF (2.5 mL, 33 mmol), and a solution of 12 (857 mg, 3 mmol) dissolved in 
anhydrous DMF, 19b (687.7 mg, 73.0%) was isolated as a fluffy white solid after isolation by 
flash chromatography over silica gel (50% EtOAc in hexanes) and purification by 
recrystallization (EtOAc/hexanes).  1H-NMR (CDCl3, 500 MHz) ! 10.02 (s, 1 H), 9.34 (d, J=2.44 
Hz, 1 H), 7.76 (AA'XX', 2 H), 7.68 (d, J=9.77 Hz, 1 H), 7.32 (dd, J=9.52, 2.44 Hz, 1 H), 7.05 
(AA'XX', 2 H), 4.59 (spt, J=6.06 Hz, 1 H), 3.89 (s, 3 H), 1.41 (d, J=6.10 Hz, 6 H); 13C-NMR 
(CDCl3, 125 MHz) ! 179.32, 160.97, 157.54, 149.04, 144.17, 130.97, 125.88, 124.82, 120.93, 
116.98, 114.35, 113.80, 72.26, 55.39, 21.75; HRMS (ESI): calc’d for C18H19N2O2 [M+H]+ 
311.1396, found 311.1382.
 6-Methoxy-2-(4-methoxyphenyl)-3-vinylimidazo[1,2-a]pyridine (20a). To a solution of 
methyl triphenylphosphonium bromide (1.08 g, 3.0 mmol) in anhydrous THF (5 mL) cooled to 
-78 °C, n-BuLi (1.75mL, 1.6M in hexanes, 2.8 mmol) was added, stirred for 10 minutes and then 
allowed to warm to ambient temperature for an additional 30 minutes.  Upon warming the 
solution changed from a white heterogeneous suspension to homogeneous yellow  solution. 
The mixture was re-cooled to -78 °C, and a solution of 19a (285.7 mg, 1.0 mmol) dissolved in 
THF (5 mL) was added.  The reaction mixture was stirred at -78 °C for 20 minutes, allowed to 
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warm to ambient temperature for two hours, re-cooled to 0 °C, and quenched with distilled 
water.    The mixture was transferred to a separatory funnel, saturated NaHCO3 (aq) added, 
added and exhaustively extracted with DCM.  The organic phase was dried over MgSO4, 
vacuum filtered, and concentrated by rotary evaporation.  Crude product was isolated by flash 
chromatography  over silica gel (15% acetone in DCM), and recrystallized (EtOAc/hexanes) to 
yield 20a (239.1 mg, 84.3%) as light green needles.  1H-NMR (CDCl3, 500 MHz) ! 7.90 (d, 
J=2.20 Hz, 1 H), 7.74 (AA'XX', 2 H), 7.55 (dd, J=9.77, 0.49, 1 H), 7.02 (dd, J=9.77, 2.44 Hz, 1 
H), 6.99 (AA'XX', 2 H), 6.93 (dd, J=18.31, 11.96 Hz, 1 H), 5.69 (dd, J=18.07, 0.73 Hz, 1 H), 5.53 
(dd, J=11.96, 0.73 Hz, 1 H), 3.86 (s, 3 H), 3.85 (s, 3 H); HRMS (ESI): calc’d for C17H17N2O2 [M
+H]+ 281.1290, found 281.1287.
 6-Isopropoxy-2-(4-methoxyphenyl)-3-vinylimidazo[1,2-a]pyridine (20b).  Following 
the same procedure for 20a from methyl triphenylphosphonium bromide (1.07g, 3 mmol), n-BuLi 
(1.75mL, 1.6M in hexanes, 2.8 mmol), and 19b (306.5 mg, 1 mmol) the crude product was 
isolated by flash chromatography (50% EtOAc in hexanes) to yield a yellow-green oil, which 
solidified upon standing, but was not amenable to recrystallization.  This material was further 
purified by MPLC using a CombiFlash® instrument (gradient elution, 0-50% EtOAc in hexanes) 
to yield X (178.4 mg, 58.6%) as a light beige solid.  1H-NMR (CDCl3, 500 MHz) ! 8.00 (dd, 
J=2.20, 0.49 Hz, 1 H), 7.74 (AA'XX', 2 H), 7.60 (d, J=9.52 Hz, 1 H), 7.05 (dd, J=9.64, 2.32 Hz, 1 
H), 6.99 (AA'XX', 2 H), 6.92 (dd, J=18.07, 11.96 Hz, 1 H), 5.68 (dd, J=18.07, 0.73 Hz, 1 H), 5.53 
(dd, J=12.09, 0.61 Hz, 1 H), 4.46 (spt, J=6.06 Hz, 1 H), 3.86 (s, 3 H), 1.38 (d, J=6.10 Hz, 6 H); 
13C-NMR (CDCl3, 125 MHz) 159.45, 147.07, 144.70, 142.37, 130.03, 126.76, 124.63, 120.70, 
118.76, 117.44, 114.99, 113.93, 110.81, 72.51, 55.33, 21.94; HRMS (ESI): calc’d for C19H21N2O2 
[M+H]+ 309.1603, found 309.1605.
 3-Chloro-2-(4-methoxyphenyl)imidazo[1,2-a]pyridine (21a).  Following the general 
procedure for the halogentation of  imidazo[1,2-a]pyridines from 4a (453 mg, 2 mmol) and N-
chlorosuccinimide (294 mg, 2.2 mmol), 21a was isolated as a pale yellow  solid (450 mg, 86%). 
1H-NMR (CDCl3, 500 MHz) ! 8.07 (AA’XX’, 2H), 8.06 (dt, J = 6.86, 1.29, 1H), 7.59 (dt, J = 9.06, 
1.04 Hz, 1H), 7.20 (ddd, J = 9.00, 6.86, 1.29 Hz, 1H), 6.99 (AA’XX’, 2H), 6.87 (td, J = 6.86, 1.07 
Hz, 1H), 3.84 (s, 3H); 13C-NMR (CDCl3, 125 MHz) ! 159.59, 143.56, 139.67, 128.71, 125.11, 
124.58, 122.52, 117.34, 112.64, 104.72, 55.23; HRMS (ESI); calc’d for C14H11N2OCl [M+H]+ 
259.0638, found 259.0635.
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 3-Bromo-2-(4-methoxyphenyl)imidazo[1,2-a]pyridine (22a).  Following the general 
procedure for the halogentation of  imidazo[1,2-a]pyridines from 4a (452 mg, 2 mmol) and N-
bromosuccinimide (398 mg, 2.2 mmol), 22a was isolated as a grey solid (523 mg, 86%).  1H -
NMR (CDCl3, 500 MHz) ! 8.13 (dt, J = 6.86, 1.07 Hz, 1H), 8.06 (AA’XX’, 2H), 7.60 (dt, J = 9.22, 
1.07 Hz, 1H), 7.22 (ddd, J = 9.11, 6.75, 1.29 Hz, 1H), 7.00 (AA’XX’, 2H), 6.89 (td, J = 6.81, 1.18 
Hz, 1H), 3.84 (s, 3H); 13C-NMR (CDCl3, 125 MHz) ! 159.67, 145.34, 142.54, 129.13, 125.42, 
124.88, 123.82, 117.35, 113.86, 112.83, 90.85, 55.26; HRMS (ESI): calc’d for C14H11N2OBr [M
+H]+ 303.0133, found 303.0141.
! 3-Iodo-2-(4-methoxyphenyl)imidazo[1,2-a]pyridine (23a).  Following the general 
procedure for the halogentation of  imidazo[1,2-a]pyridines from 4a (455 mg, 2 mmol) and N-
iodosuccinimide (540 mg, 2.4 mmol), 23a was isolated as a yellow-green solid (668 mg, 94%). 
1H-NMR (CDCl3, 500 MHz) ! 8.20 (dt, J = 6.86, 1.07 Hz, 1H), 8.00 (AA’XX’, 2H), 7.58 (dt, J = 
9.00, 1.07 Hz, 1H), 7.23 (ddd, J = 9.00, 6.86, 1.29 Hz, 1H), 7.00 (AA’XX’, 2H), 6.90 (td, J = 6.86, 
1.07 Hz, 1H), 3.24 (s, 3H); 13C NMR (CDCl3, 125 MHz) ! 159.73, 148.06, 129.75, 126.41, 
126.07, 125.38, 117.36, 113.75, 112.98, 105.25, 55.28, 36.36; HRMS (ESI): calc’d for 
C14H11N2OI [M+H]+ 350.9994, found 350.0087.
 3-Chloro-6-methoxy-2-(4-methoxyphenyl)imidazo[1,2-a]pyridine (21b).  Following 
the general procedure for the halogenation of  imidazo[1,2-a]pyridines from 4a (252.0 mg, 1.0 
mmol) and N-chlorosuccinimide (141.6 mg, 1.1 mmol), 21b was isolated as a light purple solid 
(262.1 mg, 91.6%).  1H-NMR (CDCl3, 500 MHz) ! 8.05 (AA'XX', 2 H), 7.56 (d, J=2.44 Hz, 1 H), 
7.50 (dd, J=9.64, 0.61 Hz, 1 H), 7.01 (AA’XX’, 3 H), 3.87 (s, 3 H), 3.86 (s, 3 H); 13C-NMR 
(CDCl3, 125 MHz) ! 159.42, 149.66, 140.61, 139.66, 128.45, 125.36, 119.79, 117.62, 113.88, 
105.44, 104.25, 56.17, 55.26; HRMS (ESI): calc’d for C15H14N2O2Cl [M+H]+ 289.0744, found 
289.0737.
 3-Bromo-6-methoxy-2-(4-methoxyphenyl)imidazo[1,2-a]pyridine (22b).  Following 
the general procedure for the halogenation of  imidazo[1,2-a]pyridines from 4a (127.4 mg, 0.5 
mmol) and N-bromosuccinimide (98.7 mg, 0.55 mmol), 22b was isolated as a while solid (135.6 
mg, 81.2%).  1H-NMR (CDCl3, 500 MHz) ! 8.05 (AA'XX', 2 H), 7.65 (dd, J=2.36, 0.43 Hz, 1 H), 
7.51 (dd, J=9.65, 0.86 Hz, 1 H), 7.02 (AA’XX’, 3 H), 3.89 (s, 3 H), 3.87 (s, 3 H); 13C-NMR 
(CDCl3, 125 MHz) ! 159.50, 149.79, 142.47, 142.36, 128.89, 125.64, 120.05, 117.62, 113.82, 
105.65, 91.68, 56.20, 55.27; HRMS (ESI): calc’d for C15H14N2O2Br [M+H]+ 333.0234, found 
333.0248.
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 3-Iodo-6-methoxy-2-(4-methoxyphenyl)imidazo[1,2-a]pyridine (23b).  Method A. 
Following the general procedure for the halogenation of  imidazo[1,2-a]pyridines from 10a (502.6 
mg, 2.0 mmol) and N-iodosuccinimide (507.9 mg, 2.3 mmol), 23b was isolated as a while solid 
(710.0 mg, 94.5%).  Method 2.  Potassium hydroxide (695 mg, 12 mmol) and acetonitrile (30 
mL) were placed in a round bottomed flask and sonicated until the KOH pellets were partially 
solubilized.  4a (1.53 g, 6 mmol) and iodine (1.68g, 6.6 mmol) were then added and stirred at 
ambient temperature.  Small portions of additional iodine were added every 10 minutes until the 
reaction was complete by TLC (15% acetone in DCM).  The reaction mixture was poured into a 
solution of saturated sodium thiosulfate, transferred to a separatory funnel, and exhaustively 
extracted with DCM.  The organic phase was dried over MgSO4, vacuum filtered, and 
concentrated by rotary evaporation.  The crude product was isolated by flash chromatography 
over silica gel (15% acetone in DCM), and purified by recrystallization (EtOAc/hexanes) to yield 
23b (1.70 g, 74.3%) as a beige fluffy crystalline solid.  1H-NMR (CDCl3, 500 MHz) ! 7.99 (m, 2 
H), 7.73 (d, J=2.44 Hz, 1 H), 7.51 (dd, J=9.64, 0.61 Hz, 1 H), 7.03 (m, 2 H), 3.91 (s, 3 H), 3.88 
(s, 3 H); 13C-NMR (CDl3, 125 MHz) ! , 159.56, 149.86, 147.55, 144.82, 129.51, 126.05, 120.47, 
117.45, 113.69, 108.51, 59.83, 56.23, 55.25; HRMS (ESI): calc’d for C15H14N2O2I [M+H]+ 
381.0100, found 381.0097.
 3-Chloror-6-isopropoxy-2-(4-methoxyphenyl)imidazo[1,2-a]pyridine (21c). 
Following the general procedure for the halogenation of imidazo[1,2-a]pyridines from 12 (568 
mg, 2.0 mmol) and N-chlorosuccinimide (272 mg, 2.0 mmol), 21c (420 mg, 65.8%) was isolated 
as lavender crystals after recrystallization (EtOAc/hexanes).  1H-NMR (CDCl3, 500MHz) ! 8.06 
(AA'XX', 2 H), 7.65 (dd, J=2.20, 0.49 Hz, 1 H), 7.55 (dd, J=9.64, 0.61 Hz, 1 H), 7.02 (AA’XX’, 2 
H), 4.51 (spt, J=6.06 Hz, 1 H), 3.87 (s, 2 H), 1.40 (d, J=6.10 Hz, 4 H); 13C-NMR (CDCl3, 125 
MHz) ! ppm 159.83, 147.70, 140.84, 139.87, 128.83, 125.39, 121.37, 117.74, 114.23, 108.29, 
105.43, 72.56, 55.53, 22.10; HRMS (ESI): calc’d for C17H18N2O2Cl [M+H]+ 317.1057, found 
317.1057.
 3-Bromo-6-isopropoxy-2-(4-methoxyphenyl)imidazo[1,2-a]pyridine (22c).  Following 
the general procedure for the halogenation of imidazo[1,2-a]pyridines from 12 (565 mg, 2.0 
mmol) and N-bromosuccinimide (361 mg, 2.0 mmol) freshly recrystallized from acetic acid, 22c 
(480 mg, 66.4%) was isolated as a fluffy white solid after recrystallization (EtOAc/hexanes).  1H-
NMR (CDCl3, 500MHz) ! 8.05 (AA'XX', 2 H), 7.73 (d, J=1.95 Hz, 1 H), 7.55 (d, J=9.77 Hz, 1 H), 
7.05 (dd, J=9.64, 2.32 Hz, 1 H), 7.01 (AA'XX', 2 H), 4.51 (spt, J=6.02 Hz, 1 H), 3.87 (s, 2 H), 
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1.40 (d, J=6.10 Hz, 4 H); 13C-NMR (CDCl3, 125MHz) ! 159.63, 147.52, 142.40, 142.28, 128.98, 
125.39, 121.31, 117.43, 113.89, 109.53, 91.35, 72.35, 55.28, 21.86; HRMS (ESI): calc’d for 
C17H18N2O2Br [M+H]+ 361.0552, found 361.0552.
 3-Iodo-6-isopropoxy-2-(4-methoxyphenyl)imidazo[1,2-a]pyridine (23c).  Method A. 
Following the general procedure for the halogenation of imidazo[1,2-a]pyridines from 12 (2.80 g, 
9.92 mmol) and N-iodosuccinimide (2.54 g, 11.2 mmol), 23c (2.340 g, 57.7%) was isolated as a 
yellow-brown solid after recrystallization (EtOAc/Hexanes).  Method B.  Potassium hydroxide 
(1.0 g, 17.7 mmol) and acetonitrile (100 mL) were placed in a round bottomed flask and 
sonicated until the KOH pellets were partially solubilized.  12 (2.54g, 9.0 mmol) and iodine 
(2.59g, 10.2mmol) were then added and stirred at room temperature.  Small portions of 
additional iodine were added every 30 minutes until the reaction was complete by TLC (50% 
EtOAc in hexanes).  The reaction mixture was poured into a solution of  saturated sodium 
thiosulfate, transferred to a separatory funnel, and exhaustively extracted with EtOAc.  The 
organic phase was dried over MgSO4, vacuum filtered, and concentrated by rotary evaporation. 
The crude product was passed through a silica plug with a 1:1 mixture of  EtOAc in hexanes, 
and further isolated by MPLC using a CombiFlash® instrument (gradient elution, 25-75% EtOAc 
in hexanes).  This isolated material was further purified by recrystallization (EtOAc/hexanes) to 
yield 23c (2.33 g, 63.3%) as light pink crystals.  1H-NMR (CDCl3, 500MHz) ! 7.99 (AA’XX’, 2 H), 
7.81 (d, J=1.95 Hz, 1 H), 7.54 (d, J=9.52 Hz, 1 H), 7.06 (dd, J=9.77, 2.20 Hz, 1 H), 7.02 (AA'XX', 
1 H), 4.52 (spt, J=6.02, 1 H), 3.87 (s, 3 H), 1.41 (d, J=6.10 Hz, 6 H); 13C-NMR (CDCl3, 125 MHz) 
! 159.71, 147.68, 147.60, 144.91, 132.30, 129.63, 126.00, 121.67, 117.39, 113.79, 112.53, 
72.45, 21.88; HRMS (ESI): calc’d for C17H18IN2O3 [M+H]+ 409.0413, found 409.0399.
 3-Chloro-7-methoxy-2-(4-methoxyphenyl)imidazo[1,2-a]pyridine (21d).  Following 
the general method for the halogenation of  imidazo[1,2-a]pyridines from 18a (205.4, 0.8 mmol) 
and N-chlorosuccinimide (116.2 mg, 0.9 mmol), 21d was isolated as a light purple solid (180.3 
mg, 77.4%).  1H-NMR (CDCl3, 500 MHz) ! 8.06 (AA'XX', 2 H), 7.91 (dd, J=7.40, 0.54 Hz, 1 H), 
7.01 (AA'XX', 2 H), 6.89 (d, J=2.36 Hz, 1 H), 6.63 (dd, J=7.50, 2.57 Hz, 1 H), 3.88 (s, 3 H), 3.87 
(s, 3 H); 13C-NMR (CDCl3, 125 MHz) ! 159.40, 158.00, 153.03, 144.98, 138.95, 128.42 , 
125.33, 123.01, 113.89, 107.70, 94.70, 55.58, 55.26.
 3-Bromo-7-methoxy-2-(4-methoxyphenyl)imidazo[1,2-a]pyridine (22d).  Following 
the general method for the halogenation of  imidazo[1,2-a]pyridines from 18a (148.8, 0.6 mmol) 
and N-bromosuccinimide (121.1 mg, 0.7 mmol), 22d was isolated as an off-white solid (114.6 
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mg, 58.8%).  1H-NMR (CDCl3, 500 MHz) ! 8.06 (AA'XX', 2 H), 7.97 (dd, J=7.57, 0.49 Hz, 1 H), 
7.01 (AA'XX', 2 H), 6.92 (d, J=2.44 Hz, 1 H), 6.63 (dd, J=7.57, 2.44 Hz, 1 H), 3.88 (s, 3 H), 3.87 
(s, 3 H); 13C-NMR (CDCl3, 125 MHz) ! 159.48, 158.20, 146.59, 141.94, 128.83, 125.58 , 
124.24 , 113.82, 107.79, 94.71, 88.92, 55.62, 55.28; HRMS (ESI): calc’d for C15H14N2O2Br [M
+H]+ 333.0239, found 333.0237.
 3-Iodo-7-methoxy-2-(4-methoxyphenyl)imidazo[1,2-a]pyridine (23d).  Following the 
general method for the halogenation of  imidazo[1,2-a]pyridines from 18a (383.1 mg, 1.5 mmol) 
and N-iodosuccinimide (345.2 mg, 1.5 mmol), 23d was isolated as a yellow  crystalline solid 
(307.4 mg, 53.7%) after recrystallization (EtOAc/hexanes).  1H-NMR (CDCl3, 500 MHz) ! 8.01 
(AA’XX’, 2 H) 7.01 (AA'XX', 2 H), 6.90 (d, J=2.57 Hz, 1 H), 6.63 (dd, J=7.50, 2.36 Hz, 1 H), 3.88 
(s, 3 H), 3.87 (s, 3 H); 13C-NMR (CDCl3, 125 MHz) ! 159.72, 158.73, 149.03, 147.66, 129.52, 
128.54, 126.75, 126.22, 113.80, 107.84, 94.88, 55.69, 55.30; HRMS (ESI): calc’d for 
C15H14N2O2I [M+H]+ 381.0100, found 381.0101.
 3-Cyano-6-methoxy-2-(4-methoxyphenyl)imidazo[1,2-a]pyridine (24).  To a pear 
shaped round bottomed flask 23b (1.14 g, 3 mmol), dppf  (334.8 mg, 0.6 mmol), Pd2dba3 (157.7 
mg, 0.3 mmol), zinc dust (46.6 mg, 0.72 mmol), and zinc(II) cyanide (258.0 mg, 2.2 mmol) were 
added.  The flask was evacuated and backfilled with argon (x3), dimethylacetamide (DMA, 12 
mL) was injected, and the mixture was heated with rapid stirring to 130 °C for three hours. 
Upon cooling, the reaction mixture was transferred to a separatory funnel, suspended in 
saturated NaHCO3 (aq), and exhaustively extracted with DCM.  The resulting organic phase 
was dried over MgSO4, vacuum filtered, and concentrated by rotary evaporation.  The crude 
product was isolated by flash chromatography over silica gel (10% acetone in DCM) and further 
purified recrystallized (EtOAc/hexanes) following a hot filtration to yield 24 (475.6 mg, 56.8%) as 
fluffy light yellow  crystalline solid.  1H-NMR (CDCl3, 500 MHz) ! 8.10 (m, 2 H), 7.79 (d, J=2.36 
Hz, 1 H), 7.60 (d, J=9.86 Hz, 1 H), 7.19 (dd, J=9.65, 2.36 Hz, 1 H), 7.01 (m, 2 H), 3.89 (s, 3 H), 
3.87 (s, 3 H); 13C-NMR (CDCl3, 125 MHz) ! 160.87, 152.72, 150.70, 143.52, 128.43, 123.92, 
123.56, 117.88, 114.27, 113.36, 107.28, 93.80, 56.40, 55.34; HRMS (ESI): calc’d for 
C16H14N3O2I [M+H]+ 280.1088, found 280.1088.
 6-Methoxy-2-(4-methoxyphenyl)-3-phenylimidazo[1,2-a]pyridine (25a).  Following 
the general procedure for SM coupling of aryl iodides from 23b (195.0 mg, 0.5 mmol), 
phenylboronic acid (133.5 mg, 1.0 mmol), Pd(dppf)·CH2Cl2 (39.1 mg, 0.05 mmol), Cs2CO3 
(500.1 mg, 1.5 mmol), and anhydrous THF (1.0 mL) the desired product was isolated by flash 
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chromatography over silica gel (20% acetone in DCM) to yield 25a (150.4 mg, 88.8%) as off-
white needles after recrystallization (DCM/hexanes).  1H-NMR (CDCl3, 500 MHz) ! 7.56 (m, 5 
H), 7.48 (m, 4 H), 7.01 (dd, J=9.52, 2.44 Hz, 1 H), 6.82 (AA'XX', 2 H), 3.80 (s, 3 H), 3.72 (s, 3 
H); 13C-NMR (CDCl3, 125 MHz) ! 159.00, 149.23, 142.28, 141.77, 130.58, 130.18, 129.59, 
129.07, 128.79, 126.72, 121.15, 119.54, 117.45, 113.68, 105.17, 56.20, 55.17; HRMS (ESI): 
calc’d for C21H19N2O2I [M+H]+ 331.1447, found 331.1446.
 6-Isopropoxy-2-(4-methoxyphenyl)-3-phenylimidazo[1,2-a]pyridine (25b).  Following 
the general procedure for SM coupling of aryl iodides from 23c (304.4mg, 0.75 mmol), 
phenylboronic acid (187.6 mg, 1.5 mmol), Pd(dppf)·CH2Cl2 (62.0 mg, 0.075 mmol), Cs2CO3 
(758 mg, 2.3 mmol), and anhydrous THF (2mL), the desired product was isolated by flash 
chromatography over silica gel (50% EtOAc in hexanes) to yield 25b (208.1 mg, 77.9%) as a 
beige solid after recrystallization (EtOAc/hexanes).  1H-NMR (CDCl3, 500 MHz) ! 7.63 (d, 
J=9.52 Hz, 1 H), 7.57 (AA'XX', 2 H), 7.50 (m, 6 H), 7.04 (dd, J=9.64, 2.32 Hz, 1 H), 4.33 (spt, 
J=6.06 Hz, 1 H), 3.80 (s, 3 H), 1.30 (d, J=6.10 Hz, 6 H); 13C-NMR (CDCl3, 125 MHz) ! 159.09, 
146.81, 142.08, 141.70, 130.60, 129.94, 129.55, 129.18, 129.11, 128.83, 126.39, 120.78, 
117.17, 113.72, 109.56, 72.35, 55.13, 21.79; HRMS (ESI): calc’d for C23H23N2O2 [M+H]+ 
359.1760, found 359.1760.
 3-Cyclopropyl-6-methoxy-2-(4-methoxyphenyl)imidazo[1,2-a]pyridine (26a). 
Following a modification of the general procedure for SM coupling of  aryl iodides from 23b 
(381.2 mg, 1.0 mmol), cyclopropylboronic acid (172.0 mg, 2.0 mmol), Pd(dppf)·CH2Cl2 (84.9 mg, 
0.01 mmol), and Cs2CO3 (996.5 mg, 3.0 mmol), a second equivalent of boronic acid was added 
after 30 minutes.  The desired product was isolated by flash chromatography over silica gel 
(20% acetone in DCM) to yield 26a (241.1 mg, 82.0%) as a brick red solid.  This material could 
be further purified by dissolving in THF and adding conc. HCl dropwise.  The resulting 
precipitate was filtered, washed with additional THF, dried, and redissolved in DCM.  This 
solution was transferred to separatory funnel to which saturated NaHCO3 (aq) was added and 
extracted with DCM.  The organic layer was dried over MgSO4, vacuum filtered, and 
concentrated by rotary evaporation.  The obtained solid was recrystallized (DCM/hexanes) to 
yield purple rhomboidal crystals.  1H-NMR (CDCl3, 500 MHz) ! 7.90 (AA'XX', 2 H), 7.78 (dd, J= 
1.71, 0.73 Hz, 1 H), 7.52 (dd, J= 9.77, 0.73 Hz, 1 H), 7.00 (dd, J=7.32, 2.44 Hz, 1H), 6.99 
(AA'XX', 2 H), 3.89 (s, 3 H), 3.86 (s, 3 H); 13C-NMR (CDCl3, 125 MHz) ! 158.97, 148.92, 143.17, 
140.88, 129.53, 126.98, 120.87, 118.73, 117.21, 113.49, 105.90, 56.28, 55.23, 7.67, 4.30; 
HRMS (ESI): calc’d for C18H19N2O2 [M+H]+ 295.1447, found 295.1445.
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 3-Cyclopropyl-6-isopropoxy-2-(4-methoxyphenyl)imidazo[1,2-a]pyridine (26b). 
Following  a modification of the general procedure for SM coupling of  aryl iodides from 23c 
(609.9 mg, 1.5 mmol), cyclopropylboronic acid (253.3mg, 3.0 mmol), Pd(dppf)·CHCl2 (119.2 mg, 
0.15 mmol), and Cs2CO3 (1.47 g, 4.5 mmol), a second equivalent of boronic acid was added 
after 30 minutes.  The desired product was isolated by flash chromatography over silica gel 
(gradient elution, 50%-75% EtOAc in hexanes) to yield 26b (299.4 mg, 62.2%) as a brown 
crystalline solid after recrystallization (EtOAc/hexanes).  1H-NMR (CDCl3, 500 MHz) ! 7.91 
(AA'XX', 2 H), 7.88 (d, J=2.44 Hz, 1 H), 7.55 (d, J=9.52 Hz, 1 H), 7.02 (dd, J=9.64, 2.32 Hz, 1 
H), 6.99 (AA'XX', 2 H), 4.49 (spt, J=6.10 Hz, 1 H), 3.87 (s, 2 H), 1.97 (tt, J=7.97, 5.22 Hz, 1 H), 
1.40 (d, J=5.86 Hz, 4 H), 1.16 (m, 1 H), 0.52 (m, 1 H); 13C-NMR (CDCl3, 125 MHz) ! 159.01, 
146.39, 143.14, 140.93, 129.58, 126.76, 120.54, 120.10, 117.02, 113.51, 110.27, 72.46, 55.24, 
22.90, 7.69, 4.25; HRMS (ESI): calc’d for C20H23N2O2 [M+H]+ 323.1760, found 323.1750.
 6-Methoxy-2-(4-methoxyphenyl)-3-trifluoromethylimidazo[1,2-a]pyridine (27a).  10a 
(568.3 mg, 2.2 mmol) and 5-(trifluoromethyl)dibenzothiophenium trifluoromethanesulfonate 
(750.9 mg, 1.9 mmol) were suspended in anhydrous THF yielding a heterogenous orange 
solution and stirred at ambient temperature for 45 minutes.  The reaction mixture was 
subsequently heated to 60°C for three hours, whereby the solution became homogeneous upon 
heating.  The reaction was allowed to cool, transferred to a separatory funnel, suspended in 
saturated NaHCO3 (aq), and exhaustively extracted with DCM.  The resulting organic phase 
was dried over MgSO4, vacuum filtered, and concentrated by rotary evaporation.  The desired 
product was isolated by flash chromatography over silica gel (5% acetone in DCM) to yield 27a 
(183.8 mg, 30.6%) as an amber solid.  1H-NMR (CDCl3, 500 MHz) ! 7.78 (d, J=2.2 Hz, 1H), 
7.62 (AA'XX', 2H), 7.60 (d, J=10 Hz, 2H), 7.16 (dd, J=9.6, 2.3 Hz, 1H), 6.98 (AA'XX', 2H), 3.88 
(s, 3H), 3.87 (s, 3H); 13C-NMR (CDCl3, 125 MHz) ! 160.16, 150.06, 147.26, 142.78, 130.73, 
125.06, 123.02, 122.15, 120.89, 117.77, 113.64, 107.49, 56.29, 55.28; 19F-NMR (CDCl3, 470 
MHz) ! -58.40; HRMS (ESI): calc’d for C16H14N2O2F3 [M+H]+ 323.1007, found 323.1002.
 6-methoxy-2-(4-methoxyphenyl)-3-trifluoromethyl[1,2-a]pyridine (27b).  Following 
t h e s a m e p r o c e d u r e a s f o r 2 8 a f r o m X ( 2 5 3 . 1 m g , 1 m m o l ) a n d 5 -
(trifluoromethyl)dibenzothiophenium trifluoromethanesulfonate (411.2 mg, 1 mmol), and THF 
(2mL), the desired product was isolated by flash chromatography over silica gel (10% acetone 
in DCM) to yield 27b (131.0 mg, 40.8%) as a light red solid.  1H-NMR (CDCl3, 500 MHz) ! 8.10 
(d, J=7.72 Hz, 1 H), 7.64 (AA'XX', 2 H), 6.99 (m, 3 H), 6.69 (dd, J=7.50, 2.57 Hz, 1 H), 3.91 (s, 4 
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H), 3.87 (s, 3 H);  13C-NMR (CDCl3, 500 MHz) ! 160.35, 159.40, 147.79, 147.62, 130.78, 
125.85, 125.13 , 123.20, 121.07, 113.73, 108.77, 95.08, 55.73 , 55.31.
 4-Imidazo[1,2-a]pyridine-2-ylphenol (28a).  Following the general procedure for the 
cleavage of  aryl-alkyl ethers from 4a (457 mg, 2 mmol), 28a was isolated as a brown solid (216 
mg, 50%).  1H-NMR (DMSO-d6, 500 MHz) ! 9.57 (s, 1H), 8.46 (dt, J = 6.71, 1.16 Hz), 8.19 (s, 
1H), 7.76 (AA’XX’, 2H), 7.51 (dd, J = 9.03, 0.49 Hz, 1H), 7.18 (ddd, J = 9.03, 6.84, 1.22, 1H), 
6.83 (td, J = 6.59, 1.22 Hz), 6.82 (AA’XX’, 2H); 13C-NMR (DMSO-d6, 125 MHz) ! 157.27, 
144.90, 144.65, 126.95, 126.60, 124.94, 116.29, 115.47, 111.92, 107.54; HRMS (ESI): calc’d for 
C13H10N2O [M+H]+ 211.0871, found 211.0869.
 4-(3-Chloroimidazo[1,2-a]pyridine-2-yl)phenol (28d).  Following the general 
procedure for the cleavage of aryl-alkyl ethers from 21a (322 mg, 1.25 mmol), 28d was isolated 
as a fine grey powder (316 mg, 104%).  1H-NMR (DMSO-d6, 500 MHz) ! 9.77 (s, 1H), 8.34 (dt, 
J = 6.86, 0.96 Hz, 1H), 7.90 (AA’XX’, 2H), 7.63 (dt, J = 9.11, 0.91 Hz, 1H), 7.37 (ddd, J = 9.00, 
6.86, 1.29 Hz, 1H), 7.08 (td, J = 6.86, 1.07 Hz, 1H), 6.89 (AA’XX’, 2H); 13C-NMR (DMSO-d6, 125 
MHz) ! 157.76, 142.75, 138.61, 128.42, 125.72, 123.37, 122.80, 116.53, 114.52, 113.38, 
103.55.  HRMS (ESI): calc’d for C13H9N2OCl [M+H]+ 245.0482, found 245.0476.
 4-(3-Bromoimidazo[1,2-a]pyridine-2-yl)phenol (28e).  Following the general 
procedure for the cleavage of  aryl-alkyl ethers from 22a (382 mg, 1.25 mmol), 28e  was isolated 
as a grey powder (273 mg, 75%).  1H-NMR (DMSO-d6, 500 MHz) ! 9.74 (s, 1H), 8.34 (d, J = 
6.43 Hz, 1H), 7.92 (AA’XX’, 2H), 7.62 (d, J = 8.58 Hz, 1H), 7.35 (t, J = 7.50 Hz, 1H), 7.06 (t, J = 
6.54 Hz, 1H), 6.89 (AA’XX’, 2H); 13C-NMR (DMSO-d6, 125 MHz) ! 157.74, 128.77, 125.64, 
124.46, 123.51, 116.70, 115.41, 113.41, 109.35; HRMS (ESI): calc’d for C13H9N2OBr [M+H]+ 
288.9976, found 288.9976.
 4-(3-Iodoimidazo[1,2-a]pyridine-2-yl)phenol (28f).  Following the general procedure 
for the cleavage of aryl-alkyl ethers from 23a (206 mg, 0.57 mmol), 28f was obtained and further 
purified by flash chromatography over silica gel (25% hexanes in EtOAc) to yield a white 
crystaline powder (94.8 mg, 48%).  1H-NMR (DMSO-d6, 500 MHz) ! 9.69 (s, 1H), 8.37 (dt, J = 
6.86, 0.96 Hz, 1H), 7.88 (AA’XX’, 2H), 7.37(dt, J = 8.95, 0.99 Hz, 1H), 7.32 (ddd, J = 8.95, 6.81, 
1.18 Hz, 1H), 7.03 (td, J = 6.81, 1.18 Hz, 1H), 6.87 (AA’XX’, 2H); 13C-NMR (DMSO-d6, 125 
MHz) ! 157.58, 147.18, 146.97, 129.35, 126.87, 125.68, 124.55, 116.63, 115.17, 113.27, 48.62; 
HRMS (ESI): calcd for C13H9N2OI [M+H]+ 336.9838, found 336.9835.
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 4-(3-Methylimidazo[1,2-a]pyridin-2-yl)phenol (28b).  Following the general procedure 
for the cleavage of  aryl-alkyl ethers from 4b (116 mg, 0.53 mmol ), 28b was isolated as a light 
brown solid (115 mg, 106%).  1H-NMR (DMSO-d6, 500 MHz) ! 9.60 (s, 1H), 8.28 (d, J = 6.43 
Hz, 1H), 7.61 (AA’XX’, 2H), 7.53 (d, J = 8.79 Hz, 1H), 7.21 (t, J = 7.61 Hz, 1H), 6.92 (t, J = 6.75 
Hz, 1H), 6.87 (AA’XX’, 2H), 2.58 (s, 3H); 13C-NMR (DMSO-d6, 125 MHz) ! 156.91, 129.15, 
124.25, 123.73, 116.10, 115.42, 111.81, 9.41.  HRMS (ESI) calc’d for C14H12N2O [M+H]+ 
225.1028, found 225.1024.
 4-(3-Ethylimidazo[1,2-a]pyridine-2-yl)phenol (28c).  Following the general procedure 
for the cleavage of aryl-alkyl ethers from 4c (252 mg, 1.2 mmol) 28c was isolated as a beige 
solid (197 mg, 69.6%).  1H-NMR (DMSO-d6, 500 MHz) !  9.61 (s, 1H), 8.39 (d, J = 6.65 Hz, 1H), 
7.58 (m, 2H), 7.55 (AA’XX’, 1H), 7.25 (ddd, J = 8.79, 6.86, 0.64 Hz, 1H), 6.94 (t, J = 6.75 Hz, 
1H), 6.87 (AA’XX’, 2H), 3.07 (q, J = 7.43 Hz, 2H), 1.24 (t, J = 7.50, 3H); 13C-NMR (DMSO-d6, 
125 MHz) ! 157.02, 142.87, 140.15, 128.92, 125.06, 124.24, 120.81, 116.11, 115.46, 112.12, 
59.76, 16.38, 12.19; HRMS (ESI): calc’d for C15H14N2O [M+H]+ 239.1184, found 239.1188.
 2-(4-hydroxyphenyl)imidazo[1,2-a]pyridin-6-ol (29a).  Following the general 
procedure for the cleavage of aryl-alkyl ethers from 10a (254.2 mg, 1.0 mmol) and BF3·SMe2 
(4.2 mL, 40 mmol), the desired product was isolated by flash chromatography over silica gel 
(20% IPA in DCM) to give 29a as a purple solid (212.9 mg, 94.1%).  1H NMR (DMSO-d6, 400 
MHz) ! 9.50 (s, 2H), 8.07 (s, 1H), 7.92 (dd, J = 2.20, 0.73 Hz, 1H), 7.70 (m, 2H), 7.38 (d, J = 
9.52 Hz, 1H), 6.90 (dd, J = 9.52, 2.20 Hz, 1H), 6.80 (m, 2H); 13C NMR (DMSO-d6, 100 MHz) ! 
156.98, 145.39, 144.65, 141.69, 126.62, 125.36, 119.38, 116.36, 115.42, 109.89, 107.90; HRMS 
(ESI): calcd for C13H10N2O2 [M + H]+ 227.0821, found 227.0830.
 2-(4-Hydroxyphenyl)-3-methylimidazo[1,2-a]pyridin-6-ol (29b).  Following the general 
procedure for the cleavage of aryl-alkyl ethers from 10b (256.8 mg, 0.72 mmol) and BF3·SMe2 
(6.0 mL, 57 mmol), the desired product was isolated by flash chromatography over silica gel 
(10% MeOH in DCM) to give 29b as brown solid (49.8 mg, 30.9%).  1H-NMR (CD3OD, 500 
MHz) !  7.85 (d, J=1.71 Hz, 1 H), 7.59 (d, J=9.52 Hz, 1 H), 7.49 (AA'XX', 2 H), 7.41 (dd, J=9.52, 
2.20 Hz 1 H), 6.94 (AA’XX’, 2 H), 4.96 (br. s., 2 H) 2.56 (s, 3 H); 13C-NMR (CD3OD, 125 MHz) ! 
160.08, 150.29, 137.89, 136.73, 131.06, 125.55, 121.56, 118.84, 117.12, 113.90, 110.57, 9.15; 
HRMS (ESI): calc’d for C14H13N2O2 [M+H]+ 241.0977, found 241.0971.
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 3-Ethyl-2-(4-hydroxyphenyl)imidazo[1,2-a]pyridin-6-ol (29c).  Following the general 
procedure for the cleavage of aryl-alkyl ethers from 10c (518.2 mg, 1.8 mmol) and BF3·SMe2 
(8.0 mL, 76 mmol), the desired product was isolated by flash chromatography over silica gel 
(10% MeOH in DCM) to give 29c as brown solid (193.3 mg, 82.9%).  1H-NMR (CD3OD, 500 
MHz) ! 7.87 (d, J=17.82 Hz, 1 H), 7.53 (d, J=9.77 Hz, 1 H), 7.48 (AA'XX', 2 H), 7.30 (dd, 
J=9.52, 2.20 Hz, 1 H), 6.93 (AA'XX', 2 H), 4.95 (br. s., 2 H), 3.04 (q, J=7.57 Hz, 2 H), 1.32 (t, 
J=7.57 Hz, 3 H); 13C-NMR (CD3OD, 125 MHz) ! 159.72, 149.66, 139.20, 130.83, 124.33, 
123.86, 123.14, 116.99, 115.02, 109.96, 79.59, 17.55, 12.11; HRMS (ESI): calc’d for C15H15N2O2 
[M+H]+ 255.1134, found 255.1130.
 2-(4-Hydroxyphenyl)-3-n-propylimidazo{1,2-a]pyridin-6-ol (29d).  Following the 
general procedure for the cleavage of aryl-alkyl ethers from 10d (197.9 mg, 0.67 mmol) and 
BF3·SMe2 (5.0 mL, 48 mmol), the desired product was isolated by flash chromatography over 
silica gel (10% MeOH in DCM) to give 29d as green-yellow  solid (166.8 mg, 90.1%).  1H-NMR 
(CD3OD, 500 MHz)  ! 8.06 (dd, J=2.20, 0.73 Hz, 1 H), 7.73 (dd, J=9.77, 0.73 Hz, 1 H), 7.60 (dd, 
J=9.64, 2.08 Hz, 1 H), 7.50 (AA'XX', 2 H), 6.99 (AA'XX', 2 H), 4.89 (s, 2 H), 3.06 (t, J=7.81 Hz, 2 
H), 1.76 (sxt, J=7.57 Hz, 2 H), 1.02 (t, J=7.45 Hz, 2 H); 13C-NMR (CD3OD, 125 MHz) ! 160.87, 
151.25, 136.32, 134.42, 131.21, 127.69, 123.62, 119.34, 117.45, 113.08, 111.41, 25.51, 21.45, 
14.16; HRMS (ESI): calc’d for C16H17N2O2 [M+H]+ 269.1290, found 269.1299.
 3-Cyclopropyl-2-(4-hydroxyphenyl)imidazo[1,2-a]pyridin-6-ol (29e).  Following the 
general procedure for the cleavage of aryl-alkyl ethers from 26b (159.8 mg, 0.5 mmol) and 
BF3·SMe2 (1.05 mL 10 mmol), the desired product was purified by MPLC using a CombiFlash® 
instrument (gradient elution, 0-20% IPA in DCM) to yield 29e (37.4 mg, 28.3%) as a brown solid. 
1H-NMR (DMSO-d6, 500 MHz) ! 9.54 (s, 1 H), 9.48 (s, 1 H), 7.87 (dd, J=2.20, 0.73 Hz, 1 H), 
7.73 (AA'XX', 2 H), 7.40 (dd, J=9.52, 0.73 Hz, 1 H), 6.95 (dd, J=9.52, 2.20 Hz, 1 H), 6.82 
(AA'XX', 2 H), 2.02 (tt, J=7.84, 5.22 Hz, 1 H), 1.13 (m, 2 H), 0.34 (m, 2 H); 13C-NMR (DMSO-d6, 
125 MHz) ! 156.55, 145.22, 142.43, 139.82, 129.07, 125.60, 119.48, 118.79, 116.43 , 114.81, 
107.60, 7.61, 4.12; HRMS (ESI): calc’d for C16H15N2O2 [M+H]+ 267.1143, found 267.1135.
 3-Chloro-2-(4-hydroxyphenyl)imidazo[1,2-a]pyridin-6-ol (29f).  Following the general 
procedure for the cleavage of aryl-alkyl ethers from 21b (288 mg, 1.0 mmol) and BF3·SMe2 (8.5 
mL 80 mmol), the crude product was obtained as an oil and was triturated from hexanes to give 
29f (229.6 mg, 88.0%) as a grey solid.  1H-NMR (CD3OD, 500 MHz) ! 8.07 (dd, J=2.14, 0.64 
Hz, 1 H), 7.79 (dd, J=9.65, 0.64 Hz, 1 H), 7.73 (AA'XX', 2 H), 7.68 (dd, J=9.65, 2.14 Hz, 1 H), 
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6.97 (AA'XX', 2 H), 4.95 (br. s., 2 H); 13C-NMR (CD3OD, 500 MHz) ! 161.51, 152.07, 135.93, 
133.37, 130.55, 128.92, 117.41, 117.30, 113.48, 110.51, 109.47, 49.15; HRMS (ESI): calc’d for 
C13H10N2O2Cl [M+H]+ 261.0431, found 261.0422.
 3-Bromo-2-(4-hydroxyphenyl)imidazo[1,2-a]pyridin-6-ol (29g).  Following the general 
procedure for the cleavage of aryl-alkyl ethers from 22b (103.2 mg, 0.31 mmol) and BF3·SMe2 
(1.3 mL, 12.4 mmol), the desired product was isolated by flash chromatography over silica gel 
(15% IPA in DCM) to yield 29g (25.4 mg, 26.9%) as dark brown solid.  1H-NMR (CD3OD, 500 
MHz) ! 7.88 (m, 1 H) 7.67 (AA'XX', 2 H), 7.37 (d, J=9.52 Hz, 1 H), 7.03 (dd, J=9.64, 2.32 Hz, 1 
H), 6.83 (AA'XX', 2 H), 4.96 (br. s., 2 H); 13C-NMR (CD3OD, 125 MHz) ! 158.93, 148.09, 146.08, 
143.30, 128.41, 126.03, 122.10, 116.69, 116.50, 111.69, 109.56; HRMS (ESI): calc’d for 
C13H10N2O2Br [M+H]+ 304.9926, found 304.9918.
 2-(4-Hydroxyphenyl)-3-iodoimidazo[1,2-a]pyridin-6-ol (29h).  Following the general 
procedure for the cleavage of aryl-alkyl ethers from 23b (193.7 mg, 0.5 mmol) and BF3·SMe2 
(2.1 mL, 20 mmol), the desired product was isolated by flash chromatography over silica gel 
(15% IPA in DCM) to yield 29h (76.9 mg, 42.9%) as a purple glassy solid.  1H-NMR (CD3OD, 
500 MHz) ! 7.40 (m, 1 H), 6.98 (AA’XX’, 2 H), 6.90 (d, J=9.52 Hz, 1 H), 6.71 (dd, J=9.64, 2.08 
Hz, 1 H), 6.23 (AA’XX’, 2 H), 4.39 (br. s., 2 H); 13C-NMR (CD3OD, 125 MHz) !  160.30, 150.08, 
141.01, 139.42, 128.65, 125.87, 121.30, 117.11, 114.06, 113.11, 110.32; HRMS (ESI): calc’d for 
C13H10N2O2I [M+H]+ 352.9787, found 352.9795.
 2-(4-Hydroxyphenyl)-3-phenylimidazo[1,2-a]pyridin-6-ol (29i).  Following the general 
procedure for the cleavage of aryl-alkyl ethers from 25b (92.2 mg, 0.26 mmol) and BF3·SMe2 
(0.53 mL 5 mmol).  The crude material was purified by purified by MPLC using a CombiFlash® 
instrument (gradient elution, 0-20% IPA in DCM) to yield 29i (47.8 mg, 61.5%) as light brown 
solid.  1H-NMR (DMSO-d6, 500 MHz) ! 9.45 (s, 1 H), 9.44 (s, 1 H), 7.58 (m, 2 H), 7.49 (m, 5 H), 
7.36 (AA'XX', 2 H), 6.97 (dd, J=9.64, 2.32 Hz, 1 H), 6.65 (AA'XX', 2 H); 13C-NMR (DMSO-d6, 
125 MHz) ! 156.72, 145.75, 141.55, 140.71, 130.53, 130.15, 129.57, 128.71, 128.48, 125.31, 
119.67, 119.49, 116.81, 115.01, 106.34; HRMS (ESI): calc’d for C19H15N2O2 [M+H]+ 303.1134, 
found 303.1128.
 3-Cyano-2-(4-hydroxyphenyl)imidazo[1,2-a]pyridin-6-ol (29j).  24 (286.3 mg, 1.0 
mmol) was placed in a pear shaped round bottomed flask followed by enough pyridine·HCl to 
completely cover the starting material.  The solid mixture was then heated to 220 °C resulting in 
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the formation of a melt which was stirred for two hours.  The reaction mixture solidified upon 
cooling, and was resuspended in distilled water with sonication.  The solution was transferred to 
a separatory funnel and exhaustively extracted with EtOAc.  The organic phase was dried over 
MgSO4, vacuum filtered, and concentrated by rotary evacuation.  The desired product was 
isolated by flash chromatography over silica gel (100% EtOAc) to yield 29j (92.6 mg, 36.0%) as 
light beige solid.  1H-NMR (DMSO-d6, 500 MHz) ! 10.20 (s, 1 H), 9.96 (s, 1 H), 7.93 (dd, J=2.14, 
0.64 Hz, 1 H), 7.89 (AA'XX', 2 H), 7.67 (d, J=9.65 Hz, 1 H), 7.27 (dd, J=9.54, 2.25 Hz, 1 H), 6.92 
(AA'XX', 2 H); 13C-NMR (DMSO-d6, 125 MHz) ! 158.95, 151.77, 147.83, 142.85, 128.05, 
123.80, 122.47, 117.52, 115.84, 113.48, 109.97, 91.80; HRMS (ESI): calc’d for C14H10N3O2 [M
+H]+ 252.0773, found 252.0771.
 2-(4-Hydroxyphenyl)-3-trifluoromethylimidazo[1,2-a]pyridin-6-ol (29k).  27a (183.8 
mg, 0.57 mmol) was redissolved in anhydrous DCM (4 mL), transfered to a round bottomed 
flask, and cooled to 0°C in an ice bath under an atmosphere of  argon.  BBr3 (3.0 mL of  1.0 M 
solution) was added slowly, and the reaction was allowed to warm to ambient temperature with 
stirring overnight.  The reaction mixture was re-cooled to 0°C, quenched with MeOH (10 mL), 
and concentrated by streaming N2.  The resulting solid was transfered to a separatory funnel, to 
which distilled water and saturated NaHCO3 (aq.) was added and exhaustively extracted with 
EtOAc.  The organic layer was dried over MgSO4, vacuum filtered, and concentrated by rotary 
evaporation.  The desired product was isolated by flash chromatography over silica gel (25% 
hexanes in EtOAc) to yield 29k (27.3 mg, 16.2%) as an orange solid.  1H-NMR (DMSO-d6, 500 
MHz) ! 10.04 (s, 1 H), 9.74 (s, 1 H), 7.90 (dd, J=1.39, 0.75 Hz, 1 H), 7.65 (d, J=9.86 Hz, 1 H), 
7.42 (m, 2 H), 7.24 (dd, J=9.65, 2.14 Hz, 1 H), 6.85 (m, 2 H); 13C-NMR (DMSO-d6, 125 MHz) ! 
158.02, 147.20, 142.33, 130.47, 123.65, 123.24, 122.53, 121.11, 117.60, 114.99, 109.07; HRMS 
(ESI): calc’d for C14H10N2O2F3 [M+H]+ 295.0694, found 295.0688.
 2-(4-hydroxyphenyl)imidazo[1,2-a]pyrdin-7-ol (30a).  Following the general procedure 
for the cleavage of aryl-alkyl ethers from 18a (95.8 mg, 0.38 mmol) and BF3·SMe2 (3.2 mL, 30.4 
mmol), 30a (79.3 mg, 93.0%) was isolated as light beige.  1H-NMR (CD3OD, 500 MHz) ! 8.39 
(d, J=7.32 Hz, 1 H), 7.96 (s, 1 H), 7.53 (AA'XX', 2 H), 6.90 (dd, J=7.32, 2.44 Hz, 1 H), 6.86 (m, 3 
H), 5.00 (br. s., 2 H); 13C-NMR (CD3OD, 125 MHz) ! , 164.98, 160.70, 144.61, 136.95, 131.10, 
128.48 , 119.17, 117.29, 112.32, 108.91, 94.07; HRMS (ESI): calc’d for C13H11N2O2 [M+H]+ 
227.0821, found 227.0810.
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 3-Ethyl-2-(4-hydroxyphenyl)imidazo[1,2-a]pyrin-7-ol (30b).  Following the general 
procedure for the cleavage of aryl-alkyl ethers from 18b (237.6 mg, 0.84 mmol) and BF3·SMe2 
(7.0 mL, 80 mmol), to yield 30b (56.7 mg, 26.5%).  1H-NMR (CD3OD, 500 MHz) ! 8.52 (d, 
J=7.32 Hz, 1 H), 7.47 (AA'XX', 2 H), 7.05 (dd, J=7.32, 2.20 Hz, 1 H), 6.97 (AA’XX’, 2 H), 6.96 
(m, 1 H), 4.94 (br. s., 2 H) ,3.07 (q, J=7.57 Hz, 2 H), 1.35 (t, J=7.57 Hz, 3 H).
 3-Benzyloxypyridine (31).  To a round bottomed flask charged with NaH (250.9 mg, 6 
mmol, 60% by wt. in mineral oil) stirring in anhydrous DMF (10 mL) and cooled to 0°C under 
argon, 3-hydroxypyridine (578.4 mg, 6 mmol) was added and stirred for 15 minutes.  Benzyl 
bromide (0.6 mL, 5 mmol) was slowly injected and the reaction was allowed to warm to ambient 
temperature and proceed overnight (~20 hrs).  The reaction mixture was transferred to a 
separatory funnel, distilled water added, and exhaustively extracted with EtOAc.  The organic 
layer was dried over MgSO4, vacuum filtered, and concentrated by rotary evaporation.  The 
desired product was purified by flash chromatography over silica gel (25% hexanes in EtOAc) to 
yield 31 (212.1 mg, 22.7%) as a yellow  oil.  1H-NMR (CDCl3, 400 MHz ) ! 8.41 (dd, J=2.81, 0.61 
Hz, 1 H), 8.24 (dd, J=4.39, 1.46 Hz, 1 H), 7.41 (m, 5 H), 7.24 (m, 2 H), 5.12 (s, 1 H).
 5-benzyloxy-N-t-butylpyridin-2-amine (32).  To a round bottomed flask charged with 
31 (400 mg, 2.2 mmol) dissolved in DCM, m-CPBA (497 mg, 2.2 mmol, 77% max. by wt.) was 
added and stirred overnight.  The solvent was removed by rotary evaporation and dried under 
reduced pressure.  The crude material was dissolved in anhydrous toluene (10 mL) to which 
TsCl (839 mg, 4.3 mmol) was added, cooled to 0°C, stirred or 15 minutes, and followed by the 
addition of t-butyl amine (2.4 mL, 22 mmol).  The reaction was allowed to proceed for 4 hours, 
transferred to a separatory funnel, saturated NaHCO3 (aq) was added, and exhaustively 
extracted with DCM.  The organic layer was dried over MgSO4, vacuum filtered, and 
concentrated by rotary evaporation.  The desired product was purified by flash chromatography 
over silica gel (25% EtOAc in hexanes) to yield 32 (201.1 mg, 36.3%) as a green oil.  1H-NMR 
(CDCl3, ) ! 7.72 (dd, J=5.1, 1.5 Hz, 1H), 7.41 (m, 4H), 7.36 (m, 1H), 6.85 (dd, J=7.7, 1.5 Hz, 
1H), 6.44 (dd, J=7.7, 1.5 Hz, 1H), 5.05 (s, 2H), 4.94 (s, 1H), 1.49 (s, 9H).
 5-methoxy-N-t-butylpyridin-2-amine (33).  A round bottomed flask was charged with 4-
methoxypyridine-N-oxide monohydrate (2.00 g, 16 mmol), t-butyl amine (8.4 mL, 80 mmol), and 
anhydrous toluene (140 mL).  The reaction flask was cooled to 0°C and TsCl (6.11 g, 32 mmol) 
was added in slowly in small portions over 5 minutes.  The reaction was stirred maintaining 0°C 
for 4 hours, quenched with distilled water, transferred to a separatory funnel, and exhaustively 
extracted with DCM.  The organic layer was dried over MgSO4, vacuum filtered and 
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concentrated by rotary evaporation.  The desired product was purified by flash chromatography 
over silica gel (25% EtOAc in hexanes) to yield 34 (2.78 g, 96.4%) as an orange oil.  1H-NMR 
(CDCl3, 500 MHz) ! 7.91 (d, J=6 Hz, 1H), 6.16 (dd, J=5.9, 2.3 Hz, 1H), 5.95 (d, J=2.1 Hz, 1H), 
3.76 (s, 3H), 1.41 (s, 9H); 13C-NMR (CDCl3, 125 MHz) ! 166.61, 159.92, 149.27, 129.43, 
126.96, 100.32, 92.59, 54.78, 50.56, 30.11, 29.50.
 2-Bromo-1-(4-methoxyphenyl)-ethanone O-methyloxime (34).  2-Bromo-4’-
methoxyacetophenone (921 mg, 4 mmol), methoxyamine hydrochloride (515 mg, 6 mmol), and 
sodium carbonate (635 mg, 6 mmol) were dissolved in MeOH (10 mL) and stirred at room 
temperature for two hours.  The reaction mixture was transferred to a separatory funnel, distill 
water added, and exhaustively extracted with DCM.  The organic layer was dried over MgSO4, 
vacuum filtered, and concentrated by rotary evaporation.  The desired product was purified by 
flash chromatography over silica gel to yield 34 (741 mg, 71%) as a light yellow  oil.  1H-NMR 
(CDCl3, 500 MHz) !  7.65 (AA’XX’, 2H), 6.91 (AA’XX’, 2H), 4.33 (s, 2H), 4.06 (s, 3H), 3.83 (s, 
3H); 13C-NMR (CDCl3, 100 MHz) !  160.77, 152.19, 127.39, 125.83, 114.02, 62.61, 55.31, 18.06; 
HRMS (ESI): calc’d for C10H12BrNO2 [M+H]+ 258.0130, found 258.0117. 
 1-[2-Methoxyimino-2-(4-methoxyphenyl)-ethyl]-pyridinium  bromide (35).  34 (550 
mg, 2.1 mmol) was reacted with neat pyridine (1 mL) and stirred at ambient temperature for one 
hour.  The excess pyridine was removed by concentration under reduced pressure to yield 35 
(674 mg, 94%) as a white solid.  1H-NMR (DMSO-d6, 500 MHz) ! 8.99 (dd, J = 6.47, 1.10 Hz, 
2H), 8.58 (tt, J = 7.81, 1.34 Hz, 1H), 8.11 (m, 2H), 7.68 (m, 2H), 6.96 (m, 2H), 6.01 (s, 2H), 3.94 
(s, 3H), 3.76 (s, 3H); 13C-NMR (DMSO-d6, 125 MHz) ! 160.84, 150.24, 146.27, 145.12, 128.34, 
128.28, 124.13, 114.32, 62.60, 55.36, 54.18; HRMS (ESI) calc’d for C15H17N2O2 [M-Br]+ 
257.1290, found 257.1289. 
MOLECULAR MODELING
Ligand Docking.
 The structures for ER" (accession code: 2QGW) and ER# (accession code: 1U9E) were 
obtained from the PDB databank and prepared using the Molecular Operating Environment 
(MOE).  Any excess chains were removed to yield the monomeric structure, to which explicit 
hydrogens were added, followed by minimization to a termination gradient of 0.5 using 
MMFF94x charges.  The coactivator peptide, ligand, and all waters were deleted, with the 
exception of the single water molecule involved in the hydrogen bonding network within the 
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binding pocket.  The resulting structure was further processed using AutoDock Tools (ADT) to 
compute Gasteiger charges and assign AD4 atom types.
 All docked compounds were constructed in MOE and minimized to a termination 
gradient of 0.5 using MMFF94x charges.  The ligands were prepared for docking using 
AutoDock Tools to assign AD4 atom types, calculate Gasteiger charges, and set all rotatable 
bonds as active torsions.  Each ligand was docked into the receptor using AutoDock Vina 
(ADV).  The grid box was centered on the crystal structure ligand, and measured 20 Å by 20 Å 
by 20 Å.  The exhaustiveness parameter was set to 100 (default=8, linear scale); all other 
default settings were used.
 The top ten poses for each ligand were visually inspected in MOE.  Unreasonable poses 
were discarded, and the lowest energy conformation for each unique pose was selected for 
further use.  The receptor structure and each selected pose were merged into a single file, all 
hydrogens were explicitly added, MMFF94x partial charges added, and the protein-ligand 
complex was minimized.  This minimization was conducted in four stages: stage 1 minimized 
the hydrogen atoms that were added to the structure in the previous step; stage 2 minimized the 
ligand; stage 3 minimized any residues within 4.5 Å of the ligand; and stage 4 minimized both 
the ligand and any residues within 4.5 Å.  The raw  docking output, receptor-ligand complex prior 
to the multistage minimization (denoted “merged structure”), and the minimized structure 
(denoted as “worked-up structure”) were used in subsequent calculations and analyses.
Docking Rescore
 The raw  docking output file for each selected pose was re-scored using FRED.  The 
prepared structure was used as the receptor input, and the following scoring algorithms were 
used: plp, chemgauss2, chemgauss3, shapegauss, oechemscore, screenscore, zapbind, and 
consensus.
Interaction and Binding Energies
 Each of the merged and worked-up structures was opened in MOE and the total energy of 
the receptor-ligand complex was calculated (ERL).  The ligand was deleted from the structure 
and the receptor energy was calculated (ER).  The pocket residues (within 4.5A of the ligand) 
and associated water molecule were minimized to a termination gradient of 0.01, and the 
minimized receptor energy was calculated (ERmin).  The worked up structure was reloaded, the 
receptor was deleted, and the ligand energy was calculated (EL).  Using these values, the 
minimized ligand energy (ELmin) was calculated following a minimization of the ligand to a 
termination gradient of 0.01.  The interaction and binding energies were calculated from 
equations (1) and (2), respectively.
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 Einteraction = ERL - (ER + EL) (2.1)
 Ebinding = ERL - (ERmin + ELmin) (2.2)
Hydrogen Bonding Score
 The merged and worked-up structures for each selected pose was opened in MOE and the 
hydrogen bonds formed between the ligand and protein were scored using the 
“dock_HydrogenBonds” module found in the standard scientific vector language (SVL) library for 
MOE. This module forms the basis for the “ligand interactions” feature accessible from MOE’s 
graphical user interface. The mean score was subsequently calculated as the geometric mean 
of the individual scores.
Protonation Energetics
 Relative Basicity, E(PT).  The neutral species for each compound was constructed in 
Spartan’08 and minimized using the toolbar minimization function.  The optimal geometry in the 
gas phase was calculated at the Hartree-Fock level of theory using the 6-31G* basis set. 
Setting the calculation to start from the MMFF geometry reduced the number of failed 
optimization calculations; however, was not necessary in all cases.  The single point energy was 
subsequently calculated at the DFT level of theory using B3LYP functionals and the 6-311+G** 
basis set, starting from the current geometry.  The protonated species of each compound was 
generated by modifying N1 to adopt a square-planar geometry using the inorganic toolkit and 
adjusting the adjacent carbon bonds as necessary.  The geometry optimization and single point 
energy calculations were performed as previously described, noting that the charge must be 
adjusted to +1.  The relative basicity was calculated relative to imidazole from equation (3)
 E(PT) = (Ecompound-H+ + Eimidazole) - (Ecompound + Eimidazole-H+) (2.3)
 Proton Affinity, P(A).  The neutral and protonated species for each compound were 
constructed in MOE, minimized to a termination gradient of  0.01, and saved as pdb files.  The 
atoms and atom coordinates were extracted using Open Babel conversion to the text format, 
and used to generate a GAMESS input file for calculating the optimized geometry in the gas 
phase at the Restricted Hartree-Fock level of theory using the 6-31G* basis set.  The atom 
coordinates were parsed from the geometry optimization output file and used to generate a new 
GAMESS input file to calculate a single point energy at the DFT level of theory using B3LYP 
functionals and the 6-311+G** basis set.  Finally, the total energy and zero point energy were 
parsed from the output file, and used to calculate the P(A) for each compound from equation 
(4).
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 P(A) = -(EH+ - Eneutral) - (ZPEH+ - ZPEneutral) + (5/2)RT (2.4)
Calculation of Electrostatic Potential, HOMO and LUMO, and Dipole Moment.
 The vector or surface for each metric was taken from the single point energy calculated in 
Spartan ’08, as described in section V (B, C, D).  The dipole moment is projected onto the 
structure, originating on the center of mass.  The electrostatic potential is projected onto a fixed 
electron density isosurface at 0.002 au.  The HOMO and LUMO are shown at the 0.032 au 
surface.
pKa Prediction
 Each compound was drawn separately in the Marvin Sketch editor, and the pKa predicted 
using the pKa module accessible from the “Tools/Protonation” menu.  The optimal pH for 
obtaining the maximal concentration of  the neutral species was taken from the distribution chart 
option, available from the “pKa options” window.
Dipole Moment of ER! Ligand Binding Pocket.
 The structure for ER! (PDB accession code: 1UE9) was opened in MOE and all hydrogens 
were explicitly added.  All residues containing an atom within 4.5 Å of the ligand were extracted 
from the structure.  Any disrupted peptide linkages were capped as amides, and the protonation 
state of each side chain was checked (i.e. Glu305 = -1, Arg346 = +1).  The resulting structure 
was loaded in Spartan’08, and the gas phase single point energy calculation conducted at the 
MMFF and semi-empirical level of theory based on the current geometry.  In the latter case, the 
calculation was performed using the AM1 and PM3 methods.
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CHAPTER 3
MODIFYING KNOWN ESTROGEN RECEPTOR LIGANDS FOR
NOVEL ANTI-INFLAMMATORY ACTIVITY
I. Introduction
 A relatively new  area in ER research involves controlling crosstalk between ERs and NF-
!B.  NF-!B is itself a transcription factor that when inactive is bound by I!B in the cytoplasm, 
masking a nuclear localization sequence.  Upon activation by cytokines and other cellular 
stress, I!B is degraded, followed by translocation of  NF-!B to the nucleus where it stimulates an 
inflammatory response, including the recruitment of macrophages which are known to promote 
aggressive tumor growth, metastasis, and resistance towards chemotherapeutics. It has 
recently been found that ER agonists suppress NF-!B inflammatory pathways, although the 
specific interactions involved in this regulation are unknown.1,2 This receptor crosstalk 
represents an opportunity to develop a new  class of  breast cancer therapeutics that act as 
antagonists on classical ER transcriptional pathways but retain agonistic activity associated with 
the suppression of NF-!B.
 To date, only a few  ligands exhibit this highly desired pharmacological profile: the 
indazole WAY-169916 first published by Wyeth in 2004,3,4 and a unique oxabicycloheptene 
(OBH) scaffold more recently discovered in our labs in collaboration with Kendall Nettles, of the 
Scripps Research Institute, Florida.5,6  In crystal structures of ER bound to ligands exhibiting a 
more standard pharmacology, His524 in the binding pocket serves as a hydrogen bond acceptor 
that is responsible for increased ligand affinities for both agonists and traditional antagonists. 
Careful analysis of crystal structures for both WAY-169916 and OBHS, however, indicates that 
His524 is significantly displaced from the binding pocket.6-8 Recent MD simulations have 
identified His524 as the keystone in a hydrogen bonding network responsible for stabilizing the 
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Figure 3.1. Compounds WAY-169916, developed by Wyeth, and OBHS, developed in our labs, show 
minimal activation of classical ER transcriptional pathways but retain agonist-like activity in ER-modulated 
suppression of NF-!B.
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WAY-169916 Oxabicycloheptene Sulfonate (OBHS)
ends of  helices 3 and 11,9 which are essential to positioning helix 12 in the agonist 
conformation.  The RMSD profiles of several ligands when compared to an E2-bound receptor 
highlight the broader effects of displacing His524 (Fig. 3.2). All compounds that exhibit the 
desired pharmacological profile have an RMSD >0.5 Å at position 524 while the control 
compounds are all below  0.25 Å. Our working hypothesis is that the displacement of His524 
destabilizes the end of helix 11, specifically residues 525-532, with OBHS (red) being the most 
striking example (compared to genistein [blue]).  Overlaying several crystal structures of ER-
bound OBH ligands shows that a large displacement of His524 causes two turns of helix 11 to 
unravel, giving the large increase in RMSD.  Furthermore, this increasing degree of  His524 
displacement is well correlated to the desired pharmacology within the OBH and WAY ligand 
series.6
 Efforts are currently underway in our labs and with collaborators to probe the SAR of the 
OBH scaffolds; however, synthetic access to these structures is non-trivial.  Accordingly, we 
have also set out to design a series of  ligands based on known ER scaffolds with established 
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Figure 3.2. Panel A.  The extended phenyl 
sulfonate of OBHS displaces His524 (magenta) 
from the binding pocket, causing two turns of 
helix 11 to unwind (red cylinder).  Compare to 
the genestein-bound structure (blue).  Panel B. 
Changing the size of the extended substituent 
of the OBH scaffold modulates the position of 
His524, and correlates to activity.  Panel  C. 
Ligand effects on the positioning of His524 and 
overa l l receptor s t ruc ture were a lso 
characterized by calculating the RMSD of each 
C! atom in a series of ligand-bound ER! 
structures relative to the estradiol bound 
receptor structure.  All  active compounds give 
values >0.4 for His524, while the values for 
control structures are <0.15.
His524
His524
Glu353
Arg394
synthetic routes to serve as functional analogs of OBHS and generate an expanded SAR. 
These efforts are founded on the information gleaned from the crystal structures described 
above, in which we plan to modify the established ER pharmacophores by placing an extended 
substituent towards the D-ring end of  the binding pocket.  Herein, we describe the design, 
synthesis, and preliminary biological analysis of  such ligands through iterative in silico design 
supported by synthetic chemistry and biological testing.
II. Structure-Based Design
 Several classes of ligands were designed to bind ERs in a similar mode to that observed 
for OBHS.  These ligands were based on the core scaffolds of known ER ligands, and are 
shown in Figure 3.3.10-14  To determine the most appropriate substitution patterns, multiple 
ligands of each structure were utilized, modifying substitution position and linking atom between 
the scaffold core and extended substituent.  All proposed ligands were constructed and 
minimized using the Molecular Operating Environment (MOE),15 prepared using AutoDock Tools 
(ADT),16 and docked into ER! binding volume established by OBHS using AutoDock Vina 
(ADV).17  The lowest energy poses were selected using ADV’s internal scoring algorithm, 
merged back into the receptor structure, and minimized in Sybyl.18  Each ligand-receptor pair 
was visually analyzed with particular attention to steric constraints, matched hydrogen bonding 
pairs, and lipophilicity profile.  The most promising substitution patterns, shown in Figure 3.4, 
were further pursued via synthetic methods.  Ligands based on triarylethylenes and 
benzothiophenes were pursued by Dr. Terry More, Dr. Markéta Lebl-Rinnová, and Davis 
Oldham in our labs, while the modification of steroidal scaffolds is described herein.
III. Chemistry
A. Synthesis of 16!-benzyl-17!-estradiol
 Following conditions reported in the literature,19 estrone (E1) was condensed with 
benzaldehyde to give aldol product 1 (Scheme 3.1).  The ketone at the 17-position was reduced 
with sodium borohydride in THF to yield the 17"-hydroxyl (2), followed by palladium-catalyzed 
hydrogenation of the exocyclic double bond under elevated pressure (30 psi) of hydrogen gas in 
a Parr-shaker to furnish 16"-benzyl-17"-estradiol (3).  Both reductions proceeded 
stereoselectively under substrate control without any detection of alternate stereoisomers.
B. Reductive Amination of Estrone
 The phenol of  E1 was protected as the methyl ether from sodium hydride, methyl iodide, 
and DMF to yield 4 (Scheme 3.2).  This intermediate was reacted with aniline in formic acid at 
160 °C overnight via the Leukart-Wallach reaction to give the reductive amination products 5 
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Figure 3.3.  The scaffolds of three known ER ligands were redesigned to bear substituents that extend 
towards the D-ring end of the binding pocket in order to displace His524.  The steroidal  scaffold is based 
on a known modification of estradiol  that increases affinity and selectivity for ER!.  The latter two 
structures designed herein, but synthesized by others, are based on raloxifene and tamoxifen scaffolds 
used in hormone replacement therapy and the treatment of breast cancers, respectively.
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and 6,20 which were separable by standard chromatographic methods.  The N-formyl group of  5 
was subsequently reduced with sodium borohydride in THF to yield the corresponding N-methyl 
product (8).  6 and 8 were deprotected by methyl ether cleavage under Lewis acidic conditions 
using boron tribromide in DCM to yield 7 and 9.
IV. Biological Assay
 The relative binding affinities (RBA) of all deprotected compounds were determined by 
radiometric competitive binding assay, using 17!-[3H]estradiol as the tracer.21,22  This assay was 
performed by Kathryn Carlson, and the resulting data for both ER" and ER! are given in Tables 
3.1 and 3.2 as a percentage relative to estradiol (E2=100%).  These RBA values can be easily 
converted to IC50 or Ki values, as described elsewhere.23,24  All compounds with the exception of 
the benzothiophenes were carried into cell-based assays by our collaborator Kendall Nettles.  In 
these preliminary single point assays, ERE activity was established using a luciferase reporter 
gene construct in HepG2 cells, and anti-inflammatory activity was determined by measuring IL-6 
protein levels (by ELISA) in MCF7 cells treated with TNF" (Table 3.3).
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Scheme 3.1. Synthesis of 16!-benzyl-17!-Estradiol
O
HO
O
Ph
OH
Ph
a b c
a) benzaldehyde, NaOH, EtOH.  b) NaBH4, EtOH/THF.  c) Pd/C, H2 (30 psi), EtOH/THF
OH
Ph
1, 74% 2, 91% 3, 79%
Scheme 3.2. Reductive Amination of Estrone
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a) MeI, NaH, DMF.  b) aniline, formic acid, reflux.  c) BBr3, DCM.  d) NaBH4, THF.
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8, 77%. 9, 73%
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E1
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compound Scaffold Ar ER! ER" "/!
10aa I Ph 0.004 0.005 1
10ba I 4-PhF 0.004 0.005 1
10ca I 3-PhMe 0.007 0.009 1
11ab II Ph 3.68 1.04 0.283
11bb II 3-PhF 4.17 2.75 0.659
11cb II 4-PhF 1.51 0.387 0.256
12aa III R1 = Et R2 = H Ar = H 50.6 21.1 0.417
12ba III Et H 4-PhF 110 18.4 0.17
12ca III Et H 3-PhMe 89.4 29.1 0.326
12da III Et H 1-naphthyl 20.3 18.7 0.921
12ec III Me H Ph 73.7 15.7 0.213
12fc III Me Me Ph 46.3 29.6 0.639
12gc III Me H 4-PhF 96.3 14.5 0.151
12hc III Me Me 4-PhF 34.8 28.3 0.813
12hc III CN H 4-PhF 68.7 19.4 0.282
12ic III H H 4-PhF 123 33.4 0.272
a Synthesized by Dr. Terry Moore, b Synthesized by Davis Oldham, c Synthesized by Dr. Markéta Lebl-Rinnová
SHO
O
HO
OAr
R1
OH
HO
N
R2 Ar
Table 3.2. Relative Binding Affinity of Benzothiophene and Triarylethylene Scaffolds
Scaffold I Scaffold II Scaffold III
S
HO
O
R
HO
compound ER! ER" "/!
1 1.98 0.198 0.10
2 0.368 2.12 5.76
3 1.40 8.22 5.87
7 1.09 0.670 0.615
9 0.394 0.695 1.76
Table 3.1. Relative Binding Affinity of Steriodal Scaffolds
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Compound IL-6 ELISA +/- ERE-luc +/-
1 21895 4485 24376 508
2 20626 5496 45044 5876
3 19736 2491 42715 1795
12a 42552 19799 20300 5649
12b 66642 7092 12117 2147
12c 70626 9173 6145 2416
12d 43742 8283 20277 2168
12e 70773 36359 20275 2314
12f 85977 10070 34474 8296
12g 101430 4827 20424 2994
12h 79013 11226 27664 2597
12h 149951 42290 22531 1267
12i 137040 19737 56709 2825
7 21152 4279 26476 4793
9 18092 3750 23178 4773
E2 21320 2310 114373 8527
genestein 37511 3255 159843 12128
ICI 65129 9422 5040 112
OBHS 26631 6142 44620 10049
triarylethylene cntrl 1 19033 2435 28747 3025
triarylethylene cntrl 2 44754 5139 39366 3395
pyrazolopyrimidine 1 8715 1752 24344 2183
pyrazolopyrimidine 2 26702 4484 17834 1962
Table 3.3. Transcriptional Readout of IL-6 and ERE Activities
V. Discussion
A. Structure-Based Design
 The crystal structures of the WAY and oxabicycloheptene (OBH) ligands complexed with 
ER! provide a compelling structural basis for the observed novel biological activity of these 
ligands.6  The key feature of each structure is the displacement of  His524 from the standard 
position observed for conventional ER ligands such as E2 and genistein (Fig. 3.2).  With the 
exception of  the steroidal analogs, each of  the designed ligand scaffolds is a planar aromatic 
structure that generally adheres to the established pharmacophore for high affinity ER ligands 
(see Chapter 1).  These structures bear a pendant phenol that mimics the A-ring of estradiol, 
which participates in a hydrogen bonding network between Glu353, Arg394, and a water 
molecule that is crucial for high affinity binding to ERs.  The core scaffold also bears an internal 
substituent that projects into the B-ring pocket, for which large aromatic substituents engender 
ER!-selectivity, while smaller substituents (e.g., chloro, 11"-ethyl) yield ER"-selectivity.11,25  The 
focal point of our designed ligands is the extension of  the structure towards the D-ring end of  the 
pocket.  In contrast to conventional ligands that form a hydrogen bond with His524, our 
designed ligands contain a substituent that is specifically introduced to clash with His524, 
causing the residue to rotate out of  position in a manner similar to that observed in the OBHS-
bound crystal structure.8
 Visual analysis of  the docked poses for each designed chemotype strongly suggests 
positioning the D-ring substituent in the meta-position for benzothiophene (Fig. 3.4C) and 
triarylethylene scaffolds (Fig. 3.4D).  The wider angle of diaryl ether (Ar-O-Ar) or diaryl amine 
(Ar-NH-Ar) heteroatom linkages is favored over the more acute angle observed for benzyl (Ar-
C-Ar) linkages.  The preferred substituent positioning and linkage type for steroidal-based 
ligands was less clear from the docking poses, although substitution through the 16"- and 17"-
positions appeared reasonable (Fig. 3.4B).
 Following known substitution patterns for established ER ligands, the internal 
substitution for non-steroidal ligands was comprised of  an aromatic ring attached either via a 
direct linkage to the scaffold, or through a single carbon linker such as a methylene or carbonyl 
group.  For 5,6-fused bicyclic scaffolds such as the benzothiophene ligands, attachment through 
such a linker appeared to be favored based on steric constraints in which the rotational flexibility 
allowed the aryl ring to follow  the natural progression of the extended pocket.  This was not the 
case for the triarylethylene scaffold, which was well positioned to access the channel through a 
direct connection.  The positioning of internal aromatic substituents on steroidal scaffolds is less 
well established; however, it is known that incorporating an 11"-chloromethyl or 11"-ethyl 
substituent increases affinity and engenders ER"-selectivity.10,11  Further substituting the ligand 
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at either 16!- or 17!-positions did not appear to negatively affect the positioning of this 11!-
ethyl substituent.
 Lipophilic mapping of the receptor surface reiterates that the core of  the ligand binding 
pocket is strongly lipophilic.  These properties are best matched by the benzothiophene scaffold, 
in which the internal sulfur atom engenders substantial lipophilicity to the surrounding 
hydrocarbon scaffold.  Our initial designs for this chemotype strictly followed the binding mode 
observed in the crystal structure of raloxifene bound to ER,26,27 in which the pendant phenol is 
directed towards the D-ring end of the ligand binding pocket (Fig. 3.5A).  The docked poses, 
however, showed a slight offset between a subtle pocket of strong lipophilicity in the receptor 
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Figure 3.5. Comparison of the docked poses for the benzothiophene (A) and reversed-benzothiophene 
(B) scaffolds show a subtle difference in the positioning of the sulfur atom relative to a shallow sub-pocket 
of increased lipophilicity on the receptor surface (magenta circle).  The ligand surface is represented by 
wire framework, while the receptor surface is opaque; both are mapped by lipophilicity.  The fused 
framework of the benzothiophene projects the sulfur atom towards the front of the pocket, as highlighted 
when looking down the pocket from His524 towards Glu353.  The core of the reversed-benzothiophene, 
in contrast, rotates relative to the pendant phenol  to position the sulfur atom within the lipophilic sub-
pocket.
surface, and the positioning of the sulfur atom.  Redesigning the ligand to bind in a “reversed” 
mode by attaching the phenoxy/N-phenylamine substituent at the 5-position of the core 
structure effectively repositioned the sulfur atom directly in line with the observed lipophilic 
pocket in the receptor surface, while retaining hydrogen bonding contacts and access to the B-
ring pocket (Fig. 3.5B).  The A-ring and D-ring ends of  the pocket, in contrast, appear 
significantly more hydrophilic due to the hydrogen bonding contacts and access to bulk solvent, 
respectively (Figs. 3.4, 3.5).  As described above, all designed ligands contained a phenolic 
moiety to participate in the known hydrogen bonding networks; however, due to the inability to 
effectively incorporate receptor flexibility into ligand docking routines, we were unable to 
sufficiently probe the affects of various substitution patterns on the extended D-ring substituent 
(e.g., H, F, Me, OH), or the ability to extend into bulk solvent in this direction.
B. Chemical Synthesis
 The synthesis of  16!-benzyl-17!-estradiol closely followed the published route to similar 
compounds.19  The aldol condensation was performed in straight forward manner, followed by 
two subsequent reductions.  Both the sodium borohydride reduction of the 17-ketone and the 
hydrogenation of the exocyclic olefin each proceed in a stereoselective manner, whereby 
reduction takes place from the "-face of  the steroid skeleton due to the steric bulk of the axial 
18!-methyl substituent.  All steps in this sequence were performed without the use of protecting 
groups, and each intermediate was easily purified due to the highly crystalline nature of  the 
steroidal scaffold.
 Reductive amination of  the 17-ketone was performed using the Leukart-Wallach 
reaction,20 in which formic acid serves as the hydride donor to capture the in situ formed imine, 
again, from the "-face.  The crude product was a mixture of the N-formyl and fully hydrolyzed 
amines, and protection of  the A-ring phenol as the corresponding methyl ether greatly aided in 
the separation of the product mixture.  The N-formyl component was further reduced with 
sodium borohydride to yield the N-methyl amine, and each compound was subsequently 
deprotected under Lewis acidic conditions.
C. Biological Evaluation
 All compounds were initially tested in in vitro radiometric competitive binding assays to 
gauge their ability to bind the receptor, followed by in vivo experiments carried out by our 
collaborator Kendall Nettles to probe their affect on ER and inflammatory pathways in tumor 
cells.  Our initial synthetic efforts focused on the benzothiophene scaffold based on the 
raloxifene structure.  Initial RBA data for this class, however, yielded RBA values between 
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Figure 3.6.  The in vivo activity of each compound in ERE and IL-6 transcriptional assays are plotted in a 
two-dimensional analysis.  All 17-amino (green triangles) and 16-substituted (blue diamonds) estradiol 
analogs were found within the desired activity window (blue square), along with one triarylethylene (red 
squares).  These compounds cluster into two groups (inset).  Several well-characterized ER ligands 
(black circles) and two active pyrazolopyrimidines (orange rectangles) are also included for reference.
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Figure 3.7.  Structures of compounds located within the desired activity window, organized by cluster.
0.004-0.007 and 0.005-0.009 for ER! and ER", respectively.  From this data it is evident that 
the extended D-ring substituent greatly reduced binding affinity relative to the parent scaffold. 
Accordingly, the second generation ligands were specifically designed from scaffolds that have 
previously demonstrated high affinities for ERs.  This class included steroidal structures based 
on estradiol, triarylethylenes based on tamoxifen, and the reversed-orientation benzothiophenes 
carefully redesigned to optimize the position of the sulfur atom within the binding pocket based 
on lipophilic mapping.  These compounds too demonstrated reduced binding affinities relative to 
analogous ligands lacking the extended D-ring substituent; however, measured RBA reached 
biologically interesting levels.  Reversing the binding orientation of  the benzothiophene scaffold 
and exchanging the benzoyl sidechain with an aryl substituent increased the RBA by 920-fold 
for ER! and 208-fold for ER".  16"-Substitution of estradiol was favored over replacing the 
17"-hydroxyl with an aniline; however, both compound sets yielded RBA values ranging from 
0.198 to 8.22 (Ki = 6.1-75 nM) for ER".  Most notably, all triarylethylene compounds bound with 
RBA values >34.8 (Ki = 0.57 nM) and >14.5 (Ki = 3.4 nM) for ER! and ER", respectively.
 With the exception of the benzothiophenes, each of these compounds has been tested 
for in vivo activity.  These data, shown in Figure 3.6, are represented in a two-dimensional 
analysis comparing IL-6 activity on the X-axis, and activation of ERE transcriptional pathways 
on the Y-axis.  The desired phenotype is located in the lower left corner of the plot, in which low 
IL-6 activity demonstrates suppression of inflammatory pathways, presumably through NF-#B, 
without activating conventional ER pathways (e.g., cell growth).  The data points are colored by 
scaffold type, and several well-characterized ER ligands were included as reference structures. 
Using the OBHS datapoint as a guide, two clusters of compounds appeared within the desired 
activity window.  Cluster one consists of  five compounds (Fig. 3.7) that demonstrate little ERE 
activity above vehicle, and IL-6 activity below  that observed for OBHS.  Included in this cluster 
are two pyrazolopyrimidines designed and synthesized by Davis Oldham that represent 5,6-
fused bicycles similar to the indazoles presented herein.  Cluster two, which includes OBHS, 
demonstrates slightly higher ERE activity with similar IL-6 activity.  While all five of the 
synthesized steroidal ligands were located within the desired activity window, only a single 
triarylethylene was located within the same range.  Curiously, this compound was synthesized 
as a control lacking an extended D-ring substituent all together (Fig. 3.7).  Each of the 
compounds found within the desired range will be further tested in vivo to confirm efficacy and 
establish potency.
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VI. Conclusions
 Recent data from structural biology provide compelling evidence that the displacement 
of His524 from the ligand binding pocket of  ERs is well correlated with the suppression of 
inflammatory pathways without activating classical ER pathways (e.g., cell growth).  Based on 
these data, we set out to design, synthesize, and test a series of  steroidal and non-steroidal 
ligands to achieve this highly desired pharmacology.  Using an iterative process, we 
successfully leveraged the available structural models to modify four scaffolds from known high 
affinity ER ligands in silico to determine the appropriate substitution patterns that mimic the 
desired structural effects.  A series of  compounds were subsequently synthesized for each 
scaffold type, and assayed for binding affinity in vitro, and activity on ERE and IL-6 
transcriptional pathways.  In this manner, our ligand design has been refined to yield several 
lead structures within the desired activity window  suitable for follow-up efforts expanding upon 
the observed structure activity relationships.
VII. Experimental
A. Chemistry
 General Considerations.  All chemical reagents were purchased from commercial 
suppliers without further purification.  Anhydrous DMF was obtained from Aldrich in a 
Sureseal™ bottle stored in a secondary container with desiccant; all other anhydrous solvents 
were obtained from a solvent dispensing system unless otherwise stated.  All glassware was 
oven or flame-dried and cooled under vacuum or in a dry box.  All reactions were conducted 
under argon.  NMR spectra were obtained on Varian Oxford instruments and worked up using 
ACD, Inc. 1D-NMR processing software.  The chemical shifts are reported in ppm and 
referenced to the solvent peak.  Electron Impact (EI) mass spectra were obtained on a 70-VSE 
mass spectrometer with an ionization energy of 70 eV.  Electrospray Ionization (ESI) mass 
spectra were obtained on a Q-Tof  mass spectrometer.  Melting point ranges were measured 
using a Thomas Hoover capillary melting point apparatus.
 16-Phenylmethylene-estrone (1).  Estrone (411.9 mg, 1.5 mmol), NaOH (305 mg, 7.5 
mmol), and benzaldehyde (152 !L, 1.5 mmol) were dissolved in EtOH (15 mL) and stirred at 
ambient temperature for three hours.  The reaction was quench by slow  addition of  glacial acetic 
acid until the reaction mixture became acidic, along with the precipitation of a white solid.  The 
mixture was the filtered and washed with cold EtOH to yield 12 (402.2 mg, 74%) as a white 
solid.  A portion of  this material was further purified by recrystallization (EtOH/water) prior to 
biological assay.  1H-NMR (DMSO-d6, 500 MHz) " 9.06 (br. s., 1 H), 7.65 (m, 2 H), 7.44 (m, 3 
H), 7.33 (s, 1 H), 7.05 (d, J=8.55 Hz, 1 H), 6.53 (dd, J=8.30, 2.69 Hz, 1 H), 6.47 (d, J=2.44 Hz, 1 
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H), 2.88 (ddd, J=16.24, 6.47, 1.46 Hz, 1 H), 2.78 (m, 2 H), 2.58 (ddd, J=15.93, 12.76, 2.81 Hz, 1 
H), 2.34 (m, 1 H), 2.19 (m, 1 H), 1.99 (m, 1 H), 1.87 (m, 1 H), 1.60 (m, 1 H), 1.41 (m, 4 H), 1.06 
(t, J=6.96 Hz, 1 H), 0.90 (s, 3 H); 13C-NMR (DMSO-d6, 125 MHz) ! 208.45, 155.05, 137.06, 
136.36, 135.10, 131.91, 130.30, 129.90, 129.36, 128.80, 125.99, 114.98, 112.82, 47.74, 47.20, 
43.41, 37.55, 31.36, 29.02, 28.62, 26.28, 25.58, 14.26; HRMS (ESI): calc’d for C25H27O2 [M+H]+ 
359.2011, found 359.2018.
 16-Phenylmethylene-17!-estradiol (2).  1 (348.7 mg, 1 mmol) was added to a round 
bottomed flask and resuspended in a mixture EtOH (20 mL) and THF (20 mL).  The reaction 
flask was then cooled to 0 °C in an ice bath, and NaBH4 (100 mg, 2.6 mmol) was slowly added. 
The mixture was slowly warmed to ambient temperature as the reaction was allowed to proceed 
overnight.  The THF was removed by rotary evaporation and the remaining aqueous mixture 
was transferred to a separatory funnel and exhaustively extracted with EtOAc.  The organic 
layer was dried over MgSO4, vacuum filtered, and concentrated by rotary evaporation to yield 2 
(318.3 mg, 91%) as a white solid.  A portion of this material was further purified by 
recrystallization (EtOH/water) prior to biological assay.  1H-NMR (DMSO-d6, 500 MHz) !  9.00 (s, 
1 H), 7.36 (m, 4 H), 7.18 (m, 1 H), 7.06 (d, J=8.55 Hz, 1 H), 6.52 (dd, J=8.42, 2.56 Hz, 1 H), 
6.45 (d, J=2.44 Hz, 1 H), 6.41 (d, J=2.44 Hz, 1 H), 5.15 (d, J=6.10 Hz, 1 H), 3.98 (m, 1 H), 2.71 
(m, 3 H), 2.29 (m, 1 H), 2.17 (m, 2 H), 1.91 (m, 2 H), 1.34 (m, 5 H), 0.60 (s, 3 H); 13C-NMR 
(DMSO-d6, 125 MHz) ! 154.94, 146.65, 137.88, 137.14, 130.37, 128.40, 127.87, 125.96, 
121.71, 114.94, 112.72, 83.46, 46.97, 43.55, 42.73, 38.04, 36.07, 30.28, 29.11, 27.05, 26.06, 
14.10, 11.39; HRMS (ESI): calc’d for C25H29O2 [M+H]+ 361.2168, found 361.2163.
 16!-Benzyl-17!-estradiol (3).  2 (232.6 mg, 0.6 mmol) was placed in a hydrogenation 
flask and resuspended in a mixture of EtOH (25 mL) and THF (25 mL).  A catalytic amount of 
Pd/C was added and the flask was pressurized to 30 psi with hydrogen gas and shaken 
overnight in a Parr-shaker hydrogenation apparatus.  The reaction mixture was subsequently 
filtered through celite and washed with THF.  The crude product was obtained by rotary 
evaporation and further purified by flash chromatography over silica gel (33% EtOAc in 
hexanes) to yield 3 (182.9 mg, 78.2%) as a white solid.  A portion of this material was further 
purified by recrystallization (EtOH/water) prior to biological assay.  1H-NMR (DMSO-d6, 500 
MHz) ! 8.97 (s, 1 H), 7.24 (m, 2 H), 7.18 (m, 2 H), 7.13 (m, 1 H), 7.03 (d, J=8.55 Hz, 1 H), 6.50 
(dd, J=8.42, 2.56 Hz, 1 H), 6.41 (d, J=2.44 Hz, 1 H), 4.67 (d, J=4.88 Hz, 1 H), 3.67 (dd, J=9.52, 
4.88 Hz, 1 H), 3.03 (dd, J=13.18, 3.66 Hz, 1 H), 2.66 (m, 2 H), 2.31 (m, 3 H), 2.06 (td, J=10.99, 
3.66 Hz, 1 H), 1.88 (m, 1 H), 1.66 (m, 1 H), 1.52 (m, 1 H), 1.24 (m, 4 H), 1.00 (m, 2 H), 0.76 (s, 
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3 H); 13C-NMR (DMSO-d6, 125 MHz) ! 154.88, 142.57, 137.11, 130.44, 128.61, 128.10, 125.99, 
125.31, 114.89, 112.68, 80.37, 48.09, 43.87, 43.57, 41.68, 38.11, 37.62, 37.46, 31.74, 29.15, 
27.10, 26.03, 12.75; HRMS (ESI): calc’d for C25H31O2 [M+H]+ 363.2324, found 363.2328.
 3-Methoxyestra-1,3,5(10)-trien-17-one (4).  Estrone (2.7 g, 10 mmol) was placed into a 
round bottomed flask and dissolved in DMF (20 mL).  The reaction vessel was cooled to 0 °C in 
an ice bath, and mineral oil dispersion of  NaH (60% by wt., 562 mg, 14 mmol, 60%) and MeI 
(685 "L, 11 mmol) were added sequentially.  The reaction was allowed to proceed for two hours 
an slowly warmed to ambient temperature, upon which the reaction was quenched with MeOH. 
The resulting mixture was poured into distilled water yielding a precipitated what was filtered, 
washed with additional water, and dried under reduced pressure.  The crude material was 
purified by recrystallization (DCM/MeOH) to yield 4 (2.4 g, 83.1%) as dense white flakes.  1H-
NMR (CDCl3, 500 MHz,) ! 7.22 (d, J=8.58 Hz, 1 H), 6.74 (dd, J=8.58, 2.79 Hz, 1 H), 6.66 (d, 
J=2.57 Hz, 1 H), 3.79 (s, 4 H), 2.92 (m, 2 H), 2.52 (dd, J=19.08, 8.79 Hz, 1 H), 2.41 (m, 1 H), 
2.27 (td, J=10.45, 4.18 Hz, 1 H), 2.16 (m, 1 H), 2.04 (m, 3 H), 1.96 (m, 1 H), 1.54 (m, 6 H), 0.92 
(s, 3 H); 13C-NMR (CDCl3, 125 MHz) ! 220.92, 157.51, 137.69, 131.95, 126.29, 113.80, 111.50, 
55.15, 50.33 , 47.96, 43.91, 38.31, 35.83, 31.52, 29.63, 26.50, 25.88, 21.54, 13.81; HRMS 
(ESI): calc’d for C19H25O2 [M+H]+ 285.1855, found 285.1854.
 N-Formyl-3-methoxy-N-phenylestra-1,3,5(10)-trien-17-amine (5) and 3-methoxy-N-
phenylestra-1,3,5(10)-trien-17!-amine (6).  4 (285.5 mg, 1 mmol) was placed into a pear-
shaped round bottomed flask to which aniline (0.5 mL, 5 mmol) and formic acid (0.2 mL, 5 
mmol) were added.  The reaction mixture was heated to 160 °C under an argon atmosphere for 
24 hours.  After cooling to ambient temperature, the mixture was transferred to a separatory 
funnel, to which a brine solution was added, and exhaustively extracted with EtOAc.  The 
organic layer was dried over MgSO4, vacuum filtered, and concentrated by rotary evaporation. 
Two different product spots were observed by TLC analysis and isolated by flash 
chromatography over silica gel with a gradient elution (25-50% EtOAc in hexanes).  The 
resulting material was recrystallized (MeOH/water) to yield 5 (66.5 mg, 18%) and 6 (130.0 mg, 
35.8%) as white solids.  5. major isomer: 1H-NMR (CDCl3, 500 MHz) ! 8.30 (m, 1 H), 7.36 (m, 3 
H), 7.22 (m, 3H), 6.71 (m, 1 H), 6.63 (m, 1 H), 4.51 (t, J=9.9 Hz, 1 H), 3.78 (s, 3 H), 2.86 (m, 2 
H), 2.06 (m, 7 H), 1.68 (m, 1 H), 1.40 (m, 4 H), 1.22 (m, 1 H), 0.68 (s, 3 H); 13C-NMR (CDCl3, 
125 MHz) ! 164.56, 157.36, 140.57, 137.81, 132.59, 130.07, 129.03, 128.53, 126.28, 113.71, 
111.37, 64.76, 55.16, 51.14, 45.74, 43.74, 38.52, 37.92, 29.71, 27.18, 26.17, 24.58, 22.86, 
13.60; 5. minor isomer: 1H-NMR (CDCl3, 500 MHz) ! 8.57 (s, 1 H), 7.36 (m, 3 H), 7.22 (m, 3 H), 
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6.71 (m, 1 H), 6.63 (m, 1 H), 3.82 (t, J=9.9 Hz, 1 H), 3.78 (s, 3 H), 2.86 (m, 2 H), 2.06 (m, 7 H), 
1.68 (m, 1 H), 1.40 (m, 4 H), 1.22 (m, 1 H), 0.81 (s, 3 H); 13C-NMR (CDCl3, 125 MHz) ! 163.34, 
157.46, 140.01, 137.73, 132.09, 129.01, 127.88, 127.47, 126.18, 113.77, 111.37, 70.62, 55.16, 
51.32, 44.46, 43.69, 38.61, 37.51, 29.64, 27.13, 26.14, 25.63, 22.55, 12.40; LRMS (ESI) [M+H]+ 
found 390.3.  6. 1H-NMR (CDCl3, 500 MHz) !  7.19 (m, 3 H), 6.72 (m, 5 H), 3.81 (s, 3 H), 3.52 
(m, 1 H), 2.91 (m, 2 H), 2.29 (m, 3 H), 1.95 (m, 2 H), 1.82 (m, 1 H), 1.43 (m, 7 H), 0.83 (s, 3 H); 
13C-NMR (CDCl3, 125 MHz) ! 157.38, 148.26, 137.90, 132.58, 129.13, 126.28, 116.92, 113.75, 
113.36, 111.39, 63.72, 55.16, 51.84, 43.88, 43.75, 38.98, 38.16, 29.97, 29.80, 27.35, 26.38, 
23.33, 11.99; LRMS (ESI) [M+H]+ found 362.4.
 3-Hydroxy-N-phenylestra-1,3,5(10)-trien-17!-amine (7).  A round bottomed flask 
charged with 6 (77.2 mg, 0.2 mmol) dissolved in DCM (4 mL) was cooled in a ice/NaCl bath. 
BBr3 (0.5 mL of 1M solution in DCM) was added dropwise and the reaction mixture was allowed 
to warm to ambient temperature.  After 2.5 hours the reaction was judge to be complete by TLC, 
re-cooled to 0 °C in an ice bath, and quenched with MeOH, and concentrated by rotary 
evaporation.  The crude material was isolated by flash chromatography over silica gel (25% 
EtOAc in hexanes) and purified by recrystallization (MeOH/water) to yield 7 (24.2 mg, 32.6%) as 
white needles.  1H-NMR (DMSO-d6, 500 MHz) ! 8.99 (s, 1 H), 7.01 (m, 3 H), 6.65 (d, J=7.72 Hz, 
2 H), 6.50 (dd, J=8.36, 2.57 Hz, 1 H), 6.44 (m, 2 H), 5.28 (d, J=8.36 Hz, 1 H), 3.42 (q, J=8.65 
Hz, 1 H), 2.72 (m, 2 H), 2.21 (m, 1 H), 2.09 (m, 2 H), 1.80 (m, 1 H), 1.70 (m, 2 H), 1.42 (m, 2 H), 
1.28 (m, 5 H)0.73 (s, 3 H); 13C-NMR (DMSO-d6, 125 MHz) ! 154.90, 149.23, 137.11, 130.33, 
128.70, 126.06, 116.41, 114.92, 112.69, 112.40, 62.58, 51.17, 43.76, 43.43, 38.86, 37.98, 29.18, 
28.77, 27.05, 26.17, 22.93, 12.05; HRMS (ESI): calc’d for C24H30NO [M+H]+ 348.2327, found 
348.2321.
 3-Methoxy-N-methyl-N-phenylestra-1,3,5(10)-trien-17"-amine (8)  A solution of 5 
(57.0 mg, 0.15 mmol) dissolved in THF (1 mL) was slowly added to a round bottomed flask 
charged with LAH (26 mg, 0.6 mmol) in THF (1 mL).  The reaction mixture was heated to 70 °C 
for 3 hours, after which the reaction was cooled to 0 °C, quenched with water, transferred to a 
separatory funnel, a solution of  Rochelle salt was added, and the mixture was exhaustively 
extracted with DCM.  The organic layer was dried over MgSO4, vacuum filtered, and 
concentrated by rotary evaporation.  The desired product was isolated by flash chromatography 
over silica gel (25% EtOAc in hexanes) to yield 8 (42.4 mg,77.3%) as a white solid.  1H-NMR 
(CDCl3, 500 MHz) ! 7.26 (m, 3 H), 6.96 (d, J=8.36 Hz, 2 H), 6.76 (m, 2 H), 6.68 (d, J=2.36 Hz, 1 
H), 3.85 (t, J=1.00 Hz, 1 H), 3.81 (s, 3 H), 2.91 (s, 3 H), 2.91 (m, 2 H), 2.30 (m, 2 H), 2.03 (m, 1 
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H), 1.91 (m, 4 H), 1.48 (m, 6 H), 0.88 (s, 3 H); 13C-NMR (CDCl3, 125 MHz) ! 157.38, 151.96, 
137.90, 132.70, 128.84, 126.26, 116.80, 114.11, 113.74, 111.38, 69.33, 55.17, 51.09, 45.55, 
43.96, 38.56, 38.47, 35.60, 29.82, 27.36, 26.33, 24.01, 23.23, 13.40.
 3-Hydroxyoxy-N-methyl-N-phenylestra-1,3,5(10)-trien-17!-amine (9).  Following the 
same procedure as for 7 in the cleavage of aryl-methyl ethers from 8 (46.0 mg, 0.12 mmol) and 
BBr3 (0.25 mL of a 1M solution in DCM) yielded 9 (32.4 mg, 73.2%) as light yellow  needles.  1H-
NMR (DMSO-d6, 500 MHz) ! 8.99 (s, 1 H), 7.15 (dd, J=8.55, 7.32 Hz, 2 H), 7.02 (d, J=8.55 Hz, 
1 H), 6.87 (d, J=8.06 Hz, 2 H), 6.62 (t, J=7.20 Hz, 1 H), 6.49 (dd, J=8.30, 2.69 Hz, 1 H), 6.43 (d, 
J=2.69 Hz, 1 H), 3.84 (m, 1 H), 2.80 (s, 3 H), 2.72 (m, 2 H), 2.20 (m, 1 H), 2.12 (m, 1 H), 1.99 
(m, 1 H), 1.81 (m, 1 H), 1.75 (m, 2 H), 1.63 (m, 1 H), 1.52 (td, J=12.57, 3.66 Hz, 1 H), 1.29 (m, 5 
H), 0.78 (s, 3 H); 13C-NMR (DMSO-d6, 125 MHz) ! 154.91, 151.46, 137.06, 130.33, 128.70, 
125.99, 116.23, 114.90, 113.60, 112.68, 68.11, 50.24, 45.25, 43.43, 38.30, 37.96, 35.09, 29.15, 
27.01, 26.00, 23.49, 22.85, 13.32; HRMS (ESI): calc’d for C25H32NO [M+H]+ 362.2484, found 
362.2479.
B. Molecular Modeling
 The structure for ER" complexed to OBHS was obtained from Kendall Nettles and 
prepared using Sybyl 8.1.1.  Any excess chains were removed to yield the monomeric structure, 
to which explicit hydrogens were added, partial charges calculated, and minimized with 
MMFF94 to a termination gradient of 0.5.  The coactivator peptide and all water molecules were 
deleted with the exception of  the ordered water participating in the hydrogen bonding network 
between Glu353, Arg394, and the ligand (OBHS).  The resulting structure was further processed 
using AutoDock Tools (ADT) to compute Gasteiger charges and assign AD4 atom types.
 All docked compounds were constructed in Sybyl, cleaned up using Concord, and 
minimized with MMFF94 to a termination gradient of 0.05.  The ligands were further prepared 
for docking with ADT to calculate Gasteiger charges, assign AD4 atom types, and set all 
rotatable bonds as active torsions.  Each ligand was then docked into the prepared receptor 
structure using AutoDock Vina (ADV).  The grid box was centered on the position of  OBHS and 
measured 22 Å by 20 Å by 26 Å, and the exhaustiveness parameter was set to 100 (default=8, 
linear scale).  All other default settings were used.
 The lowest energy pose as determined by the internal ADV scoring algorithm was 
selected for further use.  The docked pose was merged back into the receptor structure in 
Sybyl, all hydrogens were explicitly added, and the receptor ligand complex was re-minimized to 
a termination gradient of  0.5.  Each receptor-ligand pair was overlaid with the initial OBHS-ER" 
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crystal structure, and analyzed visually.  Particular attention was paid  to the geometric fit of the 
ligand within the binding volume, matched hydrogen bonding contacts, and positioning of the 
extended D-ring substituent relative to the phenyl sulfonate of OBHS.  Suitable ligands were 
further analyzed by generating a molCAD surface of ligand and the receptor surface within the 
binding volume, which was subsequently mapped by lipophilic potential.
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CHAPTER 4
COMPUTATIONAL METHODS IN EVALUATING THE BINDING AFFINITY OF
FLUORINATED ANALOGUES OF TANAPROGET FOR THE PROGESTERONE RECEPTOR†
I. Introduction
 The progesterone receptor (PR) is another member of  the nuclear receptor superfamily 
and is primarily found in female reproductive tissues where it is bound by the endogenous 
steroidal ligand, progesterone.  This ligand-receptor pair is commonly associated with a variety 
of biological functions related to pregnancy; however, elevated PR levels are often found in ER-
positive breast cancer tumor cells as a result of  ER-dependent expression.  This phenomenon 
has led to the investigation of  the use of PR as a target in breast cancer therapy,1-5 and as an 
indicator of responsiveness to endocrine therapies.6-8  The research described herein will focus 
on this latter application.
 An ER-positive tumor status is a well known requirement for efficacy in endocrine 
therapies; however, only 50% of such patients will respond to treatment.  One explanation for 
this outcome is that while ER is present in these tumors, ER-pathways are non-functional. 
Since PR expression is ER-dependent, the presence of  elevated PR levels in tumor cells should 
indicate properly functioning ER-mediated transcriptional pathways that would be susceptible to 
standard endocrine therapies.9,10  This theory has been investigated by a number of clinical 
studies with conflicting results,11-15 and it has been suggested that the practical difficulties in 
measuring PR levels may obfuscate these data, leading to significant mis-categorization of  PR 
status.16
 An initial approach to addressing these issues may be to magnify the effect of ER-
dependent expression of PR by taking advantage of a phenomenon known as “clinical flare 
reaction.”16-18  During the initial stages of endocrine therapy, tamoxifen acts as an agonist on 
ER, frequently leading to a temporary worsening of disease symptoms.  These tamoxifen-
induced flares are strongly correlated to a positive response to endocrine therapies; however, it 
is difficult to differentiate between worsening of symptoms due to a flare vs. disease 
progression, or identify the sub-clinical symptoms of  mild flares.  As early as 1980, Baulieu19 
suggested using “tamoxifen as a hormonal challenge test” in which the patient is treated with 
tamoxifen for a period of  time,7 followed by analysis of  PR levels as a method to quantitate 
cellular response.  This method, however, necessitates a tumor biopsy and does not completely 
address the practical difficulties in measuring PR levels.
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 Aiming to circumvent the problems associated with directly measuring PR levels in tumor 
biopsies, the Welch laboratory at Washington University in St. Louis investigated a method for 
non-invasive quantitative assessment of  flares using positron emission tomography (PET). 
Rather than focusing on PR levels, these studies assessed the change in the metabolic state of 
tumor cells using 2-[18F]fluoro-2-deoxyglucose (FDG) as a chemical probe.20-23  The underlying 
assumption of this methodology is that the stimulation of  ER pathways responsible for flares 
during initial stages of tamoxifen treatment would be accompanied by increased metabolism, 
which is readily observed by monitoring tumor glucose uptake.  Accordingly, FDG was 
administered prior to and 7-10 days after treatment with tamoxifen, and visualized by PET scan. 
It was found that quantitative analysis of the change in local concentrations of FDG was 
predictive for response to endocrine therapy (tamoxifen) in a statistically significant manner. 
While this method circumvents the need for tumor biopsy and provides a rapid assessment of 
therapeutic response, it hinges the readily available but otherwise general FDG as the chemical 
probe for changes in metabolism.  We have subsequently suggested that the use of a probe 
specifically targeted for an ER-gene product (e.g., PR) would yield better results,23-25 and 
therefore, we selected a newly disclosed synthetic PR agonist, Tanaproget,26 to serve this 
purpose.
 All PR agonists currently approved for use in oral contraceptives are steroidal analogs of  
progesterone, which suffer from a number of side effects due to low  selectivity for PR. 
Tanaproget, specifically developed by Wyeth as a non-steroidal PR agonist,27 boasts 
significantly higher affinity and better selectivity for PR, and is currently in Phase II clinical trials. 
In addition to reporting activity data for various analogs, the researchers at Wyeth were able to 
obtain a crystal structure of  Tanaproget bound to PR that explains the observed trends in 
activity, primarily through increased hydrogen bonding.28  We have leveraged this information to 
introduce a 18F-radiolabel into several analogs of Tanaproget using rational design, which were 
subsequently synthesized by Dr. Haibing Zhou and Dr. Jae Hak Lee in our labs.29
 The binding affinities for the Tanaproget analogs shown in Table 4.1 show  a strong 
dependence on the nature and position of the alkyl or fluoroalkyl substituent on the pyrrole-
benzoxazin-2-thione ligand core. Thus, while the pyrrole N-methyl group of  1 is well tolerated (1, 
RBA = 151), the larger fluoroalkyl substituents are not (3 = 18.5, 4 = 0.99), indicating that the 
ligand-binding pocket of PR has very limited tolerance for more than a methyl group. By 
contrast, when fluoroethyl or propyl substituents replace one of the C4 methyl groups of the 
benzoxazin-2-thione unit, high affinity compounds are produced, with three compounds (5, 6, 8) 
having equivalent or higher binding affinity than that of  compound 1 itself  and indicating that this 
region of the PR ligand binding pocket has good bulk tolerance, as suggested by prior work.26
 Intriguingly, there appears to be some “reciprocity” between the substituent on the pyrrole 
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nitrogen and at the C4 position such that larger groups (fluoroethyl and fluoropropyl) are more 
readily accommodated at C4 when there is a smaller group (H) on the pyrrole nitrogen. Also, it 
is of note that while the pyrrole N-substituted compounds 3 and 4 are achiral, the high affinity 
Tanaproget analogs modified at C4 position of benzoxazin-2-thione are chiral, but thus far have 
only been studied as racemates. Thus, it is possible that one enantiomer will have higher 
binding affinity than the other.
 To investigate further the structure-binding affinity correlations we have uncovered, 
including the apparent reciprocity between the pyrrole N-substituent and the C4-substituents, 
and to explore possible enantioselectivity, we set out to build structural models for each ligand 
using molecular modeling software.  Each model was evaluated both visually and with a series 
of quantitative analyses to identify structural characteristics that modulate the observed RBA 
values.
II. Ligand Docking
 Structural models of each receptor-ligand pair were constructed in silico by docking the 
ligand into the ligand binding pocket of PR.  Conveniently, a 2 Å resolution crystal structure of 
PR complexed to 1 was available in the PDB (accession code 1ZUC),28 and used as a guide for 
each docking.  All ligands were constructed using Sybyl30 and docked into the protein structure 
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Table 4.1. Relative Binding Affinities (RBAs) of Tanaproget Derivatives
N
H
ON
R2Me
S
NC
R1
compound R1 R2 RBAa (R5020 = 100)
Tanaproget (1) CH3 CH3 151±39
2 H CH3 600±8
3 CH2CH2F CH3 18.5±5.2
4 CH2CH2CH2F CH3 0.99±0.28
5b CH3 CH2CH2F 151±13
6b H CH2CH2F 198±30
7b CH3 CH2CH2CH2F 90.9±27
8b H CH2CH2CH2F 189±40
a RBA values determined by competitive radiometric binding assay, using [3H]R5020 as a tracer.
b Compounds 5, 6, 7, 8 were studied as racemates.
using AutoDock Vina.31  Acceptable low  energy poses were manually selected by visual 
analysis, further minimized using a multistep protocol, and finally analyzed using several 
numerical methods within the Molecular Operating Environment (MOE).32
III. Visual Analysis
 Visual analysis of  the N-substituted analogs yielded a relatively straightforward 
explanation for the reduced affinity with increasing substituent size.  As depicted in Figure 4.1, 
the benzoxazine-core establishes a consistent position in the binding pocket while the pyrrole 
rotates away from Gln725 with increasing substituent size.  This rotation greatly reduces the 
ability of the nitrile substituent to engage the known hydrogen bonding network between Gln725 
and Arg766, an interaction that is essential for high affinity binding.  Furthermore, the largest 
substituent, CH2CH2CH2F (compound 4), begins to challenge the confines of  the available 
binding volume while Me substituent easily fits entirely within the pocket.
 Shifting our focus to C4-substitution, we observed that while docked poses for the N-Me 
and N-H series of  analogues show  a conserved binding mode, the C4-substituent only subtly 
affects ligand conformation and placement of the benzoxazine-core.  Overlaying the docked 
poses for compounds in the N-Me (Fig. 4.2) and N-H series (not shown) suggest that the gem-
dimethyl substituted compounds adopt an intermediate position.  As the size of the C4-
substituent increases, the compound rotates to a degree related to the steric bulk and in the 
direction that reflects the stereochemical configuration.
 The poses presented in Figure 4.2 imply that the stereochemical configuration at C4 
should have a marked effect on the ligand-protein interactions.  The R-configuration directs the 
substituent down in the binding pocket, where steric constraints force the core to rotate up and 
adopt a relatively small dihedral angle.  As will be discussed in section IV.A., the shift to a 
smaller dihedral angle represents a higher energy ligand conformation.  It is notable that the N-
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Figure 4.1. Docking Poses for N-substituted analogs of Tanaproget.  (A) The steric bulk of the pyrrole N-
substituent for 1 (cyan), 3 (blue), and 4 (red) induces an increasingly large dihedral angle, rotating the 
nitrile away from Gln725, and resulting in reduced hydrogen bonding.  (B) The van der Waals surface of 1 
(cyan lines) clearly fits within the binding volume (purple solid); however, (C) the surface of 4 (red lines) 
begins to challenge the confines of the pocket.
A B C
H analogues follow  a similar trend, albeit with a much smaller energy difference.  The S-
configuration, in contrast, directs the substituent up in the pocket, causing the core to rotate 
downward and adopt a more energetically favorable dihedral angle. 
IV. Numerical Analysis
 While visual analysis provided qualitative observations that explained the observed 
binding affinities for N-substituted analogs and suggests enantioselectivity for C4-substituted 
analogues, there is no obvious structural basis to differentiate the C4-substituted series of 
analogs.  Therefore, we sought out a method to quantitate receptor-ligand interactions and 
identify a relationship that directly correlates to the observed RBA values.  Such a method would 
allow  us to further elaborate on structure-activity relationships established using visual analysis, 
and evaluate additional analogues prior to engaging synthetic efforts.
A. Torsion Energetics
 Evaluating Figure 4.1, the benzoxazine-core of each ligand adopts a strikingly similar 
pose within the binding volume regardless of N-substitution, highlighting the rotation of the 
pendant pyrrole as the driving force behind reduced binding affinity within the N-R series, but 
also carries over to N-Me.  Accordingly, we targeted the effects of substituent size on ligand 
conformation by analyzing the torsional energetics of the ligand independently of  the protein. 
The contributing energy terms were calculated separately while rotating the pyrrole from 0° to 
90° with respect to the benzoxazine-core as shown in Figure 4.3.  For the unsubstituted pyrrole 
2, the torsional (tor), electronic (ele), and van der Waals (vdW) terms all significantly contribute 
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Figure 4.2. Effects of methyl (cyan), fluoroethyl (blue), and fluoropropyl (red) substitution at C4 of 
Tanaproget.  As substituent bulk increases, the core of the R-enantiomer (A) is forced upward to adopt a 
higher energy ligand conformation, while the S-enantiomer (B) allows a downward rotation to a more 
energetically favorable dihedral angle.
to the total energy.  For all cases of N-substitution (e.g., N-Me, Fig 4.3B.), however, the vdW 
term dominates the total ligand energy.  Increasing the substituent size further magnifies this 
effect (Fig. 4.3C), and by extension, results in a shift in the minimum energy to larger dihedral 
angles (Fig. 4.3C-inset).  This shift in dihedral angle mirrors the rotation of the pyrrole in the 
minimized docking poses for N-substituted analogues.
B. Interaction Energy
 The torsional energetics of the ligand indicate a shift to larger dihedral angles with N-
substitution; however, it is unclear what role the protein plays in accommodating or opposing the 
rotation of  the pyrrole towards reaching a low  energy ligand conformation.  To this end, we 
probed the rotational freedom of the pyrrole within the binding pocket through the calculation of 
an “interaction energy” as the pyrrole was rotated relative to the core.  The interaction energy, 
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Figure 4.3. Ligand energy dependence on pyrrole-benzoxazin-2-thione core dihedral  angle.  At relatively 
small angles, several  energy terms contribute to the change in total ligand energy when rotating around 
the bond connecting the N-H pyrrole and benzoxazin-2-thione core (A).  N-Substitution at the pyrrole (B) 
changes these torsional dynamics by drastically increasing the magnitude of the vdW energy term.  This 
effect is magnified with increasing substituent size (3C) and results in a shift to larger dihedral angles for 
the minimum energy conformations (C inset).  (Note differences in the energy scales on the different 
panels).
defined as the energy difference between the receptor-ligand complex and the individual energy 
contributions of the receptor and ligand, represents the energy associated directly with the 
interaction between the receptor and ligand pair.  It is important to note that this calculation does 
not take into account the energy associated with changes in receptor or ligand conformation due 
to a binding event, and therefore, is not a binding energy (see section VI.).  Based on these 
calculations the width of the energy well represents the rotational freedom of the pyrrole within 
the context of the binding volume.  Figure 4.4 shows the anticipated outcome in which the 
unsubstituted pyrrole enjoys a wide range of dihedral angles that form low  energy contacts, 
while the N-substituted analogs display increasingly narrow  energy wells corresponding to a 
tighter fit.  Somewhat unexpectedly, the N-methyl pyrrole demonstrates a lower energy 
interaction compared to the unsubstituted analog, indicating the presence of a positive non-
specific interaction between the N-methyl and receptor.  Any energy gained from this positive 
interaction would serve to help offset the energy penalty resulting from forcing the ligand into a 
sub-optimal conformation in order to fit into the binding volume, as observed from the docking 
poses.
C. Hydrogen Bond Scoring
 From experimental SAR and PR-ligand crystal structures, it has been well established 
that hydrogen bonding with residues Gln725, Arg766, Asn719, and a crystallographic water is a 
requirement for tight binding.26,28  Hydrogen bonding is heavily dependent on the distance and 
angle between the two contacts; therefore, the subtle shifts in the position of the core potentially 
attenuates these interactions in a measurable manner.  Accordingly, the hydrogen bonding 
contacts were scored using the “ligand interactions” module in MOE and are given in Table 4.2. 
On the basis of  the position and interdependence of the hydrogen bonding partners, we 
modeled RBA values as a function of  the geometric mean of the calculated hydrogen bonding 
scores.  Linearization of this function yielded a highly correlated relationship (Figure 5, slope = 
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Figure 4.4.  Calculating the interaction energy using Eq. (4.1) suggests that small  substitutions (e.g., N-
Me and N-EtF) have less rotational  freedom but make beneficial  contacts with the receptor compared to 
unsubstituted analogues.
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Table 4.2. Calculated Hydrogen Bonding Scoresa for Docked Poses of Tanaproget Analogues
Series ligand Gln725 Arg766 Asn719 H2O
geometric 
mean
AVG RBA
NR 3 0.57 0.42 0.38 0.27 0.396 0.396 18.5
4 0.23 0.35 0.40 0.29 0.311 0.311 0.99
NMe 1 0.61 0.49 0.40 0.27 0.424 0.424 151
R-5 0.57 0.50 0.45 0.24 0.419
0.425 151
S-5 0.62 0.47 0.42 0.28 0.430
R-7 0.60 0.54 0.44 0.20 0.411
0.421 90.9
S-7 0.62 0.49 0.42 0.27 0.431
NH 2 0.68 0.45 0.43 0.30 0.446 0.446 600
R-6 0.65 0.46 0.46 0.27 0.439
0.445 198
S-6 0.69 0.44 0.44 0.31 0.451
R-8 0.66 0.49 0.44 0.25 0.434
0.440 189
S-8 0.71 0.47 0.44 0.27 0.446
a Calculated using the “ligand interactions” module in MOE.
Figure 4.5.  Linear Fit Relating the Calculated Hydrogen Bonding Score to RBA.
0.43, R2 = 0.96), and the mean hydrogen bonding scores correctly predict the relative order of 
binding affinity across all three series, including extremely low  (e.g., 3, 4) and high (e.g., 2) 
affinity compounds.
V. A Unified Model for Assessing Binding Affinity
 As described in the previous sections, we have successfully identified three methods for 
the analyzing structural models of receptor-ligand complexes.  Together, these methods (visual 
analysis, torsional energetics, and hydrogen bonding) represent a cohesive model for assessing 
the molecular basis behind the observed trends in ligand binding affinity.  The application of  our 
model to understand the observed RBA values for compounds 3 and 4 is rather straightforward. 
The rotation of  the pyrrole away from Gln725, as highlighted in Figure 4.1, corresponds to the 
erosion of  the mean hydrogen bonding score (Table 4.2, series N-R) with increased substituent 
size. The difference between RBA values for the remainder of  the compounds in Table 4.1 are 
much smaller, and the analysis correspondingly more subtle. We propose that the ligand binds 
in a pose generally conserved for all analogs; the ligand conformation strikes a delicate balance 
between positioning the core to accommodate substitution at C4, maximizing hydrogen bonding 
contacts and positive interactions between the pyrrole and receptor, and minimizing internal 
ligand energy. 
 The interplay between these interactions is best illustrated by the marked decrease in RBA 
value for compound 7. The large substituent at C4 restricts the rotational freedom of the core, 
while N-Me substitution increases the internal vdW energy of the ligand, resulting in a high-
energy conformation that precludes strong hydrogen bonding interactions. The reduction of  C4-
substituent size allowing the core to rotate to a more favorable position (ex. 5), or the removal of 
the N-substituent reducing the energy associated with internal torsion (ex. 8), results in 
increased hydrogen bonding scores that correspond well to the observed higher RBA values. 
This model also supports the prediction that the S-configuration of  the C4-substitued systems 
will have higher affinity than the R-stereoisomer.
 While our model is rather simplistic, we obtain with it a linear relationship between HB score 
and ln(RBA) having a correlation coefficient over 0.95 (Fig. 4.5). This relationship accurately 
predicts the relative order of binding affinity, and it gives predicted RBA values within an average 
factor of  1.4 (and always better than a factor of 2) relative to experimentally determined ones, 
comparable to the error in experimentally determined values (cf. Table 4.1). We suspect that the 
limitations in our model could be reduced through the development of  a more complex model 
that includes a direct treatment of  energy calculations, the evaluation of  non-specific protein-
ligand interactions, and multivariate analysis. Alternative methodologies such as molecular 
dynamics simulations33 or quantum mechanical calculations34 require substantially more 
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computational resources and the development of new  parameters and methodologies.  Our very 
simple approach of analyzing ligand binding affinity through the quantification of the hydrogen 
bonding contacts, however, is suitable for explaining the binding trends of  the compounds we 
have studied (Table 4.1), and it generates a valuable predictive model for exploring 
enantioselectivity using pre-built modules and minimal computational resources.
VI. Alternative Approaches
 The observation that the N-methyl pyrrole forms positive non-specific contacts with the 
binding pocket based on our binding interaction calculations may suggest that the MMFF94x 
forcefield is competent in assessing the energetics of  matched or unmatched van der Waals 
contacts, at least for this relatively simple binary comparison (N-Me vs. N-H).  These 
interactions in conjunction with the well defined electrostatic components of  hydrogen bonding 
comprise the majority of  protein-ligand interactions in PR.  With this in mind, we extended the 
interaction energy calculation to the docked poses for all ligands in the hope that it would 
correlate to observed RBA values.  This data, shown in Table 4.3, correctly predicted the relative 
order of RBA within N-R and N-Me series; however, failed to properly order the N-H series or 
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Table 4.3.  Calculated Total, Interactiona, and Bindingb Energies for Docked Poses of Tanaproget 
Series ligand ERL Eint Ebin AVG ERLd AVG Eint AVG Ebin RBA
NR 3 488.9 -55.0 -367.0 488.9 -55.0 -367.0 18.5
4 498.7 -52.5 -355.6 498.7 -52.5 -355.6 0.99
NMe 1 486.0 -58.0 -371.1 486.0 -58.0 -371.1 151
R-5 490.3 -60.6 -366.9
488.1 -60.9 -368.5 151
S-5 485.9 -61.2 -370.1
R-7 500.5 -55.0 -359.6
496.7 -55.6 -361.4 90.9
S-7 493.0 -56.1 -363.3
NH 2 481.9 -55.4 -368.4 481.9 -55.4 -368.4 600
R-6 485.8 -58.4 -366.7
484.0 -58.4 -367.1 198
S-6 482.2 -58.5 -367.5
R-8 496.7 -54.4 -355.7
493.3 -53.5 -357.9 189
S-8 490.0 -52.5 -360.2
a Interaction Energy calculated from Eq. (4.1). b Binding Energy calculated from Eq. (4.2). c All energy 
calculations are given in kcal/mol. d ERL represents the total energy of the receptor-ligand complex.
Ebin = ERL - ( ERmin + ELmin )     (4.2)
allow cross-series comparisons.
 While these calculations provide some insight into isolated interactions between highly 
related species, the interaction energy does not take into account the energy associated with 
the change in the receptor and ligand conformations between the unbound and bound states. 
This shortcoming is clearly born out in the failure of cross-series comparisons, in which the 
energy required to adopt the internal torsion angle of the docked ligand is substantially different 
for substituted vs. unsubstituted pyrrole species as highlighted by Figure 4.3.  In order to 
account for these discrepancies, Eq. (4.1) was readily modified to approximate the binding 
energy by minimizing the receptor and protein individually prior to calculating their energies, as 
given in Eq. (4.2).  This methodology was applied to the docking pose for each ligand and given 
in Table 4.3.  Performing slightly better than the interaction energy, this method was capable of 
predicting the relative order of RBA within all sereis; however, it also failed in cross-series 
comparisons.
VII. Proposed Ligands as Radiotherapeutics
 Preliminary data from work by Dr. Ephraim Parent in our lab suggests that estrogens 
labeled with 76Br/77Br may be an effective ER-directed radiotherapy for breast cancers.  One 
potential drawback to this type of targeting system is that ER is expressed in many different 
non-target tissues which could be damaged in addition to the tumor.  PR, in contrast, is 
expressed in many fewer tissues yet can reach high expression levels in some breast tumors, 
potentially making it a better target for this type of  therapy.  Our collaborators in the Welch group 
have approached this strategy using fluoro furanyl norprogesterone (FFNP) analogs; however, 
these compounds demonstrated only low to moderate RBA values (0.81-65).35,36
 We have designed a set of  synthetically tractable compounds based on the Tanaproget 
core probing different labeling strategies for the incorporation of 76Br/77Br or 123I/124I.  Each 
compound was then docked into the PR ligand binding pocket, post-processed, and evaluated 
using our unified model as described above.  Visual analysis suggested that placing a bromide 
at position 1 strongly interfered with hydrogen bonding to Asn719 through steric shielding. 
Moving the bromine to positions 2 or 3, on the other hand, introduced steric bulk ortho to the 
pyrrole, causing it to rotate away from the optimal position required to engage the hydrogen 
bonding network between Gln725, Arg766, and the crystallographic water.  Introducing the 
desired isotope into the R-position introduced more subtle effects to the positioning of the 
benzoxazine core.  The trans-configuration of vinyl iodide yielded an extended system that 
challenged the confines of  the binding pocket, while the cis-configuration positioned the iodide 
over the face of the heterocyclic core where there was more available space to occupy (Fig. 
4.6A).  Linear bromoalkyl substituents adopted conformations similar to the CH2CH2F (6) and 
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Figure 4.6. Docked Poses of Two Potential  Radiotherapeutics.  (A) The S-cis-vinyl substituent at C4 is 
positions the vinyl  iodide over the face of the benzoxazine-2-thione core, where there is available space. 
(B) The S-bromopropyl subtituent adopts a pose very similar to 5 (see Fig. 2B).
Table 4.4. Calculated Hydrogen Bonding Scoresa of Potential Radiopharmaceuticals
N
H
ON
H
4Me
S
NC
1
2
3
1 2 3 4 Gln725 Arg766 Asn719 H2O
geometric  
mean
AVG 
mean
Br H H CH3 0.589 0.460 0.264 0.313 0.387 0.387
H Br H CH3 0.559 0.519 0.425 0.204 0.398 0.398
H H Br CH3 0.674 0.471 0.446 0.195 0.408 0.408
H H H
CH2CH2Br
0.616 0.424 0.409 0.279 0.415
0.417
H H H 0.740 0.510 0.362 0.224 0.418
H H H
CH2CH2CH2Br
0.627 0.440 0.454 0.279 0.432
0.433
H H H 0.757 0.476 0.418 0.236 0.434
H H H
-CH=CHI (trans)
0.684 0.534 0.384 0.210 0.414
0.414
H H H 0.710 0.521 0.366 0.216 0.414
H H H
-CH=CHI (cis)
0.716 0.580 0.444 0.167 0.419
0.421
H H H 0.682 0.550 0.439 0.196 0.424
a Calculated using the “ligand interactions” module in MOE.
CH2CH2CH2F (8) conformations described in previous sections (Fig. 4.6B); however, the 
increased size of bromine relative to fluorine appeared to affect ideal positioning of the core . 
Each of  these observations is also mirrored in the calculated hydrogen bonding scores given in 
Table 4.4.  Based on these data, the synthesis of compounds bearing a cis-vinyliodide or 
bromopropyl substituent at the R-position are currently under consideration as initial synthetic 
targets.
VIII. Conclusions
 We set out to probe the molecular basis for the binding trends observed for a series of 
analogues of Tanaproget, given in Table 1.  Structural models were constructed in silico using 
ligand docking software followed by a multistage minimization protocol.  The resulting receptor-
ligand complexes were investigated both qualitatively and quantitatively using a variety of 
computational methods.  From these data, we have been able to rationalize the distinct 
structure-binding affinity relationships in this series by molecular modeling of  ligand internal 
energy and ligand-receptor hydrogen bonding score, and our model yields an intriguing 
explanation for the interaction between substituents at the two ends of the Tanaproget core as 
well as offering predictions of enantioselectivity.  Finally, we have applied these methods to 
identify two compounds of  interest as radiotherapeutics for the targeted treatment of breast 
cancer. 
IX. Experimental
A. Procedure for docking Tanaproget (1) and analogs.
 The PR structure was obtained from the PDB databank (1ZUC)28 and prepared using the 
Molecular Operating Environment (MOE).32 Explicit hydrogen atoms were added, partial 
charges were computed using the MMFF94x force field, and the receptor-ligand complex was 
minimized with a termination gradient of  0.5. All water molecules were then deleted except the 
single water molecule hydrogen bound to Gln725 and Arg766. Finally, the ligand was removed 
and the receptor structure was processed using AutoDock Tools37 to define the AD4 atom types 
and calculate Gasteiger charges.
 All compounds in Table 4.1 were constructed in Sybyl 8.1.1,30 cleaned up using the built-in 
Concord module,38 and minimized using the Powell method with a termination gradient of 
0.5kcal/(mol*A), 100K maximum iterations, and MMFF94 force fields and charges. The ligands 
were prepared for docking using AutoDock Tools to assign AD4 atom types, calculate Gasteiger 
charges, and set all rotatable bonds as active torsions. Each ligand was docked into the 
receptor using AutoDock Vina.31 The grid box was centered on the ligand in the original crystal 
structure, and measured 18 Å by 18 Å by 22 Å. To ensure that the proper binding conformation 
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was found, the exhaustiveness parameter was set to 100 (default=8, linear scale); all other 
default settings were used.
 The top five poses for each ligand were visually inspected in MOE. Unreasonable poses 
were discarded and the lowest energy conformation of the remaining poses was selected for 
further use. The selected pose and receptor structure were merged into a single file, all 
hydrogen atoms were explicitly added, the partial charges were calculated using the MMFF94x 
force field, and the protein-ligand complex was minimized. The minimization was conducted in 
four stages: stage 1 minimized the hydrogen atoms that were added to the structure in the 
previous step; stage 2 minimized the ligand; stage 3 minimized any residues within 4.5 Å of the 
ligand; and stage 4 minimized both the ligand and any residues within 4.5 Å. This worked up 
structure was used for all other calculations and analyses.
B. Procedure for calculating the torsion energetics of N-substituted analogs.
 The worked up structure was opened in MOE and all atoms deleted except for the ligand. 
The dihedral angle relating the pyrrole to the benzoxazin-2-thione core was rotated from 0-90 
degrees, measuring each energy term in 0.5-degree increments. The relative value of each term 
was calculated by subtracting the minimum measured value.
C. Procedure for calculating the effect of N-substitution on interaction energy of the pyrrole.
 Similar to the above process, the pyrrole was rotated with respect to the core by setting the 
dihedral angle from 0-90 degrees, measuring the interaction energy [Eq. (1)] in 0.5-degree 
increments. To ensure that any observed change in the interaction energy was due solely to a 
difference in the N-substitution, we started from the worked up pose of compound 5a, deleting 
atoms as necessary to obtain N-Me (1) and N-H (2). The partial charges were recalculated 
using MMFF94x force field prior to beginning the rotation.
D. Procedure for calculating the interaction and binding energies of the protein-ligand complex.
 The worked up structure was opened in MOE and the total energy of  the receptor-ligand 
complex was calculated (ERL).  The ligand was deleted from the structure and the receptor 
energy was calculated (ER).  The pocket residues (within 4.5A of the ligand) and associated 
water molecule were minimized to a termination gradient of 0.01, and the minimized receptor 
energy was calculated (ERmin).  The worked up structure was reloaded, the receptor was 
deleted, and the ligand energy was calculated (EL).  Using these values, the minimized ligand 
energy (ELmin) was calculated following a minimization of  the ligand to a termination gradient of 
0.01.  The interaction and binding energies were calculated from equations (4.1) and (4.2), 
respectively.
113
E. Procedure for calculating the mean hydrogen bond score (Table 4.4).  
 The hydrogen bonds formed between the ligand and protein were scored using the 
“dock_HydrogenBonds” module found in the standard scientific vector language (SVL) library for 
MOE. This module forms the basis for the “ligand interactions” feature accessible from MOE’s 
graphical user interface. The mean score was subsequently calculated as the geometric mean 
of the individual scores.
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CHAPTER 5
PROBING THE PRESENCE AND IMPORTANCE OF A PUTATIVE
SECOND LIGAND BINDING VOLUME IN THE ESTROGEN RECEPTOR
I. Introduction
 Long term interests in the development of synthetic non-steroidal ligands for ERs have 
led to the development of well-establish pharmacophores, as discussed in Chapter 1.  These 
pharmacophores, however, are built upon relatively similar classes of heterocyclic cores, 
namely, 5-membered and 6,5-fused bicyclic heterocycles.  This dearth of  novel core structures 
represents a bottleneck to expanding overall ligand diversity, and impedes the development of 
SERMs with novel biological properties.
 Many crystal structures for both ER! and ER" exist in the PDB, and the availability of 
commercial virtual compound libraries lends itself to in silico screening for potentially useful ER 
ligands containing fundamentally new  scaffolds.  A virtual screen of  the Maybridge HitFinder™ 
library containing ~2000 compounds was conducted by our group identified nineteen initial 
structures of interest.  These compounds were subsequently purchased from Maybridge and 
tested for in vitro binding affinity to ER.  The highest affinities were observed for compounds 
BTB-10314 and S-08084, as given in Figure 5.1.  These RBA data may appear low  relative to 
E2; however, the corresponding Ki values for S-08084, for example, are 71 nM and 161 nM for 
ER! and ER", respectively.  Initial S-08084 and BTB-10314 binding affinities in the mid to high 
nanomolar range provided hope for their potential as effective ER ligands, particularly for the 
development of sub-type selective ligands.
 The most intriguing property of  these compounds, however, was the extended non-polar 
alkyl chain.  Docking of S-08084 analog 1d in ER" suggested that the ligand might bind with the 
tetradecyl chain extending into a solvent channel (Figure 5.2) previously described as a possible 
second binding site within both ER subtypes.  The presence of a second binding volume was 
proposed by Klinge1 in response to fluorescence data demonstrating the non-competitive 
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Figure 5.1.  BTB-10314 and S-08084 were identified as potential  SERMs from an in silico screening of 
the Maybridge HitFinder™ library consisting of ~2000 compounds.  These compounds are of particular 
interested based on their novel  structures and the presence of the extended alkyl  sidechain, which may 
have implications as to the existence, importance, and function of a putative second binding pocket in ER.
binding of  tetrahydrochrysene ketone (THCK) in the presence of E2.  A subsequent modeling 
study by van Hoorn2 identified the solvent channel described above as the potential binding 
volume; however, concluded that this site was too far from the ligand binding site to affect the 
conformation of helix 12, and therefore, could not be used to influence agonist versus 
antagonist behavior in either ER subtype.  A similar binding mode has also been observed in 
related nuclear hormone receptors such as the glucocorticoid and vitamin D receptors.  A recent 
crystal structure of  deacylcortivazol (DAC) complexed with GR3 highlights the flexibility of the 
receptor in this direction, expanding the pocket volume to nearly double the original size, and 
leading to the design of new  non-steroidal high affinity GR ligands.4  Accordingly, we set out to 
further investigate analogs of  BTB-10314 and S-08084, as chemical probes for the existence, 
importance, and function of  a putative second binding pocket within both ER subtypes. 
Analogues of  BTB-10314 were pursued by John Comninos in our lab, and S-08084 are 
described herein.
II. Chemistry
 Analogues of  S-08084 were synthesized from 5-amino-1,3,4-thiadiazole-2-thiol and a 
series of alkyl halides in a suspension of NaH (60% wt. dispersion in mineral oil) in anhydrous 
DMF (Table 5.1).  These reactions were initially performed according to method A, in which the 
UV-active thiadiazole represented the limiting reagent in order to facilitate reaction monitoring, 
and the desired product was isolated from remaining mineral oil via trituration from hexanes. 
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Figure 5.2. 5-Tetradecylsulfanyl-1,3,4-thiadiazol-2-ylamine (1d) docked into ER! crystal structure using 
Sybyl (performed by John Comninos).  The thiadiazole core binds in the ligand binding pocket while 
the tetradecyl alkyl sidechain protrudes through the channel created by Glu305 and Leu343 into 
the proposed second binding pocket.
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NN
S
H2N SH
Br-R+
NN
S
H2N S
R
NaH
DMF
Compound Halide Method1 Rxn Time (hrs) Yield
1a Br (CH2)7CH3 a 1 22%
1b Br (CH2)9CH3 a 1 16%
1c Br (CH2)11CH3
a
b
<1
2
31%
35%
1d Br (CH2)13CH3
a
b
<1
13
12%
77%
2a
Br
b 4 74%2
2b
Br
b 4.5 22%
2c
Br
b 16 41%
3
Br
b 3 68%
4a
Br
OMe
b 5 54%
4b
Br
OH
b 3 21%
1 a = alkyl halide used in excess, product isolated from mineral oil by trituration from hexanes; b = thiadiazole used in excess and 
removed during workup by KOH (aq) extraction, and the mineral oil was removed from NaH prior to reaction.  2 crude yield
Table 5.1. S-Alkylation of 5-amino-1,3,4-thiadiazole-2-thiol using various halides
Scheme 5.1. Preparation of 4-(2-bromoethyl)-phenol
Br
OMe
BF3·SMe2
DCM
Br
OH
5, 83%
Under these conditions, extended chain alkyl halides generated emulsions during the aqueous 
workup, complicating the isolation and purification process.  Optimization of  the reaction 
conditions resulted in the development of  method B, in which the NaH was purified from the 
mineral oil dispersion prior to the reaction, the thiadiazole was used in excess and removed 
during the workup by a KOH (aq) wash, and the reaction time was significantly extended in most 
cases due to difficulty in monitoring the reaction.  Alkyl halide 5 was synthesized from 
commercially available 4-methoxyphenethyl bromide via cleavage of the aryl-methyl ether using 
the mild Lewis acid BF3·SMe2 in dichloromethane (DCM). 
III. in vitro Biological Data
 The in vitro binding affinity was determined by radiometric competitive binding assay 
relative to estradiol (E2) for products 1-4.  All compounds tested yielded RBA measurements at 
or below  the sensitivity of the assay (RBA ~0.007).  Subsequently, new  samples of  S-08084 and 
BTB-10314 were purchased from Maybridge and retested for binding affinity; both failed to bind 
significantly above the sensitivity of the assay, in contrast to initial data (Figure 5.1).
IV. Results and Discussion
 In order to probe the importance and variability of the alkyl side chain and volume 
constraints of a second binding pocket, we prepared S-08084 along with a series of analogues 
bearing linear alkyl and cycloalkyl substitutents.  The 5-amino-1,3,4-thiadiazole-2-thiol core has 
recently been substituted via S-alkylation using a biphasic system in which the desired product 
precipitated from water (the reaction solvent) under basic conditions, requiring only filtration and 
purification by recrystallization.5  These reaction conditions, however, failed to yield product 
when alkylating with extended chains, presumably due to slow  kinetics inherent in the minimal 
solubility of the alkyl halide at the solvent interface.  The reaction conditions were then altered to 
a single phase reaction using DMF as a solvent, affording the desired products over a range of 
yields (Table 5.2, 1-4).
 Optimization of  this reaction scheme was difficult primarily due to the inability to monitor 
the presence of alkyl halide by TLC with any significant sensitivity.  Furthermore, as the alkyl 
chain lengths increased for an emulsion observed during the workup and correlated to reduced 
yields, most likely due to reduced solubility of longer alkyl chains in the reaction and workup 
solvents (DMF and EtOAc, respectively).  Subsequent alteration of  reaction conditions and 
workup, as denoted by the alkylation method in Table 2, eliminated the appearance of the 
emulsion and increased yield considerably as illustrated by 1d.
 With the exception of  entry 1d, the yields are lower than would be expected for a simple 
nucleophilic displacement of  a halide.  An increased yield with the overnight reaction time 
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suggests surprisingly slow  kinetics and further research into the 5-amino-1,3,4-thiadiazole-2-
thiol core clarified this situation.  X-ray crystal,6 FT-IR, and FT-RAMAN spectroscopy7 studies 
have demonstrated that the predominant tautomer present at ambient temperatures is the 
thione form (Figure 5.3a).  From the X-ray crystal structure, Downie estimated the C-SH bond at 
approximately 75% double bond character (Figure 5.3b); therefore, resonance stabilization of 
the negative charge through the heteroaromatic ring strongly decreases the nucleophilicity of 
the sulfur atom.  Evidence of  this is also observed in the NMR of the 5-amino-1,3,4-
thiadiazole-2-thiol starting material.  As an example of a thiol attached to an aromatic system, 
the chemical shift of the thiol proton of benzenethiol is predicted at ! 2-4.8  In contrast, the thiol 
peak of  the 5-amino-1,3,4-thiadiazole-2-thiol is observed at ! 13.15 in DMSO, indicating a 
strongly deshielded proton.
 We subsequently selected 4-hydroxy phenethyl and benzyl substituents in an effort to 
improve binding affinity by mimicking the A-ring and 17" hydroxyl substituents of E2.  Previous 
experience with these types of systems and protection schemes has demonstrated product 
decomposition due to elimination of the core as a leaving group from the benzyl carbon upon 
deprotection (Figure 5.4a).  In an attempt to circumvent this, we deprotected the 4-hydroxyl 
substituent prior to alkylating the thiadiazole core.  The deprotection of 4-methoxybenzyl 
bromide using BF3.SMe2 appeared complete by TLC; however, the product underwent 
decomposition during isolation, presumably due to the elimination of bromide ion and formation 
of quinone methide (Figure 5.4b) among other decomposition products.  In a subsequent 
attempt, the deprotection reaction was quenched and pre-formed thiadiazole anion was injected 
directly.  NMR analysis of the crude product suggested that the desired product was formed; 
however, attempts at isolation failed.  In order to isolate the 4-hydroxylbenzyl system as the 
cause of  the observed decomposition, the 5-amino-1,3,4-thiadiazole-2-thiol core was alkylated 
with benzyl bromide (Table 5.1, 3) and 4-methoxyphenethyl bromide (Table 5.1, 4a); both 
products were stable and isolable.  The presence of an additional carbon linking the thiadiazole 
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Figure 5.3.  a) Tautomerization between the thiol and thione form; the thione form is predominate at 
ambient temperatures.  b) Double bond character (%) as approximated from spectroscopic studies.[refs] 
!
core and the 4-hydroxylphenyl substituent prevented the aforementioned quinone-type 
decomposition pathway.  The deprotection of 4-methoxyphenethyl bromide yielded the desired 
phenol isolated in 90% yield.  Subsequent S-alkylation of  the thiadiazole core afforded the 
desired product 4b.
 With a number of thiol alkylated products in hand, the next option was N-substitution, 
which would reverse the orientation of  the core within the pocket, allowing hydrogen bonding 
from 2-SH versus 5-NH2.  Two methods for N-alkylation were attempted: imine formation 
followed by reductive amination, and amide formation followed by reduction to the amine. 
Despite a variety of aldehyde substrates and reaction conditions, the desired imine was never 
formed.  Although surprising, these data are attributed to reduced nucleophilicity of the amine 
due to the presence of  less reactive thiadiazole tautomers.  Similar spectroscopic evidence 
places the C-NH2 bond at 30% double bond character (Figure 5.3b).6  After substantial attempts 
at refining reaction conditions, this scheme was eventually abandoned in favor of amide 
formation.
 Examples of similar amides formed using the 5-amine-1,3,4-thiadiazole-2-thiol core 
existed in the literature.9,10  Due to the low  RBA values for all compounds synthesized by this 
point, we only chose one target, 5-(4-hydroxybenzyl)amino-1,3,4-thiadiazole-2-thiol, from p-
anisoyl chloride (Scheme 5.2).  The desired intermediate appears to have been obtained by 
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Figure 5.4.  A) Proposed decomposition mechanism for the elimination of the thiadiazole core from the 
benzyl  carbon upon deprotection of the 4-methoxy substituent.  B) The analogous mechanism is 
proposed to explain the observed decomposition of 4-methoxybenzyl bromide upon isolation.
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Scheme 5.2. Retrosynthetic analysis of 5-(4-hydroxybenzyl)amino-1,3,4-thiadiazole-2-thiol 5.
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reacting with Et3N in refluxing THF; however, it could not be isolated and purified despite several 
attempts.  These failures were due to low  solubility in solvents utilized for flash chromatography 
and recrystallization, and product decomposition prior to successful isolation.  Optimization of 
the reaction conditions, workup, isolation, and purification were never fully explored as all 
compounds tested yielded RBA values below the sensitivity of the assay.
V. Conclusions
 Computational screening of Maybridge’s HitFinder™ virtual library yielded two 
compounds, S-08084 and BTB-10314 that appeared to have potential for the development as 
SERMs backed by favorable docking and initial binding affinities relative to estradiol (Figure 
5.1).  S-alkylation of  the 2-thiol required significant optimization due to the hydrophobicity of the 
alkylating agents and the reduced nucleophilicity of the thiol.  Furthermore, substitution of the 
amine via imine formation was never achieved using a variety of  reaction conditions.  Alternate 
N-substitution schemes via amide formation showed promise, but were not followed to 
completion due to poor binding data for all products synthesized.  New  samples of  the original 
compounds were purchased from Maybridge in larger quantities and re-tested for binding 
affinity; both failed to bind significantly above the sensitivity of the binding assay, implying 
contamination or misidentification of the original samples.  As a result, 5-amino-1,3,4-
thiadiazole-2-thiol is no longer of immediate interest as a scaffold in the development of SERMs.
VI. Experimental
 General Considerations.  All chemical reagents were purchased from commercial 
suppliers without further purification.  Anhydrous DMF was obtained from Aldrich in a 
Sureseal™ bottle stored in a secondary container with desiccant; all other anhydrous solvents 
were obtained from a solvent dispensing system unless otherwise stated.  All glassware was 
oven or flame-dried and cooled under vacuum or in a dry box.  All reactions were conducted 
under argon.  NMR spectra were obtained on Varian Oxford instruments and worked up using 
ACD, Inc. 1D-NMR processing software.  The chemical shifts are reported in ppm and 
referenced to the solvent peak.  Electron Impact (EI) mass spectra were obtained on a 70-VSE 
mass spectrometer with an ionization energy of 70 eV.  Electrospray Ionization (ESI) mass 
spectra were obtained on a Q-Tof  mass spectrometer.  Melting point ranges were measured 
using a Thomas Hoover capillary melting point apparatus.
 General Procedure for S-Alkylation.  Method A. 2-amino-1,3,4-thiadiazole-2-thiol (266 
mg, 2.0 mmol) was dissolved in anhydrous DMF (3 mL).  NaH (60% in mineral oil, 120 mg, 3.0 
mmol) was added in a glove bag filled with N2.  The corresponding alkyl halide (2.4 mmol) was 
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added with stirring and heated to 60 °C under Ar until the reaction was complete by TLC (3:1 
hexanes:EtOAc), usually within one hour.  The reaction products were isolated using a standard 
workup consisting of  (a) a quench in water, (b) exhaustive extraction with ethyl acetate, (c) 
drying over magnesium sulfate, (d) vacuum filtration, (e) re-suspension in hexanes, (f) a second 
vacuum filtration, and (g) concentration by rotary evaporation.  The products were purified by 
recrystallization (EtOAc).  Method B. NaH (60% in mineral oil, 80.0 mg, 2.0 mmol) was added to 
a 3-necked 25 mL round bottomed flask and dissolved in anhydrous THF (2.5-5.0 mL).  While 
the solution was stirring under Ar the THF and mineral oil mixture was removed using a pipet 
with a cotton tip held under vacuum.  The remaining solid was dissolved in 2 mL anhydrous 
DMF.  2-amino-1,3,4-thiadiazole-2-thiol (2.0 mmol, 266.4 mg) and the corresponding alkyl halide 
(1.8 mmol) were added subsequently; the reaction mixture was heated to 60 °C and stirred 
under Ar until done by TLC.  The reaction products were isolated using a standard workup 
consisting of (a) a quench in 1 M KOH, (b) exhaustive extraction with EtOAc, (c) drying over 
MgSO4, (d) vacuum filtration, and (e) concentration by rotary evaporation.  The products were 
purified by recrystallization (EtOAc).
 5-octylsulfanyl-1,3,4-thiadiazol-2-ylamine (1a).  Following the general procedure for 
alkylation according to method A, 1a was isolated as a beige solid (220.1 mg, 22.2%).  1H-NMR 
(DMSO-d6, 400 MHz) ! 7.26 (s, 2H), 3.00 (t, J = 7.29 Hz, 2H), 1.93 (s, 2H), 1.59 (m, 2H), 1.32 
(m, 2H), 1.20 (m, 8H), 0.82 (t, J = 7.0 Hz, 3H); 13C-NMR (DMSO-d6, 100 MHz) ! 170.10, 
150.90, 34.97, 31.90, 29.74, 29.28, 29.15, 28.56, 22.77, 14.56.  HRMS (EI): calc’d for 
C10H19N3S2 [M+H]+ 245.1020, found 245.1020; mp 113-114oC.
 5-decylsulfanyl-1,3,4-thiadiazol-2-ylamine (1b).  Following the general procedure for 
alkylation according to method A, 1b was isolated as a beige solid (86.1 mg, 15.7%).  1H-NMR 
(DMSO-d6, 500 MHz) ! 7.24 (s, 2H), 3.00 (t, J = 7.18 Hz, 2H), 1.59 (m, 2H), 1.32 (m, 14H), 0.82 
(t, J = 6.75 MHz, 3H); 13C-NMR (DMSO-d6, 125 MHz) ! 170.09, 150.87, 34.95, 32.00, 29.74, 
29.65, 29.63, 29.41, 29.21, 28.57, 22.80, 14.57.  HRMS (EI): calc’d for C12H23N3S2 [M+H]+ 
273.1333, found 273.1340; mp 113-114oC.
 5-dodecylsulfanyl-1,3,4-thiadiazol-2-ylamine (1c). Following the general procedure for 
alkylation according to method A (186.7 mg, 31.3%) and method B (391.7 mg, 36.2%), 1c was 
isolated as a yellow  solid.  1H-NMR (DMF-d7, 500 MHz) ! 7.38 (s, 2H), 3.09 (t, J = 7.29, 2H), 
1.69 (m, 2H), 1.41 (m, 2H), 1.27 (m, 18H), 0.87 (t, J = 6.86 Hz, 3H); 13C-NMR (DMF-d7, 125 
MHz) !  170.14, 151.21, 34.85, 32.04, 29.80, 29.78, 29.77, 29.73, 29.67, 29.49, 29.24, 28.60, 
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22.76, 13.95.  HRMS (EI): calc’d for C14H27N3S2 [M+H]+ 301.1646, found 301.1636; mp 
114-116oC.
 5-tetradecylsulfanyl-1,3,4-thiadiazol-2-ylamine (1d).  Following the general procedure 
for alkylation according to method A (70.5 mg, 11.9%) and method B (906.3 mg, 76.5%), 1d was 
isolated as yellow-white solid.  1H-NMR (DMSO-d6, 500 MHz) ! 7.26 (s, 2H), 3.01 (t, J = 7.29 
Hz, 2H), 1.59 (m, 2H), 1.33 (m, 2H), 1.21 (m, 20H), 0.83 (t, J = 6.85 Hz, 3H); 13C-NMR (DMSO-
d6, 125 MHz) !  169.44, 150.23, 34.30, 31.32, 29.08,29.07, 29.06, 29.04, 28.98, 28.93, 28.75, 
28.49, 27.87, 22.12,13.95.  HRMS (EI): calc’d for C16H31N3S2 [M+H]+ 329.1960, found 
329.1951; mp 114-117oC.
 5-cyclopentylsulfanyl-1,3,4-thiadiazol-2-ylamine (2a).  Following the general 
procedure for alkylation according to method B, 2a was isolated as a yellow-white fibrous solid 
(267.6 mg, 73.6% crude).  1H-NMR (DMSO-d6, 500 MHz) ! 7.32 (s, 2H), 3.68 (m, 1H), 2.01 (m, 
2), 1.61 (m, 6H); 13C-NMR (DMSO-d6, 125 MHz) ! 170.63, 150.42, 48.21, 33.71, 24.91.  HRMS 
(EI): calc’d for C7H11N3S2 [M+H]+ 201.0394, found 201.0389; mp 173-174oC.
 5-cyclohexylsulfanyl-1,3,4-thiadiazol-2-ylamine (2b).  Following the general 
procedure for alkylation according to method B, 2b was isolated as a white fibrous solid (86.3 
mg, 21.6%).  1H-NMR (DMSO-d6, 500 MHz) ! 7.33 (s, 2H), 1.93 (m, 2H), 1.67 (m, 2H), 1.52 (m, 
1H), 1.28 (m, 6H); 13C-NMR (DMSO-d6, 125 MHz) ! 170.94, 148.94, 48.38, 33.50, 25.91, 25.67. 
HRMS (EI): calcd for C8H13N3S2 [M+H]+  215.0551, found 215.0544; mp 178-179oC.
 5-cycloheptylsulfanyl-1,3,4-thiadiazol-2-ylamine (2c).  Following the general 
procedure for the alkylation according to method B and scaling up by two-fold, 2c was isolated 
as yellow-white solid (346.8 mg, 41.1%).  1H-NMR (DMSO-d6, 500 MHz) ! 7.32 (s, 2H), 3.48 
(ddd, J = 13.45, 8.95, 4.39, 1H), 1.98 (m, 2H), 1.53 (m, 10H); 13C NMR (DMSO-d6, 125 MHz) ! 
170.83, 149.92, 50.26, 34.95, 28.31, 25.74.  HRMS (EI): calc’d for C9H15N3S2 [M+H]+ 229.0707, 
found 229.0700; mp 155-157oC.
 5-benzylsulfanyl-1,3,4-thiadiazol-2-ylamine (3).  Following the general procedure for 
S-alkylation according to method B, 3 was isolated as a yellow  solid (306.3 mg, 68.0%).  1H-
NMR (DMSO-d6, 500 MHz) ! 7.34-7.23 (m, 4H), 7.27 (s, 2H), 7.25 (tt, J = 6.91 Hz, 1.72 Hz), 
4.28 (s, 2H); 13C-NMR (DMSO-d6, 125 MHz) ! 169.94, 149.55, 137.14, 129.02, 128.52, 127.48, 
38.49.  HRMS (EI): calcd for C9H9N3S2 [M+H]+  223.0238, found 223.0244; mp 157-159oC.
124
 5-(4-methoxyphenethyl)sulfanyl-1,3,4-thiadiazol-2-ylamine (4a).  Following the 
general procedure for S-alkylation according to method B, 4a was isolated as yellow-white solid 
(288.0 mg, 54.3%).  1H-NMR (DMSO-d6, 500 MHz) ! 7.28 (s, 2H), 7.14 (m, 1H), 6.84 (m, 1H), 
3.70 (s, 3), 3.24 (t, J = 7.50 Hz, 2H), 2.85 (t, J = 7.50, 2H); 13C-NMR (DMSO-d6, 125 MHz) ! 
169.53, 157.93, 150.26, 131.46, 129.64, 113.81, 54.84, 35.84, 34.21.  HRMS (EI): calc’d for 
C11H13N3OS2 [M+H]+ 267.0500, found 267.0502; mp 144-147oC.
 4-(2-bromoethyl)-phenol (5).  4-methoxyphenethyl bromide (430 mg, 2.0 mmol) was 
added to a 50 mL 3-necked round bottomed flask and dissolved in 10 mL DCM.  After purging 
with Ar, BF3.SMe2 (0.850 mL, 8.0 mmol) was injected and the solution stirred at room 
temperature overnight (~12 h).  The reaction was quenched with MeOH, and the solvent 
removed by a stream of N2.  The remaining red oil was dissolved in EtOAc, washed with water, 
dried over MgSO4, vacuum filtered, and concentrated by rotary evaporation.  The product was 
purified by flash chromatography over silica gel (50% EtOAc in hexanes), and isolated as a 
white powder (362.5 mg, 82.9%).  1H-NMR (CDCl3, 500 MHz) ! 7.07 (AA'XX', 2H), 6.78 
(AA'XX', 2H), 4.77 (s, 1H), 3.51 (t, J=7.6 Hz, 2H), 3.08 (J=7.6 Hz, 2H); 13C-NMR (CDCl3, 125 
MHz) ! 154.41, 131.29, 129.93, 115.46, 38.56, 33.42.
 5-(4-hydroxyphenethyl)-sulfanyl-1,3,4-thiadiazol-2-ylamine (4b).  Following the 
general procedure for S-alkylation according to method B, 4b was isolated as white flakey solid 
(90.9 mg, 21.2%).  1H-NMR (DMSO-d6, 500 MHz) ! 9.22 (s, 1H), 7.27 (s, 2H), 7.00 (m, 2H), 
6.66 (m, 2H), 3.21 (t, J = 7.5 Hz, 2H), 2.79 (t, J = 7.5 Hz, 2H); 13C-NMR (DMSO-d6, 125 MHz) ! 
170.10, 156.57, 150.91, 130.32, 130.18, 115.80, 36.55, 34.94.  HRMS (ESI): C10H11N3OS2 [M
+H]+ calc’d 254.0422, found 254.0408.
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APPENDIX A
TEMPLATES, SCRIPTS AND PROGRAMS
I. Docking Code
A. Templates
i. Filetree
/docking_out
 /date-labelled subfolders
  /compound basenames
   raw docking output (pdbqt/pdb files)
/etc
 LOGs
/ligands
 various collected ligand files; general storage
/ligands2dock
 pdbqt/pdb for ligands to be docked
/runfiles
 prepared receptor pdbqt files
 configuration file(s) (eg. conf.txt)
/src
 DockWkup.svl
 docking.bash
 moe2pdb.svl
 prepare_ligands.bash
 prepare_moe_min.bash
ii. Sample AutoDock Vina Configuration File
receptor = ../runfiles/2QGW_empty.pdbqt
center_x = 14.836
center_y = 3.854
center_z = 33.806
size_x = 20
size_y = 20
size_z = 20
exhaustiveness = 100
B. Bash Scripts
i. prepare_ligands.bash
# Written by Christopher Mayne, 02/10/2010
# converts all pdb files in ../ligands2dock to pdbqt files; shouldn't do anything to pdbqt files
cd ../ligands2dock
for f in `ls *.pdb`
do
 pythonsh /library/MGLTools/1.5.4/MGLToolsPckgs/AutoDockTools/Utilities24/
prepare_ligand4.py -l $f
done
cd ../src
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ii. Docking.bash
#!/bin/bash
# Written by Christopher Mayne
# Date: 02/10/2010
# A better control file for docking using autodock vina
# Change Log
# 06/29/2010 - fix vina command line parameters to place ligand out and log file in $b folder
# 06/29/2010 - add the echo line to report the basename for each ligand during docking
# 06/29/2010 - add a timestamp at beginning and end of docking 
#########################################################################
#                                                                                                                                             #
# Requires a specific filetree format:                                                                                      #
#    ./src contains docking.bash (this file)                                                                               #
#    ./runfiles contains receptor_file.pdbqt and conf.txt                                                          #
#    ./ligands2dock contains all pdbqt files                                                                             #
#    ./docking_out will hold the output files                                                                             #
#                                                                                                                                            #
# The docked output will be held in ./docking_out folder, organized by date                        #
# and basename                                                                                                                    #
#                                                                                                                                            #
# The output will also be post-processed to convert the pdbqt files to pdb                           #
#                                                                                                                                            #
#########################################################################
# Beginning Timestamp
echo 'Script Start: '`date`
# Set docking run variables
date_folder=`date +%Y.%m.%d`
# Start a loop that docks each ligand with a pdbqt extension in the ligands2dock
# subdirectory
for f in `ls ../ligands2dock | grep .pdbqt`
do
# Find and set basename
 b=`basename $f .pdbqt`
# Create the subdirectory in the ../docking_out/<date> folder to place all docking output
 mkdir -p ../docking_out/$date_folder/$b
 
# Run Vina with common parameters
 echo 'Currently Docking: ' $b
 vina --config ../runfiles/conf.txt --ligand ../ligands2dock/$f --ligand_out ../docking_out/
$date_folder/$b/out_ --log ../docking_out/$date_folder/$b/log.txt
# Post-process the pdbqt files
 cd ../docking_out/$date_folder/$b
 for outfile in `ls *.pdbqt`
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 do
  pythonsh /library/MGLTools/1.5.4/MGLToolsPckgs/AutoDockTools/Utilities24/
pdbqt_to_pdb.py -f $outfile
 done
 cd ../../../src
 
done
# End Timestamp
echo 'Script End: '`date`
iii. prepare_moe_min.bash
!/bin/bash
# Written by Christopher Mayne
# Date: 02/10/2010
# Post Processing of Docking files for MOE Processing
# Passed: requires the docking directory passed as argument
# Returns: writes file with full path to lowest energy pdb files
# Change the CWD to the appropriate docking_out subfolder
cd ../docking_out/$1
mkdir moe_wkup
# Loop through each sub folder
for f in `find * ! -name moe* -type d`
do
 cd $f
 
 # Find the lowest energy output file
 pdb_file=`ls *1.pdb | awk '/out_(01|1)\.pdb/'`
 
 # Set a variable to the full path of the lowest energy pdb file
 dir_path=`pwd`
 full_file_path=$dir_path\/$pdb_file
 
 # Reset CWD
 cd ..
 
 # Write the path to a txt file in specific docking_out subfolder
 echo $full_file_path >> ./moe_wkup/moe_min_inputfile
 
done
C. Scientific Vector Language (SVL) Programs
i. moe2pdb.svl
carbocycle:src cmayne$ cat moe2pdb.svl 
// Written by Christopher G. Mayne
// Created: 09/18/2010
// Description: Converts .moe to pdb
// Input: save directory, moe files
// Output: .pdb files
// ---Change Log---
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//
global function moe2pdb [savedir, moefiles]
 local mfile, basename, savename;
 
 for mfile in moefiles loop
 
  Open mfile;
  View Atoms[];
  basename = ftail (fbase mfile);
  savename = twrite ['{}/{}.pdb', savedir, basename];
  SaveAs savename;
  Close[force:1];
 
 endloop
 
endfunction
ii. DockWkup.svl
// Written by Christopher G. Mayne
// Created: 11/02/2009
// Description: Multistep minimization of docking poses
// Input: receptor structure, file containing path to poses
// Output: merged and minimized ligand-protein complex file (_wkup.moe)
// ---Change Log---
// 06/28/2010 - change 'third' to 'last' when selecting the ligand.  This will generalize the
// selection in the event that there are not crystallographic waters left in, which occupied
// the second chain in the development files.  Since the ligand file is opened after the 
// receptor, it will always occupy the last chain.
// Import Built-in Functions
function PartialCharge, MM;
//--------------Proximal Residue Search Subroutine----------------------------------------
// 11/2/0/2009 taken from ProxResFind.svl and converted to local function
local function ProxResFind [atom_set, sel_atoms, radius]
    if not length sel_atoms then return 0; endif;
    const PACKET = 50;
    local r = max [0, radius];
    local mask = zero atom_set;
    local x;
    for x in split [x_id atom_set, PACKET] loop
 local key = prox_open [r, aPos atom_set[x], r/2];
 local idx = uniq second prox_find [ key, aPos sel_atoms, r/2 ];
 prox_close key;
 mask = put [mask, x[idx], 1];
    endloop
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 // set the found atoms subtracting the initially selected atoms
 local found_atoms = diff [ atom_set | mask, sel_atoms ];
 // extend the atom set to include atoms of residues that contain an atom within radius
 local ext_found_atoms = cat oChildren ( uniq oParent found_atoms);
 // return the extended found atoms that are also present in the full atom set
 return join [ atom_set, ext_found_atoms ];
endfunction
//-----------------------------------------------------------------------------------
//----------Main Code Block----------
global function DockWkup [receptor_file, ligand_poses]
 local orig_atoms, pose, pocket_res, pocket_res_notBB, basename, savename;
 local [q,pos] = [];
 for pose in ligand_poses loop
 
  Open receptor_file;
  Open pose;
  View Atoms[];
  
  orig_atoms = Atoms[];
  
  Add_H Atoms[];
  [q,pos] = PartialCharge [ Atoms[], 'MMFF94*' ];
  aSetCharge [ Atoms[], q ];
  
  write 'File Opened, Hydrogens Added, Charges Computed\n';
  
  // Stage 1: minimize added hydrogens
  write '\nStage 1: Minimizing added hydrogens\n\n';
  Beep[];
  aSetFixed [ orig_atoms, 1 ];
  MM[gtest:0.0001];
  aSetFixed [ Atoms[], 0 ];
  
  // Stage 2: minimize ligand
  write '\nStage 2: Minimizing Ligand\n\n';
  Beep[];
  aSetFixed [ diff [ Atoms[], cat oAtoms last Chains[] ], 1 ];
  MM[gtest:0.0001];
  aSetFixed [ Atoms[], 0 ];
  
  // Stage 3: minimize residues in pocket
  write '\nStage 3: Minimizing Residues in Pocket\n\n';
  Beep[];
  pocket_res = ProxResFind [ Atoms[], cat oAtoms last Chains[], 4.5 ];
  pocket_res_notBB = diff [ pocket_res, aBackbone pocket_res ];
  aSetFixed [ diff [ Atoms[], pocket_res_notBB ], 1 ];
  MM[gtest:0.0001];
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  aSetFixed [ Atoms[], 0 ];
  
  // Stage 4: minimize ligand and residues in pocket
  write '\nStage 4: Minimizing Ligand + Residues in Pocket\n\n';
  Beep[];
  aSetFixed [ diff [ Atoms[], append [ cat oAtoms last Chains[], pocket_res_notBB ] ], 
1 ];
  MM[gtest: 0.0001];
  aSetFixed [ Atoms[], 0 ];
  
  basename = ftail ( fpath pose );
  savename = twrite [ '{}_wkup.moe', basename ];
  SaveAs savename;
  Close[force:1];
 
 endloop
write 'DockWkup Module Complete\n';
endfunction
iii. pyrrole_int.svl
// Written by Christopher Mayne 12/3/09
// File: pyrrole_int.svl
// Desc: rotates pyrrole through an angle and calculates total energy and E_int for system
// Preprocessing: add hydrogens, calc charges
// Passed: atom keys to atoms in dihedral (in appropriate order), output filename
// Returns: null
// Output: output file with calculated values
// Filetree
// ./src
//  ./pyrrole_int.svl
function Potential;
global function pyrrole_int [toratoms, filename]
 local dihang, E_tot, E_int, ligand_atoms;
 local Edata = [];
 local out_handle = fopenw filename;
 
 fwrite [ out_handle, '{}\n', filename ];
 fwrite [ out_handle, 'dihang\tE_tot\tE_int\n' ];
 
 ligand_atoms = cat oAtoms third Chains[];
 
 for dihang = 0, 90, 0.5 loop
 
  aSetDihedralCWDeg [ toratoms, dihang ];
  Edata = tr [
   pot_strEnergy ligand_atoms, pot_angEnergy ligand_atoms, 
pot_stbEnergy ligand_atoms,
   pot_oopEnergy ligand_atoms, pot_torEnergy ligand_atoms, 
pot_vdwEnergy ligand_atoms,
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   pot_eleEnergy ligand_atoms, pot_solEnergy ligand_atoms, 
pot_resEnergy ligand_atoms
      ];
      
  E_tot = add Edata(1);
  E_int = add Edata(3); 
 
  fwrite [ out_handle, '{}\t{}\t{}\n', dihang, E_tot, E_int ];
 
 endloop
 fclose out_handle;
endfunction
iv. recligE_MMFF94x.svl
// Written by Christopher G. Mayne, 11/14/2009
// Calculates and writes out interaction and binding energies for a set
// receptor-ligand complexes
// Passed: filenames to full structures (moe)
// Returns: null
// Output: ./recligE.out
// Filetree
// ./src
//  ./recligE.svl
// ./docking_out
//  ./2010.02.10/full_structures/*.moe
#set title 'Complex Energies'
#set class 'MOE:user'
function MM, Potential, PartialCharge;
//--------------Proximity Selection Subroutine----------------------------------------
local function ProxFind [atom_set, sel_atoms, radius]
    if not length sel_atoms then return 0; endif;
    const PACKET = 50;
    local r = max [0, radius];
    local mask = zero atom_set;
    local x;
    for x in split [x_id atom_set, PACKET] loop
 local key = prox_open [r, aPos atom_set[x], r/2];
 local idx = uniq second prox_find [ key, aPos sel_atoms, r/2 ];
 prox_close key;
 mask = put [mask, x[idx], 1];
    endloop
 
 return ( atom_set | mask );
endfunction
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//-----------------------------------------------------------------------------------
//-------------Main Function Code----------------------------------------------------
global function recligE_MMFF94x complex_files
 // Passed: array with paths to each pdb file to open
 // Returns: null
 // Outputs: writes energy values for calculating E(interaction) and E(binding)
 
 // Declare and set some variables
 local E_RL, E_R, E_L, E_Rm, E_Lm, E_int, E_bin, dX, W;
 local [q, pos] = [];
 local lig_name, pdbfile;
 
 // Open the output file for writing energy data, and write header
 local out_handle = fopenw './recligE.out';
 fwrite [ out_handle, 'Data Output from recligE_MMFF94x.svl, date/time: {}\n', 
asctime[] ]; 
 fwrite [ out_handle, 'ligand\tE_int\tE_bin\tE_RL\tE_R\tE_Rm\tE_L\tE_Lm\n', 
lig_name, E_int, E_bin, E_RL, E_R, E_Rm, E_L, E_Lm ];
 
 // Start a loop to run over each pdb file  
 for pdbfile in complex_files loop
  
  // Preprocess pdb file
  lig_name = ftail (fbase pdbfile);
  Open pdbfile;
  View Atoms[];
  Add_H Atoms[];
  [q, pos] = PartialCharge [ Atoms[], 'MMFF94*' ];
  aSetCharge [Atoms[], q];
  
  // Define the pocket
  local ligand_atoms = cat oAtoms third Chains[];
  local pocket_atoms = diff [ (ProxFind [ Atoms[], ligand_atoms, 4.5 ]), 
ligand_atoms ];
  
  // Calculate Total Complex Energy
  [E_RL,dX,W] = Potential[];
  
  // delete out ligand and calc receptor/solvent energy
  oDestroy third Chains[];
  [E_R,dX,W] = Potential[];
  aSetFixed [ (diff [ Atoms[], pocket_atoms ] ), 1 ];
  MM[gtest:0.01];
  aSetFixed [ Atoms[], 0 ];
  [E_Rm,dX,W] = Potential[];
  
  // Close the altered pdb file
  Close[force:1];
  
  // Reopen and preprocess the pdb file
  Open pdbfile;
  View Atoms[];
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  Add_H Atoms[];
  [q, pos] = PartialCharge [ Atoms[], 'MMFF94*' ];
  aSetCharge [Atoms[], q];
  
  // delete receptor/solvent and calc ligand energy
  oDestroy first Chains[];
  oDestroy first Chains[];
  [E_L,dX,W] = Potential[];
  MM[gtest:0.01];
  [E_Lm,dX,W] = Potential[];
  
  // Close pdb file
  Close[force:1];
  
  // Calc interaction and binding energies
  E_int = E_RL - ( E_R + E_L );
  E_bin = E_RL - ( E_Rm + E_Lm );
  
  // Write out data to file
  fwrite [ out_handle, '{}\t{}\t{}\t{}\t{}\t{}\t{}\t{}\n', lig_name, E_int, E_bin, 
E_RL, E_R, E_Rm, E_L, E_Lm ];
  
  endloop
 
 // Close output file
 fclose out_handle;
endfunction
//------------End Main Function Code--------------------------------------------------------
v. HBscoring.svl
// Written by Christopher G. Mayne, 02/09/2009
// Calculates hydrogen bonding scores for receptor-ligand complex
// Passed: array containing the .moe files to score
// Returns: null
// Output: dock_wkup_metric_HBscore.csv file
// Filetree
// ./src
//  ./HBscoring.svl
// ./docking_out
//  ./2010.02.10/full_structures/*.moe
function Potential, PartialCharge, dock_HydrogenBonds;
global function HBscoring moe_files
 local file, basename, ligand, protein, energy, overall;
 local [ q, pos ] = [];
 local HBscores = [];
 local out_handle = fopenw 'dock_wkup_metric_HBscores.csv';
 
 fwrite [ out_handle, 'Ligand\tHB1\tHB2\tHB3\tHBh2o\n' ];
 
 for file in moe_files loop
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  basename = ftail (fbase file);
  Open file;
  [ q, pos ] = PartialCharge [ Atoms[], 'MMFF94*' ];
  aSetCharge [ Atoms[], q ];
  
  ligand = cat oAtoms third Chains[];
  protein = diff [ Atoms[], ligand ];
  
  energy = first Potential[dX:0];
  HBscores = third dock_HydrogenBonds [ protein, ligand ];
  overall = energy * mul HBscores;
  
  fwrite [ out_handle, '{}\t{}\t{}\t{}\t{}\n', basename, third HBscores, first 
HBscores, last HBscores, second HBscores];
  Close[force:1];
 endloop
 fclose out_handle;
endfunction
II. GAMESS Code
A. Templates
i. Filetree
General Filetree
/data
 /autogamessltd
  /compound basenames
   /theory or basis set
    inp, dat, log files
/etc
 general LOG file
 paffinity LOG file
 /autogamessltd_logs
  log files for each autogamessltd/AGltd_DFTB3LYP run
/pdbs
 general storage for pdb files
/pdbs2calc
 pdb files for compounds to be calculated
/src
 AGltd_DFTB3LYP.bash
 autogamessltd.bash
 cpunum.pl
 getcoord.pl
 getmem.pl
 paffinity.bash
 parse_D FTB3LYP.bash
 parse_ltd.bash
/templates
 /H+
  inp templates for geometry opt., MP2 and DFT single point energy
 /neutral
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  inp templates for geometry opt., MP2 and DFT single point energy
ii. Neutral Geometry Optimization inp File Header
! Minimization RHF/6-31G*)
 $CONTRL SCFTYP=RHF RUNTYP=OPTIMIZE EXETYP=RUN
 NZVAR=1 $END
 $ZMAT DLC=.TRUE. AUTO=.TRUE. $END
 $BASIS NGAUSS=6 GBASIS=N31 NDFUNC=1 $END
 $STATPT OPTTOL=0.0005 NSTEP=100 HSSEND=.TRUE. $END
 $SCF DIRSCF=.TRUE. $END
 $SYSTEM MWORDS=60 $END
iii. Neutral MP2 Single Point Energy inp File Header
! Single Point Energy MP2/6-311+G**
 $CONTRL SCFTYP=RHF MPLEVL=2 RUNTYP=ENERGY EXETYP=CHECK
 NZVAR=1 $END
 $ZMAT DLC=.TRUE. AUTO=.TRUE. $END
 $BASIS NGAUSS=6 GBASIS=N311 NDFUNC=1 NPFUNC=1
 DIFFS=.TRUE. $END
 $STATPT OPTTOL=0.0005 NSTEP=50 $END
 $SCF DIRSCF=.TRUE. $END
 $SYSTEM PARALL=.TRUE. MWORDS=20 MEMDDI=0 $END
 
 $DATA
cartesian coordinates from 6-31G* geometry optimization output
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iv. Neutral DFT Single Point Energy inp File Header
! Single Point Energy DFTB3LYP/6-311+G**
 $CONTRL SCFTYP=RHF DFTTYP=B3LYP RUNTYP=ENERGY EXETYP=RUN
 NZVAR=1 $END
 $ZMAT DLC=.TRUE. AUTO=.TRUE. $END
 $BASIS NGAUSS=6 GBASIS=N311 NDFUNC=1 NPFUNC=1
 DIFFS=.TRUE. $END
 $STATPT OPTTOL=0.0005 NSTEP=50 $END
 $SCF DIRSCF=.TRUE. $END
 $SYSTEM MWORDS=125 $END
 
 $DATA
cartesian coordinates from 6-31G* geometry optimization output
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v. Protonated Geometry Optimization inp File Header
! Minimization RHF/6-31G*)
 $CONTRL SCFTYP=RHF RUNTYP=OPTIMIZE EXETYP=RUN
 NZVAR=1 ICHARG=1 $END
 $ZMAT DLC=.TRUE. AUTO=.TRUE. $END
 $BASIS NGAUSS=6 GBASIS=N31 NDFUNC=1 $END
 $STATPT OPTTOL=0.0005 NSTEP=100 HSSEND=.TRUE. $END
 $SCF DIRSCF=.TRUE. $END
 $SYSTEM MWORDS=60 $END
vi. Protonated MP2 Single Point Energy inp File Header
! Single Point Energy MP2/6-311+G**
137
 $CONTRL SCFTYP=RHF MPLEVL=2 RUNTYP=ENERGY EXETYP=CHECK
 NZVAR=1 ICHARG=1 $END
 $ZMAT DLC=.TRUE. AUTO=.TRUE. $END
 $BASIS NGAUSS=6 GBASIS=N311 NDFUNC=1 NPFUNC=1
 DIFFS=.TRUE. $END
 $STATPT OPTTOL=0.0005 NSTEP=50 $END
 $SCF DIRSCF=.TRUE. $END
 $SYSTEM PARALL=.TRUE. MWORDS=20 MEMDDI=0 $END
 
 $DATA
cartesian coordinates from 6-31G* geometry optimization output
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vii. Protonated DFT Single Point Energy inp File Header
Single Point Energy DFTB3LYP/6-311+G**
 $CONTRL SCFTYP=RHF DFTTYP=B3LYP RUNTYP=ENERGY EXETYP=RUN
 NZVAR=1 ICHARG=1 $END
 $ZMAT DLC=.TRUE. AUTO=.TRUE. $END
 $BASIS NGAUSS=6 GBASIS=N311 NDFUNC=1 NPFUNC=1
 DIFFS=.TRUE. $END
 $STATPT OPTTOL=0.0005 NSTEP=50 $END
 $SCF DIRSCF=.TRUE. $END
 $SYSTEM MWORDS=125 $END
 
 $DATA
cartesian coordinates from 6-31G* geometry optimization output
 C1
B. Bash Scripts
i. autogamessltd.bash
#!/bin/bash
# Written by Christopher Mayne, 8/26/2010
# Filename: autogamessltd.bash
# Desc: Based on go2.bash (original autogamess), this file launches GAMESS to calculate
#       1) optimized geometry using 6-31G* basis set
#       2) single point energy calculation using MP2/6-311+G** from the 6-31G* geometry
        
# CHANGE LOG
# CUSTOM FUNCTIONS
#----------------------------
# Termination Status Function
#----------------------------
# pass gamess log file as argument (e.g. termstatus 6-31Gdp-MP2.log)
function termstatus {
 status=`awk '/EXECUTION OF GAMESS TERMINATED NORMALLY/' $1`
if (test -n "$status")
then
 echo 'OPTIMIAZATION COMPLETE'
 # continue
else
 echo OPTIMIZATION FAILED!
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 echo Moving on to next molecule
 # reset the CWD back to scr
 cd ../../../../src
 # break out of loop for this compound
 continue
fi
}
#-----------------
# PREAMBLE
#-----------------
# set variable for GAMESS version number; required by rungms script
verno=Mar252010R2
# write LOG header
echo Running AUTOGAMESSLTD
echo Description:
echo '1) optimize geometry using 6-31G* basis set'
echo '2) single point energy calculation using MP2/6-311+G**'
echo
echo Script Started: `date`
echo Input Molecules: 
echo `ls ../pdbs2calc/ | grep .pdb` 
echo 'Total: ' `ls ../pdbs2calc/ | grep .pdb | wc -l` 
#----------------
#----------------
# MAIN CODE BLOCK
#----------------
#----------------
# control loop
for f in `ls ../pdbs2calc/ | grep .pdb`
do
#--------
# PREPARATION PER PDB
#--------
# set basename, ID in LOG
b=`basename $f .pdb`
echo
echo
echo "Current Molecule: $b"
echo --------------------
# move to data folder, check for existing data
cd ../data/autogamessltd/
if (test -d $b)
then
 echo Previous data detected...deleting.
 rm -r $b
fi
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# create subfolder in data folder; change cwd
mkdir -p ./$b
cd ./$b
# determine if protonated
if [[ "$b" =~ H\+$ ]]
then
 charge=H+
else
 charge=neutral
fi
#----------------------------
# 6-31G* (6-31Gd) CALCULATION
#----------------------------
echo
echo ENTERING 6-31G* SUBROUTINE
# create 6-31Gd subfolder
echo Create 6-31Gd subfolder
mkdir -p ./6-31Gd
cd ./6-31Gd
# convert pdb to gamin
echo Converting pdb to gamin
babel -ipdb ../../../../pdbs2calc/$b.pdb -ogamin ./$b.gamin
# burn the gamin header
echo Processing gamin
pdblines=`wc -l $b.gamin | awk '{print $1}'`
coordlines=`expr $pdblines - 2`
tail -$coordlines $b.gamin > coords.footer
# generate inp file
echo Generating inp file
cat ../../../../templates/$charge/Geo6-31Gd.header coords.footer > $b-Geo6-31Gd.inp
# run the 6-31Gd Geometry Optimization
echo Running GAMESS Calc...
rungms $b-Geo6-31Gd.inp $verno 16 >& $b-Geo6-31Gd.log
echo ...GAMESS calc DONE!
# check that calculation terminated normally
echo Check termination status:
termstatus $b-Geo6-31Gd.log
# clean up the directory
echo Cleaning up directory, resetting variables
rm $b.gamin coords.footer
unset pdblines coordlines
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# move up filetree into pdb-specific subfolder (/data/autogamessltd/$b)
cd ..
#--------------------------------------------
# MP2/6-311+G** (= MP2/6-311+Gdp) CALCULATION
#--------------------------------------------
echo
echo ENTERING MP2/6-311+G** SUBROUTINE
echo Calculation from 6-31G* geometry
# make subfolder and move into it
echo Create MP2-6-311\+Gdp subfolder
mkdir ./MP2-6-311\+Gdp
cd ./MP2-6-311\+Gdp
# extract final coords from 6-31Gdp calculation
echo Extract coords from previous calc
perl ../../../../src/getcoord.pl ../6-31Gd/$b-Geo6-31Gd.log > ./coords.xyz
# generate the check inp file
echo Generate the check inp file
cat ../../../../templates/$charge/EnerMP2-6-311\+Gdp.header ./coords.xyz > $b-
EnerMP2-6-311\+Gdp-crash.inp
echo ' $END' >> $b-EnerMP2-6-311\+Gdp-crash.inp
# crash the first check
echo Intentionally crash GAMESS check...
rungms $b-EnerMP2-6-311\+Gdp-crash.inp $verno 1 >& crash.log
echo ...Intentionally crashed check complete
# extract OK MWORDS and MEMDDI value
echo Extracting memory values
memvals1=`awk '$1 ~ /CORES/ && $2 ~ /MEMDDI/ {getline; mwords=$4; memddi=$2} END 
{printf ("MWORDS=%i MEMDDI=%i", mwords, memddi)}' crash.log`
echo Found memory values are: $memvals1
# make some changes the inp file
echo Fixing the inp file
sed -e "s/MWORDS=20 MEMDDI=0/$memvals1/" $b-EnerMP2-6-311\+Gdp-crash.inp > $b-
EnerMP2-6-311\+Gdp-check.inp
# trash the dat file, and rerun the calc
echo Resetting CWD and running GAMESS check...
rm *.dat
rungms $b-EnerMP2-6-311\+Gdp-check.inp $verno 1 >& check.log
echo ...GAMESS check complete
# determine max number of utilizable cores
ncpu=`perl ../../../../src/cpunum.pl ./check.log`
echo Maximum number of utilizable cores: $ncpu
# extract MWORDS and MEMDDI values
echo Extracting memory values
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memvals2=`perl ../../../../src/getmem.pl ./check.log`
echo Found Memory Values are: $memvals2
# make some changes to the inp file
echo Generating RUN inp file
sed -e "s/EXETYP=CHECK/EXETYP=RUN/" -e "s/$memval1/$memvals2/" -e "s/
PARALL=.TRUE.//" $b-EnerMP2-6-311\+Gdp-check.inp > $b-EnerMP2-6-311\+Gdp.inp
# trash the dat file, and run the calc
echo Resetting CWD and Running GAMESS Calc...
rm *.dat
rungms $b-EnerMP2-6-311\+Gdp.inp $verno $ncpu >& $b-EnerMP2-6-311\+Gdp.log
echo ...GAMESS calc DONE!
# check that calculation terminated normally
echo Check termination status
termstatus $b-EnerMP2-6-311\+Gdp.log
# clean up directory
echo Cleaning directory, Resetting variables
rm *.xyz crash.log $b-EnerMP2-6-311\+Gdp-crash.inp $b-EnerMP2-6-311\+Gdp-check.inp
unset memvals1 memvals2
# tidy up some things before moving onto the next molecule
# move up filetree (back to src)
cd ../../../../src
# remove pdb from pdbs2calc
echo Removing molecule from pdbs2calc
rm ../pdbs2calc/$f
# rest for 10 minutes
sleep 600
done
echo Script Ending: `date`
ii. AGltd_DFTB3LYP.bash
#!/bin/bash
# Written by Christopher Mayne, 09/02/2010
# Filename: AGltd_DFTB3LYP.bash
# Desc: Based on autogamessltd.bash, this file
#       1) pull coordinates of optimized geometries (RHF/6-31G*)
#       2) single point energy calculation using DFT/B3LYP/6-311+G** from 6-31G* geometry
# CHANGE LOG
# 08/02/2010: NOTE: unlike the MP2 calcs, DFT calcs don't require MEMDDI resources to
#                     be set.  This allows me to bypass all of the complicated crash/check/run steps
#                     in the autogamessltd.bash sequence.  Hopefully by setting the MWORDS
#                     value to 1GB (125 MWORDS) I shouldn't have any memory related problems.
#                     This make my current organization a little strange, but functional.
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# CUSTOM FUNCTIONS
#----------------------------
# Termination Status Function
#----------------------------
# pass gamess log file as argument (e.g. termstatus 6-31Gdp-MP2.log)
function termstatus {
 status=`awk '/EXECUTION OF GAMESS TERMINATED NORMALLY/' $1`
if (test -n "$status")
then
 echo 'OPTIMIZATION COMPLETE'
 # continue
else
 echo OPTIMIZATION FAILED!
 echo Moving on to next molecule
 # reset the CWD back to scr
 cd ../../../../src
 # break out of loop for this compound
 continue
fi
}
#-----------------
# PREAMBLE
#-----------------
# set variable for GAMESS version number; required by rungms script
verno=Mar252010R2
# write LOG header
echo Running AGLTD_DFTB3LYP
echo Description:
echo '1) single point energy calculation using MP2/6-311+G** from 6-31G* geomtery'
echo
echo Script Started: `date`
echo Input Molecules: 
echo `ls ../pdbs2calc/ | grep .pdb` 
echo 'Total: ' `ls ../pdbs2calc/ | grep .pdb | wc -l` 
#----------------
#----------------
# MAIN CODE BLOCK
#----------------
#----------------
# control loop
for f in `ls ../pdbs2calc/ | grep .pdb`
do
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#--------
# PREPARATION PER PDB
#--------
# set basename, ID in LOG
b=`basename $f .pdb`
echo
echo
echo "Current Molecule: $b"
echo --------------------
# move to data folder, check for existing cmpd and geometry data
cd ../data/autogamessltd
echo Looking for data dependencies...
if (test -d $b)
then
 echo ...Previous compound data FOUND
else
 echo ...Previous compound data NOT FOUND
 echo Moving on to next molecule
 # reset the CWD back to scr
 cd ../../src
 # break out of loop for this compound
 continue
fi
if (test -a $b/6-31Gd/$b-Geo6-31Gd.log)
then
 echo ...Previous geometry optimization log FOUND
else
 echo ...Previous geometry optimization log NOT FOUND
 echo Moving on to next molecule
 # reset the CWD back to scr
 cd ../../src
 # break out of loop for this compound
 continue
fi
echo Testing previous geometry optimization termination...
ptermstatus=`termstatus $b/6-31Gd/$b-Geo6-31Gd.log`
if [ "$ptermstatus" == "OPTIMIZATION COMPLETE" ]
then
 echo ...Previous geometry optimization log OK
elif [ "$ptermstatus" == "OPTIMIZATION FAILED!" ]
then
 echo ...Previous geometry optimization log FAILED
 echo Moving on to next molecule
 # reset the CWD back to scr
 cd ../../src
 # break out of loop for this compound
 continue
else
 echo ...Unidentified problem with previous geometry optimization log
 echo Moving on to next molecule
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 # reset the CWD back to scr
 cd ../../src
 # break out of loop for this compound
 continue
fi
# remove any previous DFTB3LYP data
if (test -d ./$b/DFTB3LYP)
then
 echo Previous data detected...deleting
 rm -r ./$b/DFTB3LYP
else
 echo No previous DFTB3LYP data detected...continuing
fi
# determine if protonated
if [[ "$b" =~ H\+$ ]]
then
 charge=H+
else
 charge=neutral
fi
echo Detected charge state: $charge
#--------------------------------
# DFT B3LYP/6-311+G** CALCULATION
#--------------------------------
echo
echo 'ENTERING DFT B3LYP/6-311+G** SUBROUTINE'
echo 'Calculation from 6-31G* geometry'
# create the DFTB3LYP subfolder
mkdir -p ./$b/DFTB3LYP
cd ./$b/DFTB3LYP
# extract final coords from 6-31Gdp calculation
echo Extracting coords from 6-31Gdp geometry optimization log
perl ../../../../src/getcoord.pl ../6-31Gd/$b-Geo6-31Gd.log > ./coords.xyz
# generate the check inp file
echo Generate the check inp file
cat ../../../../templates/$charge/EnerDFTB3LYP-6-311\+Gdp.header ./coords.xyz > $b-
EnerDFTB3LYP-6-311\+Gdp.inp
echo ' $END' >> $b-EnerDFTB3LYP-6-311\+Gdp.inp
# run the DFT calc
echo Running GAMESS calc...
rungms $b-EnerDFTB3LYP-6-311\+Gdp.inp $verno 16 >& $b-EnerDFTB3LYP-6-311\
+Gdp.log
echo ...GAMESS calc done!
# check that calculation terminated normally
echo Check termination status
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termstatus $b-EnerDFTB3LYP-6-311\+Gdp.log
# clean up directory
echo Cleaning directory, Resetting variables
rm *.xyz
# tidy up some things before moving onto the next molecule
# move up filetree (back to src)
cd ../../../../src
# remove pdb from pdbs2calc
echo Removing molecule from pdbs2calc
rm ../pdbs2calc/$f
# rest for 5 minutes
sleep 300
done
echo Script Ending: `date`
iii. parse_ltd.bash
#!/bin/bash
# move to the autogamessltd data folder
cd ../data/autogamessltd
# write output header
printf "cmpd\tNeutral ZPE\tNeutral Total E\tNeutral Dipole\tH+ ZPE\t H+ Total E\tH+ Dipole
\n"
# start control loop
for f in `ls -d */ | awk '/H\+/'`
do
 b=`basename $f H+`
# echo $b
 # move into the neutral subdirectory, pull out ZPE from Geo, pull out Total E from 
Energy calc
 cd ./${b}
 cd ./6-31Gd
 zpeN=`awk '/[\-0123456789\.]+ KCAL\/MOL +[\-0123456789\.]+ KJ\/MOL/ {print $1}' $
{b}\-Geo6\-31Gd.log`
 cd ../MP2-6-311\+Gdp
 tenergyN=`awk '/TOTAL ENERGY =/ {print $4}' ${b}\-EnerMP2\-6\-311\+Gdp.log`
 dipoleN=`awk '/ +DX +DY +DZ +/ {getline; print $4}' ${b}\-EnerMP2\-6\-311\+Gdp.log`
 # move into the H+ subdirectory, pull out ZPE from Geo, pull out Total E from Energy 
calc
 cd ../../${b}H\+
 cd ./6-31Gd
 zpeH=`awk '/[\-0123456789\.]+ KCAL\/MOL +[\-0123456789\.]+ KJ\/MOL/ {print $1}' $
{b}H\+-Geo6\-31Gd.log`
 cd ../MP2-6-311\+Gdp
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 tenergyH=`awk '/TOTAL ENERGY =/ {print $4}' ${b}H\+\-EnerMP2\-6\-311\+Gdp.log`
 dipoleH=`awk '/ +DX +DY +DZ +/ {getline; print $4}' ${b}H\+\-EnerMP2\-6\-311\
+Gdp.log`
 # reset the cwd
 cd ../../
 # convert total energy from hartrees to kcal/mol
 tenergyNkcal=`echo "$tenergyN * 627.53" | bc`
 tenergyHkcal=`echo "$tenergyH * 627.53" | bc`
 # output the parsed values
 printf "%s\t%f\t%f\t%f\t%f\t%f\t%f\n" $b $zpeN $tenergyNkcal $dipoleN $zpeH 
$tenergyHkcal $dipoleH
done
iv. parse_DFTB3LYP.bash
#!/bin/bash
# Written by Christopher Mayne, 09/02/2010
# Filename: parse_DFTB3LYP.bash
# Desc: pulls out DFT/B3LYP/6-311+G** Total Energy values
# move into the data subfolder
cd ../data/autogamessltd
# write output header
printf "cmpd\tNeutral Total E\tNeutral Dipole\tH+ Total E\tH+ Dipole\n"
# start control loop
for f in `ls -d */ | awk '/H\+/'`
do
 # set the basename
 b=`basename $f H+`
 # move into neutral DFT directory
 cd ./$b/DFTB3LYP
 tenergyN=`awk '/TOTAL ENERGY =/ {print $4}' ${b}\-EnerDFTB3LYP\-6\-311\+Gdp.log`
 dipoleN=`awk '/ +DX +DY +DZ +/ {getline; print $4}' ${b}\-EnerDFTB3LYP\-6\-311\
+Gdp.log`
 # move into the H+ DFT directory
 cd ../../${b}H\+/DFTB3LYP
 tenergyH=`awk '/TOTAL ENERGY =/ {print $4}' ${b}H\+\-EnerDFTB3LYP\-6\-311\
+Gdp.log`
 dipoleH=`awk '/ +DX +DY +DZ +/ {getline; print $4}' ${b}H\+\-EnerDFTB3LYP\-6\-311\
+Gdp.log`
 # reset the cwd
 cd ../../
 # convert the total energy from hartrees to kcal/mol
 tenergyNkcal=`echo "$tenergyN * 627.53" | bc`
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 tenergyHkcal=`echo "$tenergyH * 627.53" | bc`
 # output the parsed values
 printf "%s\t%f\t%f\t%f\t%f\n" $b $tenergyNkcal $dipoleN $tenergyHkcal $dipoleH 
done
v. paffinity.bash
#!/bin/bash
# move to the autogamessltd data folder
cd ../data/autogamessltd
# write output header
printf "cmpd\tNeutral ZPE\tNeutral Total E\t H+ ZPE\t H+ Total E\n"
# start control loop
for f in `ls -d */ | awk '/H\+/'`
do
 b=`basename $f H+`
# echo $b
 # move into the neutral subdirectory, pull out ZPE from Geo, pull out Total E from 
Energy calc
 cd ./${b}
 cd ./6-31Gd
 zpeN=`awk '/[\-0123456789\.]+ KCAL\/MOL +[\-0123456789\.]+ KJ\/MOL/ {print $1}' $
{b}\-Geo6\-31Gd.log`
 cd ../MP2-6-311\+Gdp
 tenergyN=`awk '/TOTAL ENERGY =/ {print $4}' ${b}\-EnerMP2\-6\-311\+Gdp.log`
 # move into the H+ subdirectory, pull out ZPE from Geo, pull out Total E from Energy 
calc
 cd ../../${b}H\+
 cd ./6-31Gd
 zpeH=`awk '/[\-0123456789\.]+ KCAL\/MOL +[\-0123456789\.]+ KJ\/MOL/ {print $1}' $
{b}H\+-Geo6\-31Gd.log`
 cd ../MP2-6-311\+Gdp
 tenergyH=`awk '/TOTAL ENERGY =/ {print $4}' ${b}H\+\-EnerMp2\-6\-311\+Gdp.log`
 # reset the cwd
 cd ../../
 # convert total energy from hartrees to kcal/mol
 tenergyNkcal=`echo "$tenergyN * 627.53" | bc`
 tenergyHkcal=`echo "$tenergyH * 627.53" | bc`
 # output the parsed values
 printf "%s\t%f\t%f\t%f\t%f\n" $b $zpeN $tenergyNkcal $zpeH $tenergyHkcal
done
C. Perl Helper Programs
i cpunum.pl
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#!/usr/bin/env perl
# Read from stdin (or perl will read from a filename given on the command line)
while(<>)
{
 # burn line unless this pattern matches
 next unless /DISTRIBUTED\s+--REPLICATED--/;
 # read some more lines from stdin
 while(<>)
 {
  # search by regex; anything in () is stored in variable
  /^\s+([0-9]+)\s+([0-9]+)\s+[0-9]+.\s+([0-9]+)/;
  
  $ncpus=$1;
  
  if ($1==16) {
   print "16";
   last;
  }
  if (/^\s*$/) {
  print $ncpus;
   last;
  }
  
 }
}
ii. getmem.pl
#!/usr/bin/env perl
# Read from stdin (or perl will read from a filename given on the command line)
while(<>)
{
 # burn line unless this pattern matches
 next unless /DISTRIBUTED\s+--REPLICATED--/;
 # read some more lines from stdin
 while(<>)
 {
  # search by regex; anything in () is stored in variable
  /^\s+([0-9]+)\s+([0-9]+)\s+[0-9]+.\s+([0-9]+)/;
  
  $mwords=$3;
  $memddi=$2;
  
  if ($1==16) {
   print "MWORDS=$mwords MEMDDI=$memddi";
   last;
  }
  if (/^\s*$/) {
  print "MWORDS=$mwords MEMDDI=$memddi";
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   last;
  }
  
 }
}
iii. getcoord.pl
#!/usr/bin/env perl
# Read from stdin (or perl will read from a filename given on the command line)
while(<>)
{
 # burn line unless this pattern matches
 next unless /EQUILIBRIUM GEOMETRY LOCATED/;
 # read some more lines from stdin
 while(<>)
 {
  # Example of using parens to capture matched regex sections
  #/^\s([A-Z]+)\s+([0-9.]+)/;
  #print "Atom $1, charge $2\n";
  # Print line to stdout if this pattern matches
  print if /^\s[A-Z]+\s+[0-9.]+/;
  # Break from this inner while if the line is blank
  last if /^\s*$/;
 }
}
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